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Abstract: DNA damage is a common threat to all cells, as it is a driver of malignant transformation.
However, it can also be exploited in cancer therapy. Commonly used chemotherapeutics induce a high
load of DNA lesions, which overwhelm the repair capacity of replicating tumor cells. Novel approaches
aim at targeting backup DNA repair pathways in order to induce synthetic lethality in cancer cells that
display specific defects in certain DNA repair enzymes. PARP inhibitors, such as Olaparib, are the prime
example and have proven to be highly effective in the treatment of BRCA1- and BRCA2-deficient tumors.
PARP1 is an enzyme involved in the repair of DNA single- strand breaks (SSBs). These small lesions may
collapse into deleterious double-strand breaks (DSBs) when they collide with the replication machinery.
In normal cells, DSBs are repaired in an accurate manner by the homologous recombination (HR) repair
pathway, which relies on the activity of functional BRCA proteins. HR-deficient tumor cells die when
treated with PARP inhibitors due to an accumulation of cytotoxic DSBs, which are then channeled into
alternative, error-prone pathways, leading to genome rearrangements and ultimately apoptosis. PARP
inhibitors are used as single-agent therapies, suggesting that the origin of lesions that rely on PARP
activity must be endogenous. Intracellular reactive oxidative species (ROS) can lead to an accumulation
of 8-oxo-2’-deoxyguanosine (GO) in genomic DNA, which is potentially mutagenic due to its base-pairing
properties with both cytosine (C) as well as adenine (A). GO-containing lesions are repaired by the
base-excision repair (BER) pathway, initiated by two different glycosylases: MYH addresses GO:A pairs,
removing the misincorporated A, while OGG1 excises the oxidized guanine (GO) directly, but only from
GO:C base-pairs. Transient SSBs are generated during BER, which likely activate PARP that primes
them for repair. Due to the abundance of endogenous oxidative DNA damage, we reasoned that their
repair by BER leads to the generation of transient SSBs, which are the main contributors to the efficacy
of PARP inhibitors in cells lacking active HR. Indeed, we show that MYH-depletion attenuates the
sensitivity and genomic instability induced by Olaparib in HR-deficient cells. These results prove that
processing of oxidative DNA lesions contributes to PARP inhibitor toxicity and therefore imply that
tissue oxygenation and MYH status affect the efficacy of treatment. An additional study in this thesis
focused on another putative DNA repair factor, ATAD5, which has been proposed to be a suppressor
of genome instability. Also we observed a hypersensitivity of ATAD5-deficient cells to certain DNA
damaging drugs, such as the methylating agent MNNG, the interstrand crosslinking agent MMC and the
PARP inhibitor Olaparib. Interestingly, ATAD5-deficiency causes retention of PCNA and ubiquitylated
PCNA on chromatin, suggesting that ATAD5 is involved in their unloading from DNA. However, it is
unclear at the moment if, and how, PCNA retention on chromatin leads to genome instability. The
interaction with PCNA further suggests a role for ATAD5 in DNA replication, but we show here that
this is in fact not the case. Instead, it might be required for post-replicative repair or other DNA repair
processes, which remains to be investigated in the future. We have generated a useful set of tools to study
the contribution of PCNA modifications on the genomic instability induced by ATAD5-deficiency, which
will hopefully shed light onto important functions of both ATAD5 and PCNA in DNA metabolism.
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SUMMARY	  DNA	  damage	   is	  a	  common	  threat	   to	  all	   cells,	  as	   it	   is	  a	  driver	  of	  malignant	   transformation.	  However,	  it	  can	  also	  be	  exploited	  in	  cancer	  therapy.	  Commonly	  used	  chemotherapeutics	  induce	  a	  high	  load	  of	  DNA	  lesions,	  which	  overwhelm	  the	  repair	  capacity	  of	  replicating	  tumor	  cells.	  Novel	  approaches	  aim	  at	  targeting	  backup	  DNA	  repair	  pathways	  in	  order	  to	  induce	  synthetic	  lethality	  in	  cancer	  cells	  that	  display	  specific	  defects	  in	  certain	  DNA	  repair	  enzymes.	  PARP	  inhibitors,	  such	  as	  Olaparib,	   are	   the	  prime	  example	  and	  have	  proven	   to	  be	  highly	  effective	   in	   the	   treatment	  of	  BRCA1-­‐	  and	  BRCA2-­‐deficient	  tumors.	  PARP1	  is	  an	  enzyme	  involved	  in	  the	  repair	  of	  DNA	  single-­‐strand	   breaks	   (SSBs).	   These	   small	   lesions	  may	   collapse	   into	   deleterious	   double-­‐strand	   breaks	  (DSBs)	  when	  they	  collide	  with	  the	  replication	  machinery.	  In	  normal	  cells,	  DSBs	  are	  repaired	  in	  an	  accurate	  manner	  by	  the	  homologous	  recombination	  (HR)	  repair	  pathway,	  which	  relies	  on	  the	  activity	   of	   functional	   BRCA	   proteins.	   HR-­‐deficient	   tumor	   cells	   die	   when	   treated	   with	   PARP	  inhibitors	  due	  to	  an	  accumulation	  of	  cytotoxic	  DSBs,	  which	  are	  then	  channeled	  into	  alternative,	  error-­‐prone	   pathways,	   leading	   to	   genome	   rearrangements	   and	   ultimately	   apoptosis.	   PARP	  inhibitors	   are	  used	  as	   single-­‐agent	   therapies,	   suggesting	   that	   the	  origin	  of	   lesions	   that	   rely	  on	  PARP	  activity	  must	  be	  endogenous.	  Intracellular	  reactive	  oxidative	  species	  (ROS)	  can	  lead	  to	  an	  accumulation	  of	  8-­‐oxo-­‐2'-­‐deoxyguanosine	  (GO)	  in	  genomic	  DNA,	  which	  is	  potentially	  mutagenic	  due	   to	   its	  base-­‐pairing	  properties	  with	  both	  cytosine	   (C)	  as	  well	  as	  adenine	   (A).	  GO-­‐containing	  lesions	   are	   repaired	   by	   the	   base-­‐excision	   repair	   (BER)	   pathway,	   initiated	   by	   two	   different	  glycosylases:	  MYH	  addresses	  GO:A	  pairs,	   removing	   the	  misincorporated	  A,	  while	  OGG1	   excises	  the	  oxidized	  guanine	  (GO)	  directly,	  but	  only	  from	  GO:C	  base-­‐pairs.	  Transient	  SSBs	  are	  generated	  during	  BER,	  which	   likely	   activate	   PARP	   that	   primes	   them	   for	   repair.	  Due	   to	   the	   abundance	   of	  endogenous	   oxidative	   DNA	   damage,	   we	   reasoned	   that	   their	   repair	   by	   BER	   leads	   to	   the	  generation	  of	  transient	  SSBs,	  which	  are	  the	  main	  contributors	  to	  the	  efficacy	  of	  PARP	  inhibitors	  in	   cells	   lacking	   active	  HR.	   Indeed,	  we	   show	   that	  MYH-­‐depletion	   attenuates	   the	   sensitivity	   and	  genomic	   instability	   induced	   by	   Olaparib	   in	   HR-­‐deficient	   cells.	   These	   results	   prove	   that	  processing	  of	  oxidative	  DNA	  lesions	  contributes	  to	  PARP	  inhibitor	  toxicity	  and	  therefore	   imply	  that	  tissue	  oxygenation	  and	  MYH	  status	  affect	  the	  efficacy	  of	  treatment.	  	  An	   additional	   study	   in	   this	   thesis	   focused	   on	   another	   putative	  DNA	   repair	   factor,	   ATAD5,	  which	   has	   been	   proposed	   to	   be	   a	   suppressor	   of	   genome	   instability.	   Also	   we	   observed	   a	  hypersensitivity	   of	   ATAD5-­‐deficient	   cells	   to	   certain	   DNA	   damaging	   drugs,	   such	   as	   the	  methylating	   agent	   MNNG,	   the	   interstrand	   crosslinking	   agent	   MMC	   and	   the	   PARP	   inhibitor	  Olaparib.	  Interestingly,	  ATAD5-­‐deficiency	  causes	  retention	  of	  PCNA	  and	  ubiquitylated	  PCNA	  on	  chromatin,	   suggesting	   that	   ATAD5	   is	   involved	   in	   their	   unloading	   from	   DNA.	   However,	   it	   is	  unclear	   at	   the	  moment	   if,	   and	  how,	  PCNA	   retention	  on	   chromatin	   leads	   to	   genome	   instability.	  The	   interaction	  with	  PCNA	  further	  suggests	  a	  role	   for	  ATAD5	  in	  DNA	  replication,	  but	  we	  show	  here	  that	  this	   is	   in	  fact	  not	  the	  case.	   Instead,	   it	  might	  be	  required	  for	  post-­‐replicative	  repair	  or	  other	  DNA	  repair	  processes,	  which	  remains	  to	  be	  investigated	  in	  the	  future.	  We	  have	  generated	  a	  useful	   set	   of	   tools	   to	   study	   the	   contribution	   of	   PCNA	  modifications	   on	   the	   genomic	   instability	  induced	  by	  ATAD5-­‐deficiency,	  which	  will	  hopefully	  shed	  light	  onto	  important	  functions	  of	  both	  ATAD5	  and	  PCNA	  in	  DNA	  metabolism.	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ZUSAMMENFASSUNG	  DNA	   Schäden	   sind	   gefährlich	   für	   alle	   Zellen,	   weil	   sie	   zu	   deren	   Entartung	   führen	   können.	  Gleichzeitig	   werden	   sie	   aber	   in	   der	   Krebstherapie	   genutzt.	   Häufig	   eingesetzte	  Chemotherapeutika	   induzieren	   eine	   grosse	   Anzahl	   von	   Schäden	   in	   der	   DNA,	   welche	   die	  Reparatur-­‐Kapazität	   replizierender	   Zelle	   überschreiten.	   Neue	   Ansätze	   in	   der	   Onkologie	   sind	  darauf	   gezielt	   redundante	   Reparaturmechanismen	   zu	   inhibieren,	   um	   synthetische	   Letalität	   in	  Krebszellen	  zu	   induzieren,	  welche	  spezifische	  Defekte	   in	  Reparatur	  Enzymen	  vorweisen.	  PARP	  Inhibitoren,	  wie	   zum	  Beispiel	  Olaparib,	   sind	  ein	  Paradebeispiel	  hierfür	  und	  haben	   sich	  bereits	  als	   wirksame	   Behandlungsmethoden	   von	   BRCA1-­‐	   und	   BRCA2-­‐defizienten	   Tumoren	   bewiesen.	  PARP1	   ist	   ein	   Enzym	   das	   an	   der	   Reparatur	   von	   DNA	   Einzelstrangbrüchen	   beteiligt	   ist.	   Diese	  kleinen	  DNA	  Schäden	  können	  zu	  folgeschweren	  Doppelstrangbrüchen	  führen,	  wenn	  sie	  mit	  der	  Replikationsmaschinerie	   kollidieren.	   Doppelstrangbrüche	   werden	   in	   normalen	   Zellen	   durch	  Homologe	   Rekombination	   akkurat	   repariert,	   welche	   von	   der	   Aktivität	   funktionsfähiger	   BRCA	  Proteine	  abhängt.	  Tumor	  Zellen	  mit	  defekter	  Homologen	  Rekombination	  sterben,	  wenn	  sie	  mit	  PARP	   Inhibitoren	   behandelt	   werden,	   aufgrund	   einer	   Anhäufung	   von	   toxischen	  Doppelstrangbrüchen.	   Diese	   werden	   schliesslich	   über	   alternative	   Mechanismen	   repariert,	   die	  allerdings	  fehlerhaft	  verlaufen,	  was	  zur	  Reorganisation	  des	  Genoms	  und	  letztendlich	  zum	  Zelltod	  führen	  kann.	  PARP	  Inhibitoren	  werden	  als	  Monotherapien	  eingesetzt,	  was	  darauf	  hindeutet,	  dass	  die	  ursprünglichen	  DNA	  Schäden	  endogener	  Natur	  sind.	  Intrazelluläre	  Sauerstoffradikale	  führen	  zur	  Akkumulation	  von	  8-­‐oxo-­‐2'-­‐deoxyguanosine	  (GO)	  in	  genomischer	  DNA,	  was	  möglicherweise	  Mutationen	  verursacht,	  weil	  GO	  mit	  Cytosin	  (C),	  sowie	  mit	  Adenin	  (A)	  Basenpaarungen	  eingehen	  kann.	   Läsionen,	   die	   GO	   beinhalten,	  werden	   durch	   die	   Basen-­‐Exzisions-­‐Reparatur	   repariert,	   die	  durch	   zwei	   verschiedene	  Glykosylasen	   initiiert	  wird:	  MYH	  beseitigt	   das	   fehl-­‐eingebaute	  A	   aus	  GO:A	   Paaren;	   OGG1	   hingegen	   entfernt	   das	   oxidierte	   Guanin	   (GO)	   direkt,	   aber	   nur	   aus	   GO:C	  Basenpaaren.	   Während	   der	   Basen-­‐Exzisions-­‐Reparatur	   werden	   vorübergehend	  Einzelstrangbrüche	   generiert,	   die	   wahrscheinlich	   PARP	   aktivieren,	   um	   sie	   für	   die	   Reparatur	  vorzubereiten.	  Aufgrund	  der	  Häufigkeit	  endogener,	  oxidativer	  DNA	  Schäden,	  folgerten	  wir,	  dass	  Einzelstrangbrüche,	   die	   während	   deren	   Reparatur	   vorübergehend	   entstehen,	   wesentlich	   zur	  Effizienz	   von	   PARP	   Inhibitoren	   in	   Zellen	   mit	   defekter	   Homologer	   Rekombination	   beitragen.	  Tatsächlich	   zeigen	   wir,	   dass	   MYH	   Knock-­‐Down	   die	   Sensibilität	   und	   genomische	   Instabilität	  reduziert,	  welche	  durch	  Olaparib	  verursacht	  werden.	  Diese	  Resultate	  zeigen,	  dass	  die	  Reparatur	  oxidativer	  DNA	  Schäden	  zur	  Toxizität	  von	  PARP	  Inhibitoren	  beiträgt	  und	  deuten	  darauf	  hin,	  dass	  Gewebe-­‐Oxygenierung	   sowie	   MYH	   Status	   die	   Wirksamkeit	   der	   Behandlung	   wesentlich	  beeinträchtigen.	  	  	  Eine	  weitere	  Studie	   in	  dieser	  Arbeit	  konzentrierte	   sich	  auf	  einen	  weiteren	  mutmasslichen	  DNA	   Reparaturfaktor,	   ATAD5,	  welcher	   als	   Unterdrücker	   genomischer	   Instabilität	   beschrieben	  wurde.	  Auch	  wir	  haben	  eine	  Hypersensibilität	  ATAD5-­‐defizienter	  Zellen	  gegenüber	  bestimmten	  DNA-­‐schädigenden	   Substanzen,	   wie	   zum	   Beispiel	   MNNG,	   MMC	   und	   Olaparib,	   beobachtet.	  Interessanterweise	   verursacht	   ATAD5-­‐Defizienz	   eine	   Akkumulation	   von	   PCNA	   und	  ubiquitiniertem	  PCNA	  auf	  Chromatin,	  was	  darauf	  hindeutet,	  dass	  ATAD5	  an	  deren	  Abladung	  von	  der	  DNA	  beteiligt	  ist.	  Jedoch	  ist	  noch	  immer	  unklar	  ob,	  und	  wenn	  ja,	  wie,	  die	  Akkumulation	  von	  PCNA	  auf	  Chromatin	  zu	  genomischer	  Instabilität	  führt.	  Die	  Interaktion	  mit	  PCNA	  legt	  ausserdem	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  nahe,	  dass	  ATAD5	  an	  der	  DNA	  Replikation	  mitwirkt.	  Wir	  zeigen	  jedoch	  hier,	  dass	  dies	  nicht	  der	  Fall	   ist.	   Stattdessen	   könnte	   es	   an	   Reparaturprozessen	   nach	   der	   Replikation	   oder	   anderen	  Reparaturmechanismen	   beteiligt	   sein.	   Wir	   haben	   nützliche	   Arbeitsmittel	   hergestellt,	   um	   die	  Beteiligung	   der	   PCNA	   Modifikationen,	   im	   Bezug	   auf	   die	   genomische	   Instabilität	   ATAD5-­‐defizienter	   Zellen,	   zu	   untersuchen.	   Diese	   werden	   hoffentlich	   neue	   Einblicke	   in	   wichtige	  Funktionen	  von	  ATAD5	  und	  PCNA	  im	  DNA	  Metabolismus	  liefern.	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ABBREVIATIONS	  
	  8-­‐oxo-­‐dGDP	   	   8-­‐oxo-­‐2’-­‐Deoxyguanosine-­‐5’-­‐Diphosphate	  8-­‐oxo-­‐dGTP	   	   8-­‐oxo-­‐2’-­‐Deoxyguanosine-­‐5’-­‐Triphosphate	  AO	   	   2-­‐oxo-­‐2'-­‐Deoxyadenosine	  (2-­‐oxo-­‐dA)	  ADPR	   	   Adenosine	  Diphosphate	  Ribose	  AMP	   	   Adenosine	  Monophosphate	  APE1	   	   Apurinic/Apyrimidinic	  Endonuclease	  1	  AP-­‐sites	   	   Apurinic	  Sites	  ATM	   	   Ataxia	  Telangiectasia	  Mutated	  ATR	   	   Ataxia	  Telangiectasia	  and	  Rad3-­‐related	  Protein	  ATRIP	   	   ATR	  Interacting	  Protein	  BER	   	   Base	  Excision	  Repair	  BRCA1,2	   	   Breast	  Cancer	  Type	  1	  Susceptibility	  Protein	  1,2	  CDC25	   	   Cell	  Division	  Cycle	  Protein	  25	  CDK	   	   Cyclin-­‐Dependent	  Kinase	  CHK1	   	   Checkpoint	  Kinase	  1	  CHK2	   	   Checkpoint	  Kinase	  2	  CKI	   	   Cyclin-­‐Dependent	  Kinase	  Inhibitor	  DDR	   	   DNA	  Damage	  Response	  dNTP	   	   2’-­‐Deoxyribonucleotide	  DSB	   	   Double	  Strand	  Break	  GO	   	   8-­‐Oxo-­‐2'-­‐Deoxyguanosine	  (8-­‐oxo-­‐dG)	  H2AX	   	   Histon	  H2AX	  variant	  HR	   	   Homologous	  Recombination	  LigI,III,IV	   	   Ligase	  I,	  III,	  IV	  MAP	   	   MYH-­‐associated	  Polyposis	  MMR	   	   Mismatch	  Repair	  MTH1,	  2	   	   MutT-­‐Homolog	  1,	  2	  mtDNA	   	   mitochondrial	  DNA	  MUTYH/MYH	  	   MutY	  Homolog	  NAD+	   	   Nicotinamide	  Adenine	  Dinucleotide	  NER	   	   Nucleotide	  Excision	  Repair	  NHEJ	   	   Non-­‐Homologous	  End	  Joining	  NO	   	   Nitric	  Oxide	  NUDIX	   	   Nucleoside	  diphosphatase	  linked	  to	  another	  moiety,	  X	  OGG1	   	   Oxoguanine	  Glycosylase	  PAR	   	   Poly	  ADP-­‐Ribose	  PARP1	   	   Poly	  (ADP-­‐Ribose)	  Polymerase	  1	  PARPi	   	   PARP	  inhibitor/inhibition	  PARG	   	   Poly	  (ADP-­‐Ribose)	  Glycohydrolase	  PCNA	  	   	   Proliferating	  Cell	  Nuclear	  Antigen	  RB	   	   Retinoblastoma	  Protein	  RNaseH2	   	   Ribonuclease	  H2	  RNKP	   	   Polynucleotide	  Kinase-­‐Phosphatase	  ROS	   	   Reactive	  Oxygen	  Species	  R5'P	   	   Ribose-­‐5'-­‐Phosphate	  RPA	   	   Replication	  Protein	  A	  SOD1,2	   	   Superoxide	  Dismutase	  1,2	  SSB	   	   Single	  Strand	  Break	  ssDNA	   	   Single	  Strand	  DNA	  TopI,II	   	   Topoisomerase	  I,	  II	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INTRODUCTION	  
	  
CANCER	  &	  CANCER	  THERAPY	  Cancer	  is	  a	  devastating	  disease,	  which	  is	  characterized	  by	  aberrant	  proliferation	  of	  cells	  due	  to	   genomic	   instability	   or,	   more	   specifically,	   by	   an	   accumulation	   of	   mutations	   favoring	   cell	  survival	   and	   growth.	   Cancer	   is	   the	   second	   leading	   cause	   of	   death	   in	   Europe	   and	   despite	   the	  tremendous	   efforts	   taken	   in	   the	   development	   of	   novel	   anti-­‐cancer	   drugs	   surgery	   still	   remains	  the	  most	  effective	  treatment	  option.	  Radiation	  and	  chemotherapy	  are	  often	  combined	  treatment	  regimens	   after	   chirurgical	   removal	   of	   the	   tumor;	   however,	   the	   side	   effects	   induced	   by	   these	  therapies	  are	  detrimental	  due	  to	  their	  poor	  specificity.	  	  To	  date,	   the	  most	   commonly	  used	  chemotherapeutics	   are	  agents	   that	   cause	  DNA	  damage,	  either	  directly	  or	  indirectly.	  The	  genomic	  instability	  induced	  by	  these	  drugs	  results	  in	  increased	  cell	   death,	   as	   cells	   are	  not	   able	   to	   cope	  with	  DNA	  damage	  exceeding	   a	   certain	   threshold.	   Cells	  possess	   elaborate	   DNA	   damage	   sensing	   mechanisms	   that	   signal	   to	   induce	   DNA	   repair	   or	  apoptosis	  if	  necessary	  in	  order	  to	  avoid	  malignant	  transformation	  and	  thus	  the	  onset	  of	  cancer.	  However,	   an	   urgent	   need	   to	   develop	   novel	   therapeutics	   to	   treat	   cancer	   arises	   from	   the	   poor	  specificity	   of	   the	   above-­‐mentioned	   agents.	   More	   selective	   targets	   and	   drugs	   are	   required	   to	  minimize	  the	  side	  effects	  that	  many	  current	  anti-­‐cancer	  therapies	  exert.	  Novel	  approaches	  aim	  at	  identifying	   synthetic	   lethal	   interactions	   to	   selectively	   target	   cancer	   cells	  while	   leaving	   normal	  cells	   unaffected	   [1].	   Synthetic	   lethality	   is	   based	   on	   pre-­‐existing	  mutations	   in	   cancer	   cells	   that	  render	  them	  dependent	  on	  a	  normally	  non-­‐essential	  pathway.	  Exploiting	  the	  mutant	  phenotype	  of	   a	   cancer	   cell	   and	   targeting	   its	   synthetic	   lethal	   partner	   has	   already	   been	   proven	   to	   be	   a	  valuable	   approach	   in	   experimental	   setups	   [2-­‐4],	   which	   have	   recently	   been	   approved	   for	   the	  treatment	  of	  a	  subset	  of	  tumors.	  Cancer	  cells	  deficient	  in	  certain	  DNA	  repair	  pathways	  are	  likely	  more	   vulnerable	   to	   further	   DNA	   damage,	   which	   can	   be	   induced	   either	   by	   increasing	   stress	  factors	   (such	   as	   oxidative	   or	  metabolic	   stress)	   or	   inhibiting	   redundant	   DNA	   repair	   pathways.	  The	  main	   challenges	   are	   now	   to	   identify	   novel	   synthetic	   lethal	   partners	   that	   are	   suitable	   for	  cancer	   therapy.	   Furthermore,	   it	   is	   crucial	   to	   overcome	   drug	   resistance,	  which	   arises	   from	   the	  high	  selection	  pressure	  and	  the	  adaptability	  of	  cancer	  cells	  due	  to	  their	  mutator	  phenotype.	  	  Alterations	   in	   the	   sequence	   and	   organization	   of	   the	   genome	   range	   from	   small	   base	  modifications	  to	  gross	  chromosomal	  rearrangements	  and	  have	  been	  shown	  to	  accumulate	  over	  the	   course	   of	   neoplastic	   progression	   [5].	   Mutations	   providing	   an	   advantage	   in	   growth	   and	  survival	   can	   cause	   uncontrolled	   cell	   division	   characteristic	   of	   malignant	   cells.	   Furthermore,	  mutations	  in	  oncogenes	  or	  tumor	  suppressor	  genes	  result	  in	  deregulation	  of	  cellular	  processes.	  This	  frequently	  leads	  to	  enhanced	  endogenous	  oxidative,	  metabolic	  and	  replicative	  stress,	  which	  in	   turn	   causes	   further	  DNA	  damage	   [6].	  Adaptation	   to	   the	   stress	  phenotype	   is	   vital	   for	   cancer	  cells;	  however,	  it	  often	  results	  in	  dependency	  upon	  non-­‐oncogenes	  to	  reduce	  the	  elevated	  stress	  levels	  and	  maintain	  balanced	  metabolism	  to	  ensure	  cell	  survival.	  Targeting	  these	  non-­‐oncogene	  dependencies,	  which	  are	  required	  for	  cancer	  cell	  survival	  but	  dispensable	   in	  normal	  cells,	  may	  result	  in	  a	  synthetic	  lethal	  interaction	  [7,	  8].	  The	  elevated	  endogenous	  oxidative	  stress	  levels	  for	  instance,	  which	  arise	  from	  increased	  metabolic	  activity	  of	  cancer	  cells	  and	  oncogene	  activation,	  require	   adaptation	   to	   avoid	   adverse	   effects,	   such	   as	   oxidative	   damage	   of	   lipids,	   proteins	   and,	  most	  importantly,	  the	  DNA.	  Disturbing	  the	  cellular	  redox	  potential	  and	  reactive	  oxygen	  species	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(ROS)	   balance	   has	   therefore	   been	   proposed	   to	   be	   a	   promising	   strategy	   for	   novel	   and	   more	  selective	   anti-­‐cancer	   treatments	   due	   to	   the	   increased	   dependence	   of	   those	   cells	   on	   the	   ROS	  stress	  response	  [9].	  Naturally,	  this	  includes	  protection	  from	  oxidative	  DNA	  injury	  by	  repair	  and	  prevention	  of	  this	  sort	  of	  damage.	  	  	  
CELL	  CYCLE	  Proliferating	   cells,	   such	   as	   most	   cancer	   cells,	   have	   to	   enter	   the	   cell	   cycle,	   which	   enables	  division	  of	  the	  cell	  into	  two	  identical	  daughters.	  It	  is	  divided	  into	  different	  phases:	  In	  G1,	  the	  cells	  grow	   and	   prepare	   for	   replication,	   which	   is	   carried	   out	   in	   S-­‐phase.	   Once	   'quality	   control'	   of	  replicated	  DNA	  and	  chromatin	  assembly	  during	  G2	  are	  completed,	  the	  cells	  are	  allowed	  to	  enter	  mitosis	  (M),	  where	  the	  duplicated	  chromosomes	  are	  separated	  into	  the	  two	  daughter	  cells.	  Most	  non-­‐proliferating	  cells	  of	  the	  human	  body	  are	   in	  a	  dormant	  or	  quiescent	  state,	  G0,	  and	  need	  to	  receive	  appropriate	  growth-­‐promoting	  signals	   to	  enter	   the	  cell	   cycle.	  Two	  hallmarks	  of	   cancer	  cells	   are	   their	   independence	   on	   external	   growth	   signals	   and	   their	   insensitivity	   to	   anti-­‐growth	  signals	   [10,	  11].	  This	   is	  mainly	  due	   to	   frequent	  oncogene	  activation	  or	   tumor	  suppressor	  gene	  inactivation,	  which	  normally	  control	  cell	  cycle	  progression	  and	  ensure	  checkpoint	  activation.	  	  








Fig.1:	   Cell	   cycle	   regulation	   by	   CDK/cyclin	  
complexes	   and	   CKIs	   in	  mammalian	   cells.	   Different	  CDK/cyclin	   complexes	   in	   active	   state	   drive	   cell	   cycle	  progression	   and	   are	   inactivated	   by	   regulatory	   CDK	  inhibitors	   of	   the	  CIP/KIP	   and	   the	   INK4	   families	   (from	  Fuster	  et	  al.,	  2010	  [14]).	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REPLICATION	  DNA	   is	   the	   carrier	   of	   the	   genetic	   information,	   encoding	   all	   proteins	  necessary	   for	   cellular	  metabolism	   and	   other	   functions	   of	   the	   cell.	   Unlike	   proteins,	   DNA	   exists	   only	   as	   a	   single	   non-­‐replaceable	   copy	   in	   most	   cells	   (considering	   maternal	   and	   paternal	   DNA	   as	   distinct).	   It	   is	  therefore	  essential	  to	  ensure	  the	  integrity	  of	  the	  molecule	  and	  its	  faithful	  duplication	  during	  S-­‐phase	  and	   transmission	   to	   the	  daughter	  cells.	  Replication	   thus	  has	   to	  be	  a	  highly	  accurate	  and	  controlled	  process.	  In	  cancer	  cells,	  replication	  is	  often	  deregulated	  and	  not	  restricted	  any	  more	  to	  a	   certain	  number	  of	   cell	  divisions.	  This	   limitless	   replicative	  potential	  was	   thus	  described	  as	  another	  hallmark	  of	  cancer	  [10,	  11].	  In	  eukaryotes	  replication	  is	  initiated	  at	  multiple	  replication	  origins,	  which	  are	  recognized	  by	  the	  hexameric	  origin	  recognition	  complex	  (ORC)	  [15].	  Origin	  consensus	  sequences	  are	  unknown	  in	   Drosophila,	   Xenopus	   and	   human	   cells	   [16-­‐18],	   but	   chromatin	   structure	   and	   histone	  acetylation	  seem	  to	  be	  important	  to	  initiate	  replication	  [19].	  Licensing	  of	  origins	  takes	  place	  in	  late	  M-­‐	  and	  G1-­‐phases	  of	  the	  cell	  cycle	  through	  assembly	  of	  the	  pre-­‐replication	  complex	  (preRC),	  consisting	  of	  ORC	  and	  the	  additional	   factors	  CDC6,	  CTD	  and	  MCM.	  In	  general,	  mammalian	  cells	  fire	   origins	   situated	   30-­‐150	   kb	   apart	   [20]	   and	   weak	   or	   dormant	   origins	   may	   be	   activated	   to	  compensate	   for	   slow	   fork	   progression	   [21].	   CDKs	   prevent	   re-­‐replication	   by	   inhibiting	   origin	  licensing	  in	  S,	  G2,	  and	  early	  M	  phase	  [22].	  Once	   origins	   have	   fired,	   replication	   has	   to	   proceed	   until	   the	   entire	   genome	   is	   fully	  replicated.	   Bidirectional	   unwinding	   of	   the	   origin	   region	   by	   the	   MCM	   helicase	   opens	   up	   a	  replication	   bubble	   with	   the	   two	   replication	   forks	   proceeding	   in	   opposite	   directions.	   Upon	  unwinding	  of	  the	  DNA,	  a	  ssDNA	  template	  is	  produced	  and	  immediately	  coated	  by	  RPA.	  Short	  30	  nucleotide	   RNA/DNA	   primers,	   termed	   Okazaki	   fragments,	   are	   synthesized	   by	   the	   primase	  activity	  of	  polymerase	  α	  (Polα).	  The	  replication	  factor	  complex	  (RFC)	  binds	  to	  primer-­‐template	  junctions	  and	  loads	  the	  ring	  shaped	  proliferating	  cell	  nuclear	  antigen	  (PCNA)	  onto	  DNA.	  PCNA	  is	  an	  essential,	  homotrimeric	  sliding	  clamp	  that	  encircles	  the	  DNA	  and	  acts	  as	  a	  scaffold	  for	  a	  wide	  variety	   of	   factors	   involved	   in	   DNA	   metabolism	   [23].	   Loading	   of	   PCNA	   onto	   the	   DNA	   during	  replication	  triggers	  a	  polymerase	  switch,	  leading	  to	  disassociation	  of	  Polα	  and	  replacement	  with	  processive	  polymerases	  Polδ	  or	  Polε	  [24,	  25],	  which	  carry	  out	  the	  bulk	  DNA	  synthesis	  in	  a	  5'	  to	  3'	  direction.	  Posttranslational	  modification	  of	  PCNA	  by	  ubiquitin	  and	  SUMO	  expands	  the	  range	  of	  interaction	  partners	  and	  controls	  replication	  of	  damaged	  templates	  [26].	  Replication	  of	  the	  leading	  strand	  is	  continuous,	  while	  the	  lagging	  strand	  synthesis	  occurs	  in	  a	  discontinuous	  fashion	  and	  is	   initiated	  at	  each	  Okazaki	   fragment.	  The	  replicative	  polymerases	  Polδ	   and	   Polε possess	   an	   intrinsic	   3'	   to	   5'	   exonuclease	   activity,	   which	   reduces	   the	   mutation	  frequency	   by	   about	   two	   orders	   of	   magnitude	   [27].	   Additionally,	   mismatch	   repair	   (MMR)	  removes	   accidentally	   misincorporated	   nucleotides	   from	   the	   newly	   synthesized	   DNA	   strand	  immediately	   after	   replication	   and	   further	   reduces	   the	   mutation	   rate	   to	   10-­‐9	   -­‐	   10-­‐10	   [28].	  Continuous	  unwinding	  of	  the	  DNA	  creates	  topological	  problems	  of	  supercoiling	  and	  catenation.	  To	  release	  torsional	  strain	  in	  the	  molecule,	  topoisomerases	  introduce	  transient	  SSBs	  or	  DSBs	  at	  sites	  of	  ongoing	  replication	  [29].	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Fig.2:	  Eukaryotic	  DNA	  replication	  fork.	  The	  MCM	  helicase	  unwinds	  the	   DNA	   strands,	   which	   are	   then	   protected	   by	   the	   single-­‐strand	  binding	  protein	  RPA.	  	  The	  leading	  strand	  is	  replicated	  in	  a	  continuous	  manner	  by	  DNA	  polymerase	  ε	  with	  the	  help	  of	   its	  processivity	  factor	  PCNA.	  	  The	   lagging	  strand	   is	  replicated	   in	  shorter	   fragments,	   termed	  Okazaki	  fragments,	  each	  beginning	  with	  a	  RNA/DNA	  primer	  made	  by	  the	   primase	   and	   subsequently	   extended	   by	   DNA	   polymerase	   δ.	  Okazaki	   fragments	   are	   ligated	   by	   the	   FEN1/DNA	   ligase	   complex	  (modified	  from	  Garg	  and	  Burgers,	  2005	  [30]).	  
	  
PCNA	  PCNA	  is	  a	  homotrimeric	  ring	  that	  encircles	  the	  double	  stranded	  DNA	  and	  plays	  a	  key	  role	  in	  replication	  and	   repair.	   It	   serves	  as	   a	  processivity	   factor	   for	   the	   replicative	  polymerases	  and	   is	  also	   a	   moving	   platform	   for	   other	   interacting	   proteins	   during	   DNA	   replication,	   repair	   and	  chromatin	   remodeling.	   Most	   of	   these	   proteins	   interact	   with	   PCNA	   via	   their	   PCNA-­‐interacting	  peptide	  (PIP)	  or	  	  -­‐motif	  [23].	  Posttranslational	  modifications	  of	  PCNA	  during	  normal	  replication	  or	   in	   response	   to	  DNA	  damage	  regulate	   its	   interaction	  with	  other	  proteins	  and	  channel	   it	   into	  different	  repair	  pathways.	  	  Mono-­‐ubiquitylation	  of	  PCNA	  at	   lysine	  164	   in	  response	   to	  replication	   fork	  stalling	  at	  DNA	  lesions	   is	   carried	   out	   by	   the	   E2	   ubiquitin-­‐conjugating	   enzyme	   Rad6	   together	   with	   the	   E3	  ubiquitin	   ligase	   Rad18	   [31]	   and	   activates	   the	   DNA	   damage	   tolerance	   pathway	   (DDR).	   Here,	  specialized	   translesion	   synthesis	   (TLS)	   polymerases,	  which	  bind	   to	  mono-­‐ubiquitylated	  PCNA,	  are	  able	   to	  bypass	   the	   lesion	  due	   to	  damage-­‐adapted	  active	  sites,	   reduced	  specificity	  and	  their	  ability	   to	   extend	   DNA	   synthesis	   from	   lesions.	   However,	   this	   mechanism	   is	   often	   error-­‐prone,	  especially	   on	   undamaged	   templates,	   due	   to	   the	   reduced	   fidelity	   of	   these	   polymerases	   and	   the	  lack	   of	   an	   exonuclease	   proofreading	   activity	   [28].	   A	   more	   detailed	   description	   of	   the	   TLS	  mechanism	  will	  be	  discussed	  in	  the	  chapter	  'DNA	  damage	  bypass'	  of	  this	  thesis.	  	  PCNA	   can	   also	   be	   poly-­‐ubiquitylated	   on	   lysine	   K164	   by	   the	   E2	   pair	   Ubc13	   and	   Mms2,	  together	   with	   the	   E3	   ligase	   Rad5	   [32].	   This	   modification	   coordinates	   an	   error-­‐free	   repair	  pathway,	  which	   is	   still	   not	   very	  well	   characterized	   but	   probably	   involves	   the	   presence	   of	   the	  sister	  chromatid	  [33].	  	  In	  addition,	  PCNA	  can	  be	  SUMOylated	  during	  S-­‐phase	  or	  upon	  high	  doses	  of	  DNA	  damage	  (e.g.	  MMS).	  This	  modification	   is	  mediated	  by	   the	   SUMO-­‐specific	  E2	  Ubc9	   together	  with	   the	  E3	  Siz1,	  primarily	  on	  K164	  and	  to	  a	  lesser	  extent	  on	  K127	  [31].	  PCNA	  SUMOylation	  affects	  pathway	  choice,	   preventing	   homologous	   recombination	   in	   favor	   of	   ubiquitin-­‐dependent	   lesion	   bypass	  [34].	  The	  helicase	  Srs2	  (or	  its	  human	  analog	  PARI)	  is	  recruited	  to	  PCNASUMO	  via	  its	  PIP	  and	  SIM	  domains.	   Once	   recruited	   to	   stalled	   replication	   forks,	   Srs2	   inhibits	   recombination	   by	   using	   its	  translocase	   activity	   to	   displace	   Rad51	   from	   ssDNA,	   preventing	   strand	   invasion	   and	   homology	  search	  [35,	  36].	  Srs2	  and	  PARI	  are	  thus	  often	  referred	  to	  as	  'anti-­‐recombinases'.	  Interestingly,	  it	  was	  recently	  shown	  that	  SUMOylation	  frequently	  targets	  entire	  groups	  of	  physically	  interacting	  proteins	   that	   bear	   SUMO-­‐interacting	  motifs	   (SIMs)	   [37].	   This	   protein-­‐group	   SUMOylation	  may	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act	   as	   a	   'glue'	   to	   promote	   and	   strengthen	   intramolecular	   interactions	   of	   functionally	   engaged	  protein	  fractions,	  e.g.	  in	  nuclear	  assemblies,	  such	  as	  DNA	  repair	  foci	  [38].	  
	  
Fig.3:	  Replication	  Fork	  Stalling	  and	  its	  consequences.	  a)	  DNA	  lesions	  (yellow	  triangles)	  may	  block	  processive	  DNA	  replication	   (dashed	   lines).	   DNA	   damage	   tolerance	   mechanisms	   allow	   bypass	   of	   such	   DNA	   damage	   by	   translesion	  synthesis	   (TLS)	   or	   using	   the	   undamaged	   sister	   chromatid	   as	   a	   template	   (template	   switching),	   which	   involves	  structural	   rearrangements	   of	   the	   replication	   fork.	   Fork	   reversal	   includes	   the	   formation	   of	   a	   four-­‐way	   junction	  ('chicken	   foot'),	  while	   recombination-­‐mediated	   template	   switching	   involves	  D-­‐loop	   formation.	  b)	   Post-­‐translational	  modifications	   of	   PCNA	   and	   enzymes	   that	   carry	   out	   the	   modifications.	   During	   S-­‐phase,	   S.	   cerevisiae	   PCNA	   is	  SUMOylated	   at	   Lys164	   (yellow	   star),	  which	   recruits	   the	   helicase	   Srs2	   to	   inhibit	   homologous	   recombination	   during	  normal	  replication.	  Although	  SUMOylation	  is	  reversible,	  deSUMOylation	  of	  PCNA	  has	  not	  been	  documented	  thus	  far.	  Upon	  induction	  of	  DNA	  damage,	  PCNA	  is	  ubiquitinated	  at	  Lys164.	  Monoubiquitinated	  PCNA	  facilitates	  recruitment	  of	  TLS	   polymerases	   and	   therefore	   lesion	   bypass,	   while	   Lys63-­‐linked	   polyubiquitylation	   of	   PCNA	   is	   associated	   with	  template	   switching.	   Rad6	   and	   Ubc13-­‐Mms2	   are	   E2	   ubiquitin-­‐conjugating	   enzymes,	   while	   Rad18	   and	   Rad5	   are	   E3	  ubiquitin	  ligases.	  Usp1	  together	  with	  Uaf1	  is	  a	  deubiquitinating	  enzyme	  (from	  Chang	  and	  Cimprich,	  2009	  [39]).	  	  
Replication	  factor	  C	  complexes	  Loading	  of	  PCNA	  onto	  the	  DNA	  at	   the	  3'	  end	  of	  a	  primer	  template	   junction	  or	  onto	  nicked	  DNA	  is	  promoted	  by	  the	  canonical	  replication	  factor	  C	  (RFC)	  complex.	  RFC	  is	  an	  essential	  hetero-­‐pentamer,	  which	  is	  comprised	  of	  five	  AAA+	  ATPase	  subunits:	  one	  large	  subunit,	  RFC1,	  and	  four	  small	   subunits	  RFC2-­‐5.	  Together	   they	  mediate	  ATP-­‐dependent	  binding	   to	  PCNA,	   ring	  opening,	  insertion	  of	  suitable	  DNA	  and	  subsequent	  ring	  closing	  [40,	  41].	  Upon	  ATP	  hydrolysis,	  RFC	  ejects	  PCNA,	   leaving	   it	  on	  the	  DNA	  in	  closed	  form	  [42,	  43].	  PCNA	  loading	  is	  required	  at	  each	  Okazaki	  fragment,	  it	  thus	  seems	  reasonable	  to	  assume	  that	  continuous	  recycling	  of	  PCNA	  is	  necessary	  for	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Fig.4:	   Known	   functions	   of	   replication	  
factor	   C	   (RFC)	   and	   replication	   factor	   C-­‐
like	   (aRFC)	   complexes.	   Summary	   of	  activities	  of	   in	  vitro	   loading	  and	  unloading	  data,	  which	  were	  derived	  from	  Bylund	  and	  Burgers	   2005,	   Majka	   and	   Burgers	   2003	  (modified	  from	  Kubota	  et	  al.	  2013	  [51]).	  	  
ATAD5-­‐RLC	  &	  ELG1-­‐RLC	  Elg1	   was	   first	   identified	   in	   yeast	   genomic	   screens	   as	   an	   important	   factor	   for	   the	  maintenance	  of	  genome	  integrity	  (hence,	   it	  was	  named	  enhanced	  levels	  of	  genome	  instability).	  Elg1	   knock-­‐out	   strains	   display,	   among	   other	   phenotypes,	   DNA	   damage	   sensitivity,	   gross	  chromosomal	   rearrangements,	   chromosome	   maintenance	   defects,	   replication	   defects,	  spontaneous	   DNA	   damage,	   enhanced	   homologous	   recombination	   events	   and	   elongated	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telomeres	   [52-­‐55].	   Yeast	   Δelg1	   mutants	   have	   been	   well	   characterized,	   displaying	   synthetic	  growth	  defects	  with	  genes	  involved	  in	  sister	  chromatid	  cohesion	  (such	  as	  the	  cohesin	  subunits	  and	  Ctf4	  that	   links	  replication	  and	  cohesion),	  checkpoint	  response	  (such	  as	  mec1	   (ATR),	  rad53	  (CHK2),	   chk1	   (CHK1),	   sgs1	   (WRN),	   rad24	   (RAD17),	   dpb11-­‐1	   (TopBP1)	   and	   dun1	   (CHEK2)),	  replication	  fork	  restart	  and	  homologous	  recombination	  (such	  as	  mutants	  of	  the	  rad52	  group	  and	  the	  nucleases	  mms4	   as	  well	   as	  mus81).	  Elg1	   seems	   to	  participate	   in	   sister	   chromatid	   cohesion	  together	   with	   the	   anti-­‐establishment	   complex	  Wpl1/Pds5	   [56]	   and	   a	  model	   was	   proposed	   in	  which	   Elg1-­‐RLC	   and	   Ctf18-­‐RLC	   promote	  momentary	   unloading	   and	   re-­‐loading	   of	   PCNA	  when	  replication	   forks	   encounter	   cohesin	   complexes	  on	   the	  DNA	   [57,	  58].	  However,	   this	  model	  was	  recently	   challenged	   by	   Kubota	   et	   al.,	   claiming	   a	   general	   genome-­‐wide	   PCNA	   unloading	   effect	  upon	  Okazaki	  fragment	  ligation	  on	  the	  lagging	  strand,	  rather	  than	  specific	  unloading	  at	  cohesion	  sites	   [59].	   Deletion	   of	   Elg1	   was	   also	   shown	   to	   increase	   telomere	   length,	   a	   phenotype	   that	   is	  dependent	  on	  telomerase	  activity	  and	  PCNA	  modification	  at	  K164	  and	  K127.	  Furthermore,	  Elg1	  mutants	   display	   hyper-­‐silencing	   at	   telomeres	   [55],	   a	   phenomenon	   termed	   'telomere	   position	  effect'	  (TPE).	  Similarly	  to	  yeast	  Elg1,	   loss	  of	  mammalian	  ATAD5	  causes	  genome	  instability,	  spontaneous	  DNA	   damage	   and	   increased	   levels	   of	   recombination.	   Homozygous	   deletion	   of	   the	   mouse	  homolog,	   FRAG1,	   leads	   to	   embryonic	   lethality	   but	   heterozygous	   mice	   display	   a	  haploinsufficiency	   phenotype	   with	   high	   levels	   of	   aneuploidy,	   apoptosis	   and	   predisposition	   to	  cancer	  [60,	  61].	  In	  human	  cells	  somatic	  mutations	  of	  ATAD5	  were	  observed	  in	  4.6%	  of	  sporadic	  endometrial	   tumors	   and	  micro-­‐deletions	   including	   ATAD5	   (located	   on	   chromosome	   17q11.2)	  were	   also	   associated	   with	   increased	   cancer	   incidence,	   suggesting	   that	   ATAD5	   is	   a	   tumor	  suppressor	  [60,	  62].	  	  Recently,	  both	  the	  yeast	  Elg1-­‐RLC	  and	  the	  human	  ATAD5-­‐RLC	  were	  proposed	  to	  function	  as	  major	  PCNA	  unloaders	  during	  normal	  replication	  [49,	  50].	  It	  was	  shown	  that	  unmodified	  as	  well	  as	  SUMOylated	  and	  ubiquitylated	  PCNA	  accumulates	  on	  DNA	  in	  elg1	  deletion	  mutants	  during	  S-­‐phase.	  'Ex-­‐vivo'	  experiments	  with	  immunopurified	  Elg1-­‐RLC	  proved	  that	  the	  complex	  was	  able	  to	  promote	  PCNA	  unloading	  from	  chromatin,	  which	  was	  isolated	  from	  an	  elg1	  mutant	  strain	  [49].	  Similarly,	  depletion	  of	  ATAD5	   in	  human	  cells	   increases	   the	  amount	  of	  PCNA	  and	  ubiquitylated	  PCNA	   on	   chromatin	   and	   also	   extends	   the	   intensity	   and	   lifespan	   of	   PCNA	   foci	   in	   replication	  factories	  [50].	  Interestingly,	  ATAD5	  interacts	  with	  the	  UAF1-­‐USP1	  complex,	  which	  is	  responsible	  for	   the	   deubiquitylation	   of	   PCNA	   and	   FANCD2,	   a	   crucial	   factor	   for	   interstrand	   crosslink	   (ICL)	  repair	   [63].	   ATAD5	   may	   thus	   promote	   not	   only	   the	   unloading	   of	   ubiquitylated	   PCNA	   from	  chromatin	  but	  also	  its	  deubiquitylation	  mediated	  by	  the	  UAF1-­‐USP1	  complex.	  On	  the	  other	  hand,	  ubiquitylation	  of	  FANCD2	  was	  not	  affected	  by	  ATAD5	  knock-­‐down,	  suggesting	  that	  ATAD5	  is	  not	  directly	  involved	  in	  ICL	  repair.	  Due	  to	  its	  interaction	  with	  PCNA	  that	  is	  mediated	  by	  a	  conserved	  PCNA-­‐interaction-­‐peptide	  (PIP),	  it	  is	  not	  surprising	  that	  ATAD5	  travels	  with	  the	  replication	  fork	  [64].	  However,	  it	  seems	  that	  ATAD5	  is	  not	  directly	  involved	  in	  replication,	  since	  no	  reduction	  in	  global	  replication	  fork	  speed	  or	  checkpoint	  activation	  was	  observed,	  merely	  a	  slight	  delay	  in	  S-­‐phase	  progression	  [49,	  50].	  While	  ATAD5/Elg1	  does	  not	  contribute	  directly	  to	  Okazaki	  fragment	  maturation,	  novel	  evidence	  suggests	  that	  yeast	  Elg1-­‐RLC	  is	  involved	  in	  genome-­‐wide	  replication-­‐coupled	  unloading	  of	  PCNA	  after	  Okazaki	  fragments	  have	  been	  successfully	  ligated	  by	  the	  Cdc9	  ligase	   [59].	  Nevertheless,	  Elg1/ATAD5-­‐RLC	  does	  not	  seem	  to	  be	   the	  only	   factor	  able	   to	  unload	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Fig.5:	   The	   Elg1-­‐RFC2-­‐5	   complex	   unloads	   PCNA	  
following	   Okazaki	   fragment	   ligation.	   Schematic	  depiction	   of	   PCNA	   trimer	   during	   replication	   of	   the	  leading	   and	   the	   lagging	   strand.	   The	   Elg1-­‐RLC	   is	  responsible	   for	   PCNA	   unloading	   after	   successful	  ligation	  	  of	  Okazaki	  fragment	  by	  the	  Cdc9	  ligase	  on	  a	  genome-­‐wide	   level	   (modified	   from	   Kubota	   et	   al.	  2015	  [59]).	  
	  Despite	   these	   recent	   advances	   in	   the	   field,	   in	   vitro	   assays,	   which	  would	   provide	   genuine	  evidence	  that	   the	  Elg1-­‐RLC/ATAD5-­‐RLC	  complexes	  have	  enzymatic	  activity	   in	  unloading	  PCNA	  from	  chromatin,	  are	  still	  lacking.	  The	  reason	  for	  this	  may	  be	  missing	  essential	  yet	  unknown	  co-­‐factors	  or	  posttranslational	  modifications,	  or	  possibly	  redundancy	  with	  other	  clamp	  unloaders,	  such	  as	  CTF18-­‐RLC.	  Furthermore,	  it	  still	  remains	  enigmatic	  how	  unloading	  of	  PCNA	  or	  modified	  forms	  of	  PCNA	  contributes	  to	  genomic	  stability,	  since	  it	  does	  not	  seem	  to	  disturb	  replication	  and	  Okazaki	  fragment	  maturation	  per	  se.	  Novel	  results	  indicate	  that	  genome-­‐wide	  PCNA	  unloading	  is	  required	   to	   promote	   genome	   stability,	   rather	   than	   unloading	   at	   specific	   DNA	   structures	   and	  locations	  in	  the	  genome,	  such	  as	  DNA	  repair	  or	  cohesion	  sites	  [65].	  This	  may	  suggest	  that	  ATAD5	  is	   needed	   post-­‐replicatively	   to	   avoid	   recruitment	   of	   interaction	   partners	   that	   initiate	  inappropriate	  DNA	  repair	  or	  recombination	  events	  [58].	  Interestingly,	  Elg1	  was	  shown	  to	  interact	  preferentially	  with	  SUMOylated	  PCNA	  via	  its	  three	  N-­‐terminal	   SUMO-­‐interacting-­‐motifs	   (SIM)	  and	  PCNASUMO	  accumulates	  on	   the	   chromatin	   in	   the	  absence	  of	  Elg1	  [66].	  SUMO-­‐modified	  PCNA	  recruits	  the	  DNA	  helicase	  Srs2	  to	  replication	  forks,	  where	   it	   prevents	   unscheduled	   recombination	   events,	   as	   described	   earlier	   [34].	   Further,	  physical	  interactions	  were	  identified	  between	  Elg1	  and	  the	  SUMO	  E2	  Ubc9	  and	  with	  the	  SUMO-­‐Targeted	   Ubiquitin	   Ligase	   (STUbL)	   complex	   Slx5/Slx8,	   that	   selectively	   ubiquitylates	  (poly)SUMOylated	   proteins	   to	   mark	   them	   for	   degradation	   [67-­‐69].	   While	   SUMO	   has	   been	  proposed	  to	  act	  as	  a	  general	  'glue',	  holding	  together	  different	  components	  of	  the	  same	  pathway	  to	  coordinate	  enzyme	  activity	  [38],	  STUbL	  may	  then	  be	  recruited	  to	  these	  sites	  and	  specifically	  degrade	  SUMOylated	  factors,	  once	  repair	  is	  completed.	  	  
Replication	  stress	  The	  replication	  fork	  is	  a	  fragile	  structure,	  especially	  due	  to	  the	  generation	  of	  ssDNA	  during	  the	   process	   of	   helix	   unwinding.	   ssDNA	   is	   vulnerable	   to	   chemical	   and	   nucleophilic	   attack,	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formation	  of	  secondary	  structures	  (such	  as	  hairpins,	  triplexes,	  G-­‐quadruplexes,	  etc.)	  and	  binding	  of	   inappropriate	   factors.	   Physical	   replication	   blocks	   in	   the	   form	   of	   bulky	   DNA	   lesions	   or	  interstrand	  crosslinks,	  secondary	  DNA	  structures	  or	  protein-­‐DNA	  adducts,	  as	  well	  as	  deprivation	  of	  essential	  replication	  factors	  (such	  as	  nucleotides,	  replication	  machinery	  components,	  histones	  and	  histone	   chaperones)	   result	   in	   fork	   stalling	   [70].	  While	  MCM	  helicase	   continues	   to	  unwind	  the	  DNA	  it	  uncouples	  from	  the	  stalled	  replication	  fork,	  leading	  to	  the	  generation	  of	  long	  stretches	  of	  ssDNA	  [71,	  72].	  Eventually,	  forks	  may	  collapse,	  resulting	  in	  the	  formation	  of	  one-­‐ended	  double	  strand	   breaks	   (DSBs)	   [73,	   74].	  While	   replication	   barriers	  may	   be	   confined	   to	   only	   one	   strand	  (leading	   or	   lagging),	   resulting	   in	   strand	   uncoupling,	   imbalance	   or	   deprivation	   of	   replication	  factors	  will	  cause	  DNA	  synthesis	  to	  cease	  at	  both	  strands.	  SSBs	   and	   longer	   stretches	   of	   ssDNA	   are	   natural	   DNA	   repair	   intermediates	   and	   also	  transiently	  generated	  by	  topoisomerases.	  Encounters	  of	  an	  active	  replication	  fork	  with	  a	  SSB	  has	  been	  proposed	  to	  result	  in	  a	  'run	  off',	  where	  the	  replication	  machinery	  disassociates	  or	  runs	  off	  the	  DNA,	   consequently	   leading	   to	   the	   formation	   of	   a	   passive	  DSB	   [75].	   Another	   very	   common	  source	  of	  DNA	  damage	  is	  created	  by	  misincorporation	  of	  ribonucleotides	  (rNTPs)	  into	  the	  DNA	  that	   was	   shown	   to	   stall	   replicative	   polymerases	   [76].	   Topoisomerase	   I	   (TopoI)-­‐mediated	  processing	   of	   rNTPs	   causes	   accumulation	   of	   non-­‐ligatable	   nicks	   that	   in	   turn	   further	   increase	  replication	   stress	   [77,	   78].	   Additionally,	   collision	   of	   the	   replication	   machinery	   with	   ongoing	  transcription,	  for	  instance	  at	   'early	  replicating	  fragile	  sites'	  or	   'common	  fragile	  sites',	  can	  cause	  replication	  fork	  collapse	  [79].	  Topological	  stress,	  resulting	  from	  tethering	  of	  transcribed	  genes	  to	  the	  nuclear	  pore,	   can	   cause	   replication	   fork	   collapse	  even	  before	   replication	  and	   transcription	  machineries	   collide	   [80,	   81].	   Other	   factors	   that	   induce	   replication	   stress	   include	   DNA	  accessibility	  and	  activation	  of	  oncogenes,	  such	  as	  HRAS,	  MYC	  and	  cyclin	  E,	  possibly	  by	  increased	  origin	  firing	  and	  deprivation	  of	  the	  nucleotide	  pool	  [82-­‐85].	  	  	  
	  
Fig.6:	  Replication	  stress	  and	  its	  causes.	  A	  variety	  of	  conditions	  or	  obstacles	  can	  slow	  down	  or	  stall	  DNA	  replication	  forks.	   These	   include	   nucleotide	   shortage,	   certain	   DNA	   lesions,	   mis-­‐incorporated	   ribonucleotides,	   repetitive	   DNA	  elements,	   transcription	   complexes	   as	   well	   as	   RNA–DNA	   hybrids,	   secondary	   DNA	   structures,	   early-­‐replication	   or	  common	  fragile	  sites,	  and	  oncogene-­‐induced	  replication	  stress.	  Key	  resolution	  pathways	  are	  indicated	  in	  bold	  (from	  Zeman	  and	  Cimprich,	  2013	  [70]).	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GENOME	  INTEGRITY	  As	  mentioned	  earlier	   it	   is	   crucial	   to	  maintain	   the	   integrity	  of	   the	   genetic	   information,	  not	  only	   during	   replication,	   but	   throughout	   the	   entire	   lifetime	   of	   a	   cell.	   However,	   our	   DNA	   is	  constantly	  exposed	  to	  different	  types	  of	  exogenous	  and	  endogenous	  damaging	  agents,	   inducing	  tens	  of	  thousands	  of	  DNA	  lesions	  every	  day	  [86].	  If	  left	  unrepaired,	  these	  lesions	  can	  hamper	  or	  deregulate	   replication	   and	   transcription,	   cause	   gene	  mutations	   or	   loss	   of	   genetic	   information,	  which	  can	  ultimately	  lead	  to	  malignant	  transformation	  of	  a	  cell.	  In	  order	  to	  protect	  the	  genome	  from	  the	  deleterious	  effects	  of	   the	  various	   types	  of	  DNA	  damaging	  agents,	  a	  network	  of	   repair	  pathways	  has	  evolved	  [87].	  	  	  
DNA	  damage	  The	   DNA	   bases	   are	   highly	   vulnerable	   to	   chemical	  modifications,	   which	   can	   be	   converted	  into	  permanent	  mutations	  by	  means	  of	  faulty	  repair	  or	  replication	  errors.	  Very	  common	  types	  of	  DNA	   damage	   are	   induced	   by	   environmental	   sources,	   such	   as	   ultraviolet	   (UV)	   light,	   ionizing	  radiation	   (IR),	   chemicals	   or	   tobacco	   smoke	   [87].	   The	   three	   major	   forms	   of	   endogenous	   DNA	  damage	   are	   caused	   by	   spontaneous	   depurinations,	   deamination	   and	   cellular	   reactive	  metabolites.	   Spontaneous	   hydrolysis	   of	   the	   N-­‐glycosidic	   bond	   results	   in	   the	   formation	   of	   an	  abasic	  site,	  while	  single-­‐strand	  breaks	  (SSBs)	  and	  oxidations	  or	  alkylations	  of	  bases	  are	  induced	  by	   reactive	  oxygen	  and	  nitrogen	   species	   (ROS	  and	  RNS,	   respectively)	   or	  other	   toxic	  metabolic	  intermediates	  [88].	  	  Depending	   on	   the	   type	   of	   lesion	   its	   abundance	   and	   location,	   DNA	   injury	   can	   either	   be	  primarily	   mutagenic,	   cytotoxic	   or	   cytostatic.	   The	   consequences	   can	   also	   be	   diverse,	   causing	  cancer	   or	   other	   disease	   phenotypes,	   cell	   death	   or	   senescence.	   The	   genomic	   maintenance	  apparatus,	   consisting	   of	   DNA	   repair,	   damage	   tolerance	   and	   cell	   cycle	   checkpoint	   pathways,	  controls	  DNA	  damage	  and	  determines	  the	  fate	  of	  a	  cell	  [89,	  90].	  	  
DNA	  damage	  response	  Upon	  detection	  of	  DNA	  damage,	  cells	  evoke	  several	  pathways	  to	  stall	  the	  cell	  cycle	  to	  allow	  sufficient	   time	   for	   repair	   of	   the	   lesions.	   A	   permanent	   arrest	   of	   the	   cell	   cycle	   antagonizes	   the	  onset	   of	   cancer,	   since	   it	   prevents	   the	   accumulation	   of	   mutations	   and	   the	   subsequent	  transformation	  into	  malignant	  cells	  [87],	  but	  it	  is	  also	  associated	  with	  ageing.	  	  DNA	  damage	   response	   (DDR)	   is	   a	   complex	  network	  of	   pathways	   activated	   in	   response	   to	  DNA	   insults.	   In	   addition	   to	   signaling	   to	   recruit	   the	   DNA	   repair	   machinery,	   DDR	   may	   induce	  temporary	   cell	   cycle	   arrest,	   senescence	   or	   even	   cell	   death	   via	   apoptosis,	   depending	   on	   the	  damage	  status.	  Swift	  and	  precise	  signaling	  is	  required	  to	  organize	  a	  fine-­‐tuned	  and	  appropriate	  response	  to	  the	  specific	  type	  of	  DNA	  damage.	  	  	  
ATM	  and	  ATR	  The	  ataxia-­‐telangiectasia	  mutated	  (ATM)	  and	  ATM-­‐and-­‐Rad3-­‐related	  (ATR)	  kinases	  belong	  to	   the	  phosphatidyl-­‐inositol	  3-­‐kinase	  related	  kinase	  (PIKK)	   family	  and	  play	  a	  major	  role	   in	   the	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Fig.7:	   DNA	   damage	   response	   mediated	   by	   ATM	  
and	   ATR.	   ATM	   and	   ATR	   are	   DNA	   damage-­‐sensing	  kinases	   that	   activate	   the	   CHK1	   and	   CHK2	   protein	  kinases.	  CHK2	  in	  turn	  targets	  the	  CDC25	  phosphatase	  for	   its	  destruction	  or	   inhibition	  of	   its	  nuclear	   import.	  This	   prevents	   activation	   of	   the	   CDK/cyclin	   complex	  and	   therefore	   cell	   cycle	   progression	   and/or	   mitotic	  entry.	   Additionally,	   the	   CDKi	   p21Kip1	   is	   activated	   by	  p53	   and	   inhibits	   CDK	   activity	   (modified	   from	   De	  Veylder,	  Beeckman	  &	  Inzé,	  2007	  [98]).	  
	  
CHK1	  and	  CHK2	  Important	  substrates	  of	  ATM	  and	  ATR	  are	  the	  checkpoint	  kinases	  CHK2	  and	  CHK1,	  which	  play	  major	   roles	   in	   downstream	   signaling	   after	   DNA	   damage	   and	   replicative	   stress	   [99].	   The	  main	   function	   of	   these	   signal	   transducers	   is	   to	   propagate	   the	   DNA	   damage	   response	   and	  translate	   it	   into	   cell	   cycle	   regulation,	   DNA	   repair	   initiation	   or	   apoptosis.	   ATR-­‐dependent	  activation	  of	  CHK1	  allows	  phosphorylation	  of	  downstream	  targets,	  such	  as	  CDC25	  phosphatases	  [100]	   and	   is	   thus	   essential	   for	   cell	   cycle	   arrest	   in	   S	   and	   G2/M	   phases.	   Additionally,	   CHK1	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regulates	  replication	  dynamics,	  primarily	  by	  inhibiting	  origin	  firing	  [101].	  CHK2	  is	  preferentially	  phosphorylated	   by	   ATM	   in	   response	   to	   DSBs	   and	   triggers	   G1/S	   arrest	   and	   DNA	   repair	   by	  activating	  CDC25	  family	  members,	  p53	  and	  BRCA1	  [102,	  103].	  	  Inhibitors	  of	  ATR	  and	  CHK1	  are	  tested	  as	  possible	  therapeutics	  in	  cancer	  therapy	  due	  to	  a	  synthetic	  lethal	  interaction	  with	  oncogene-­‐induced	  replication	  stress	  or	  loss	  of	  p53	  [104,	  105].	  	  
Cell	  cycle	  arrest	  Upon	   detection	   of	   DNA	   damage	   through	   the	   above-­‐mentioned	   DDR,	   an	   arrest	   of	   the	   cell	  cycle	   is	   triggered	   at	   three	   checkpoints	   (G1/S,	   intra-­‐S	   and	   G2/M).	   This	   mediates	   a	   delayed	  transition	  into	  the	  next	  cell	  cycle	  phase	  and	  allows	  repair	  of	  the	  damaged	  sites.	  	  In	  G1,	  the	  active	  cyclinD/CDK4,6	  complex	  phosphorylates	  the	  retinoblastoma	  (RB)	  protein,	  which	  releases	  E2F	  [13,	  106,	  107],	  a	  transcription	  factor	  for	  cyclinE	  and	  CDC25A	  [102,	  108],	  to	  promote	   transition	   into	   S-­‐Phase.	   In	   response	   to	   high	   amounts	   of	   DNA	   damage,	   the	   tumor	  suppressor	   p53	   becomes	   activated	   by	   ATM-­‐mediated	   phosphorylation	   at	   Serine	   15.	  Downstream	   targets	   of	   p53	   are	   the	   CDK	   inhibitors	   p16INK4a	   and	   p21Cip1,	   which	   induce	   a	  permanent	  arrest	  of	  the	  cell	  cycle.	  Temporary	  arrest	  of	  the	  cell	  cycle	  before	  entering	  S-­‐phase	  is	  mediated	  through	  transient	  phosphorylation	  of	  CDC25A	  by	  CHK2/CHK1	  [109-­‐111].	  	  The	   intra-­‐S	   checkpoint	   is	   activated	   by	   both	   DNA	   damage	   and	   replication	   stress,	   mainly	  through	   the	  ATR-­‐CHK1	  pathway	   [112].	  CHK1-­‐mediated	  phosphorylation	  of	  CDC25A	  marks	   the	  checkpoint	  phosphatase	  for	  degradation.	  This	   leads	  to	  abolished	  activation	  of	  CDK1	  and	  CDK2,	  resulting	  in	  reduced	  origin	  firing	  and	  delayed	  progression	  into	  S-­‐phase	  [113,	  114].	  The	   G2/M	   checkpoint	   prevents	  mitotic	   entry	   in	   response	   to	   DNA	   damage,	   that	   remained	  undetected	  upon	   completion	   of	   S-­‐phase,	   or	   that	   occured	  during	   the	  G2	  phase	   of	   the	   cell	   cycle	  [115].	   Dephosphorylation	   of	   cyclinB/CDK1	   by	   CDC25	   phosphatases	   usually	   activates	   the	  complex	  after	  faithful	  replication	  [116].	  In	  response	  to	  DNA	  damage,	  activation	  of	  cyclinB/CDK1	  is	   prevented	   mainly	   by	   CHK1-­‐mediated	   phosphorylation	   of	   CDC25	   [117].	   In	   parallel,	  stabilization	  of	  p53	  promotes	  transcription	  of	  CDK	  inhibitors	  and	  prevents	  the	  progression	  into	  mitosis.	  	  If	  the	  load	  of	  DNA	  damage	  is	  too	  high	  to	  cope	  with	  normal	  cellular	  functions,	  cells	  either	  die	  or	   induce	  a	  permanent	  arrest	  of	   the	  cell	  cycle,	  called	  senescence.	  Senescent	  cells	  are	  unable	   to	  replicate,	   however,	   they	   are	   still	   metabolically	   active	   and	   adopt	   an	   immunogenic	   phenotype.	  Apoptosis	  is	  a	  form	  of	  programmed	  cell	  death	  induced	  by	  the	  cell	  itself	  (intrinsic)	  or	  by	  extrinsic	  signals	  from	  other	  cells.	  It	  is	  a	  highly	  regulated	  and	  controlled	  process	  that	  differs	  from	  necrosis,	  which	  is	  a	  form	  of	  traumatic	  cell	  death	  resulting	  from	  massive	  cellular	  injury.	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Fig.8:	   Cell	   cycle	   checkpoints.	  The	   DNA	   damage,	   replication	  and	   spindle	   assembly	  checkpoints	   ensure	   integrity	   of	  the	  DNA	  during	  different	  phases	  of	   the	   cell	   cycle	   (from	   Chin	   and	  Yeong,	  2010	  [118]).	  	  
DNA	  repair	  Arrest	   of	   the	   cell	   cycle	   provides	   the	   cell	  with	   sufficient	   time	   to	   complete	  DNA	   repair	   and	  thus	   helps	   ensure	   the	   transmission	   of	   intact	   genetic	   information	   to	   the	   daughters.	   Several	  specialized	  DNA	  repair	  pathways	  take	  care	  of	  the	  various	  types	  of	  DNA	  lesions	  before	  they	  can	  be	   converted	   into	  mutations	   during	   replication.	   Base	   excision	   repair	   (BER)	   and	   single-­‐strand	  break	   repair	   (SSBR)	   are	   the	   most	   frequently	   used	   pathways	   in	   human	   cells	   to	   repair	   small	  alterations	  of	  DNA	  bases,	  such	  as	  oxidations	  and	  alkylations.	  Nucleotide	  excision	  repair	  (NER),	  on	  the	  other	  hand,	  removes	  gross	  distortions	  of	  the	  DNA	  double	  helix,	  such	  as	  bulky	  adducts	  and	  UV-­‐induced	  base-­‐dimers,	  by	  excising	  stretches	  of	  about	  30	  nucleotides	  surrounding	   the	   lesion.	  Homologous	  recombination	  (HR)	  and	  non-­‐homologous	  end	  joining	  (NHEJ)	  act	  in	  concert	  to	  take	  care	   of	   extremely	   cytotoxic	  DNA	  double-­‐strand	   breaks	   (DSBs)	   caused	   for	   instance	   by	   ionizing	  radiation,	  free	  radicals	  and	  chemicals,	  or	  as	  a	  consequence	  of	  replication	  stress.	  Mismatch	  repair	  (MMR)	   scans	   the	   newly	   synthesized	   DNA	   for	   inaccuracies	   and	   removes	   mismatched	   bases	  introduced	   by	   the	   replication	   machinery.	   DNA-­‐protein	   crosslinks	   are	   replication-­‐	   and	  transcription-­‐blocking	   lesions,	  which	  are	   repaired	  by	  dedicated	  proteases,	   such	  as	  yeast	  Wss1	  and	  mammalian	   Spartan	   (SPRTN,	  DVC1).	   Alternatively,	   depending	   on	   the	   type	   and	   size	   of	   the	  protein	   cross-­‐linked	   to	   DNA,	   tyrosyl-­‐DNA	   phosphodiesterases	   (TDP1/2)	   or	   the	   NER	   and	   HR	  pathways	  can	  eliminate	  these	  cytotoxic	  lesions.	  DNA	  repair	  mechanisms	  are	  discussed	  in	  detail	  in	  several	  comprehensive	  reviews	  [87,	  89,	  119-­‐121].	  	  Failure	   to	  maintain	   integrity	  of	   the	   genomic	  material	  due	   to	   errors	  or	   insufficiency	  of	   the	  DNA	   repair	   process	   may	   lead	   to	   accumulation	   of	   mutations,	   which	   fuel	   tumor	   progression.	  Furthermore,	  mutations	  in	  proteins	  involved	  in	  the	  above	  mentioned	  pathways	  may	  cause	  faulty	  DNA	   repair	   and	   have	   been	   linked	   to	   genomic	   instability	   syndromes	   with	   predisposition	   to	  various	   types	   of	   cancer	   and	   several	   other	   human	  diseases	   [122].	   Genomic	   instability	   has	   thus	  been	  included	  as	  a	  hallmark	  of	  cancer.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  INTRODUCTION	  
	  
	  _______________________________________________________________________________________________________________________________________	  26	  
	  
Fig.9:	   DNA	   damage,	   repair	  
mechanisms,	  and	  consequences.	  
a)	   DNA	   damaging	   agents	   induce	  specific	   lesions	   that	   are	   repaired	  by	   dedicated	   repair	   mechanisms.	  
b)	   DNA	   damage	   causes	   cell	   cycle	  arrest,	   inhibition	   of	   DNA	  replication	   or	   permanent	  mutations.	   Abbreviations:	   cis-­‐Pt	  (cisplatin),	   MMC	   (mitomycin	   C);	  (6-­‐4)	   PP	   (6-­‐4	   photoproduct),	   CPD	  (cyclobutane	   pyrimidine	   dimer)	  (from	   Hoeijmakers	   et	   al.,	   2001	  [89]).	  	  
Base	  Excision	  Repair	  Small	  DNA	  modifications	  that	  frequently	  occur	  through	  oxidation,	  alkylation	  or	  deamination	  of	   the	  bases	  are	   repaired	  by	  base	  excision	   repair	   (BER).	  These	   lesions	  often	   cause	  only	  minor	  distortions	  of	  the	  DNA	  double	  helix	  structure,	  but	  they	  can	  be	  mutagenic	  or	   less	  stable,	  risking	  spontaneous	  base	  loss.	  BER	  acts	  across	  the	  entire	  genome	  and	  thus	  has	  to	  be	  a	  highly	  sensitive	  and	   coordinated	   process.	   The	   basic	   steps	   of	   BER	   include	   1)	   recognition	   and	   excision	   of	   the	  modified	   base	   by	   dedicated	   DNA	   glycosylases,	   2)	   incision	   of	   the	   abasic	   (AP)	   site,	   3)	   end	  processing	   by	   an	   endonuclease	   or	   lyase	   and	   4)	   polymerase-­‐mediated	   gap	   filling	   followed	   by	  ligation.	  	  Damage-­‐specific	  DNA	  glycosylases	  scan	  the	  DNA	  for	  modified	  bases	  as	  they	  move	  along	  the	  DNA	  double	  helix.	  To	  date,	  eleven	  human	  glycosylases	  have	  been	  identified,	  which	  display	  a	  wide	  range	  of	  substrate	  specificities	  and	  are	  subdivided	  into	  four	  distinct	  superfamilies;	  helix-­‐hairpin-­‐helix	   (HhH)	  glycosylases,	  uracil	  DNA	  glycosylases	   (UDGs),	  3-­‐methyl-­‐purine	  glycosylases	   (MPG)	  and	   endonuclease	   VIII-­‐like	   (NEIL)	   glycosylases	   [123].	   Many	   of	   these	   glycosylases	   have	  overlapping	  substrate	  specificities	  and	  are	  redundant,	  as	   indicated	  by	  the	  fact	  that	  mice	  with	  a	  single	  knockout	  of	  either	  of	   these	  glycosylases	  display	  mild	  phenotypes	   (with	   the	  exception	  of	  TDG),	  while	  double	  and	  triple	  knockout	  mice	  are	  often	  very	  sick	  [88,	  124,	  125].	  An	  amino	  acid	  side	  chain	  of	   the	  DNA	  glycosylase	  (e.g.	   in	  case	  of	  OGG1:	  Phe	  114	  and	  MYH:	  Tyr	  165)	   reaches	   into	   the	  minor	  groove	  of	   the	  DNA	  helix	  and	   is	  used	   to	   search	   for	  vulnerable	  sites,	  disrupting	  pairing	  of	  non-­‐Watson-­‐Crick	  bases	  pairs.	  The	  modified	  base	   is	   flipped	  out	  and	  extruded	  into	  the	  exo-­‐site	  of	  the	  enzyme.	  After	  verification	  of	  the	  base	  aberration	  it	  is	  passed	  on	  to	  the	  active	  site	  pocket	  where	  the	  N-­‐glycosidic	  bond	  between	  the	  base	  and	  the	  DNA	  backbone	  is	  cleaved,	  leaving	  behind	  an	  apurinic/apyrimidinic	  (AP)	  site	  [126].	  	  Monofunctional	  glycosylases,	  such	  as	  MYH,	  UNG,	  SMUG1,	  MBD4,	  TDG	  and	  MPG,	  remove	  the	  base	   by	   nucleophilic	   attack	   on	   the	   C1'	   of	   the	   sugar,	   using	   a	   deprotonated	   water	   molecule	   to	  cleave	   the	  N-­‐glycosidic	  bond.	  Further	  processing	  by	   the	  apurinic/apyrimidinic	  endonuclease	  1	  (APE1)	   is	   required	   for	  cleavage	  of	   the	  DNA	  sugar-­‐phosphate	  backbone	  at	   the	  AP	  site	   to	  create	  suitable	   DNA	   ends	   for	   subsequent	   repair	   steps,	   since	   the	   polymerase	   requires	   a	   3’	   hydroxyl	  (3'OH)	  group	  to	  be	  able	  to	  replace	  the	  excised	  nucleotide	  in	  a	  5’	  to	  3’	  direction.	  Additionally,	  a	  5’	  phosphate	   group	   (5'P)	   is	   needed	   to	   reconnect	   the	   DNA	   backbone	   and	   seal	   the	   break.	   These	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termini	  are	  generated	  by	  end-­‐processing	  enzymes	  such	  as	  polynucleotide	  kinase	  3’-­‐phosphatase	  (PNKP)	  [123].	  Bifunctional	  glycosylases,	  such	  as	  OGG1,	  NTH1,	  NEIL1,	  NEIL2	  and	  NEIL3,	  possess	  an	   intrinsic	   AP-­‐lyase	   activity	   that	   cleaves	   the	   sugar-­‐phosphate	   backbone	   via	   β−	   or	  βδ−elimination	   reactions.	   However,	   APE1	   and	   PNKP	   are	   still	   required	   to	   further	   process	   the	  ends	  in	  order	  to	  create	  suitable	  ends	  for	  the	  subsequent	  gap	  filling	  and	  ligation	  reactions	  [127].	  	  The	   majority	   of	   the	   glycosylases	   actually	   bind	   the	   newly	   generated	   AP-­‐site	   with	   higher	  affinity	   than	   the	  damaged	  base.	   This	  way	   they	  protect	   the	  noncoding	   and	   chemically	   unstable	  AP-­‐site	  until	  further	  processing	  is	  enabled	  by	  cleavage	  of	  the	  phosphodiester	  bond	  [128-­‐130].	  	  Replacement	  of	  the	  excised	  nucleotide(s)	  can	  be	  achieved	  by	  short-­‐patch	  (SP)	  or	  long-­‐patch	  (LP)	   repair.	   Mammalian	   cells	   predominantly	   use	   the	   SP	   pathway	   [88],	   which	   involves	   the	  replacement	   of	   a	   single	   nucleotide,	   primarily	   by	   DNA	   polymerase	   β	   (Polβ),	   and	   subsequent	  ligation	   by	   ligase	   IIIα	   (LigIIIα).	   The	   X-­‐ray	   repair	   cross-­‐complementing	   1	   (XRCC1)	   protein	   is	  crucial	  for	  BER,	  binding	  to	  the	  single-­‐strand	  break	  and	  acting	  as	  a	  scaffold	  protein	  to	  coordinate	  the	   downstream	   repair	   processes	   [131-­‐133].	   Long-­‐patch	  BER	   includes	   re-­‐synthesis	   of	   2	   to	   12	  nucleotides	   at	   the	   damage	   site	   and	   relies	   on	  Polβ	   for	   the	   incorporation	   of	   the	   first	   nucleotide	  [134].	   Then	   replicative	   polymerases	   Polδ	   or	   Polε	   together	   with	   PCNA	   and	   its	   loading	   factor	  (RFC)	   take	   over	   to	   complete	   the	   polymerization.	   The	   flap	   endonuclease	   1	   (FEN1)	   excises	   the	  displaced	   oligonucleotide	   and	   DNA	   ligase	   1	   (LigI)	   subsequently	   seals	   the	   nick.	   Due	   to	   the	  requirement	   for	   these	   factors,	   this	  pathway	   is	  predominantly	  active	   in	  proliferating	  cells	   [135,	  136].	  	  	  Oxidized	  bases	  are	  DNA	  lesions,	  which	  are	  mainly	  processed	  by	  the	  DNA	  glycosylase	  OGG1	  and	   endonuclease	   III	   (hNTH1).	   Both	   are	   bifunctional	   glycosylases,	   which	   carry	   an	   additional	  intrinsic	  3’	  AP	  lyase	  activity	  that	  enables	  them	  to	  cleave	  the	  DNA	  phosphodiester	  bond	  at	  the	  AP	  site	  independently	  of	  APE1.	  However,	  APE1	  is	  still	  required	  for	  processing	  of	  the	  blocked	  3’	  end	  to	  allow	  DNA	  synthesis	  over	  the	  gap	  by	  Polβ [41].	  MYH	  is	  a	  unusual	  glycosylase,	  that	  recognizes	  and	   excises	   an	   unmodified	   adenine	   (A),	   which	   has	   been	  mispaired	  with	   8-­‐oxoguanine	   due	   to	  misincorporation	  by	  replicative	  polymerases.	   It	   is	   thus	  also	   involved	   indirectly	   in	   the	  repair	  of	  oxidized	  bases.	  I	  would	  like	  to	  refer	  to	  the	  chapter	  'Damage	  prevention	  and	  base	  excision	  repair	  of	   8-­‐oxoguanine'	   of	   this	   thesis	   for	   a	   detailed	   description	   of	   OGG1-­‐	   and	   MYH-­‐mediated	   BER	  reactions	   and	   chapter	   'Oxidative	   stress	   and	  disease'	   for	   further	   information	  on	  oxidative	  DNA	  damage.	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Fig.10:	   Base	   lesions	   and	   base-­‐
excision	   repair.	   A)	   Base	   lesions:	  Common	   sites	   of	   oxidation	   (red	  arrow),	   alkylation	   (brown	   arrow)	  and	   spontaneous	   hydrolysis	   (blue	  arrow)	   on	   the	   different	   bases	   of	  the	   DNA:	   adenine,	   guanine,	  thymine	   and	   cytosine.	   B)	   Base-­‐Excision	   Repair:	   1	   to	   5	   major	  repair	  steps	  and	  involved	  enzymes	  as	  well	   as	   the	   enzymatic	   activities	  are	   indicated.	   (from	   Hanssen-­‐Bauer	  et	  al.,	  2012	  [137]).	  	  
Single-­‐Strand	  Break	  Repair	  Single-­‐strand	  break	  repair	  (SSBR)	  shares	  many	  properties	  with	  the	  BER	  pathway,	  differing	  only	  in	  the	  early	  damage	  recognition	  steps.	  While	  BER	  is	  initiated	  by	  recognition	  of	  a	  damaged	  base	   by	   dedicated	   DNA	   glycosylases,	   SSBs	   are	   bound	  with	   high	   affinity	   by	   an	   enzyme	   named	  poly(ADP-­‐Ribose)polymerase	  1	  (PARP1).	  Upon	  binding	  to	  DNA	  breaks,	  PARP1	  activity	  is	  rapidly	  stimulated	  more	   than	  500-­‐fold	  and	  catalyzes	   the	  synthesis	  of	   long	  chains	  of	  poly(ADP-­‐Ribose)	  (PAR)	   units	   on	   itself	   and	   other	   acceptor	   proteins.	   PARylation	   serves	   as	   a	   platform	   to	   recruit	  downstream	  repair	   factors,	  such	  as	   the	  scaffold	  protein	  XRCC1,	  and	  accelerates	  repair	  of	  SSBs,	  predominantly	   at	   early	   times	   following	   SSB	   induction.	   SSBs	   can	   arise	   either	   directly,	   e.g.	   as	   a	  consequence	   of	   oxidative	   DNA	   damage	   resulting	   in	   the	   disintegration	   of	   desoxyribose,	   or	  indirectly	   as	   transient	   intermediates	   of	   BER	   or	   other	   DNA	   repair	   actions.	   Especially	   in	   the	  context	   of	   'direct'	   SSBs	   that	   arise	   in	   the	   complex	   environment	   of	   chromatin,	   PARP1	   activity	  might	   be	   required	   as	   a	   dedicated	   'sensor'	   system	   to	   accelerate	   lesion	   detection	   and	   promote	  their	  efficient	  repair.	  However,	  a	  requirement	  of	  PARP1	  can	  also	  be	  anticipated	  for	  the	  repair	  of	  scheduled	  SSBs	  that	  become	  'uncoupled'	  from	  BER	  and	  possibly	  other	  repair	  pathways.	  A	  more	  detailed	   discussion	   of	   the	   properties	   of	   PARP1	   and	   other	   family	   members	   can	   be	   found	   in	  chapter	  'ADP-­‐Ribose	  Metabolism'	  of	  this	  thesis.	  After	  recognition	  of	  the	  SSB,	  end-­‐processing	  by	  APE1	  and/or	  RNKP	  is	  required	  to	  generate	  suitable	  ends	  (3'-­‐OH	  and	  5'P)	  for	  gap	  filling	  and	  subsequent	  ligation.	  DNA	  breaks	  that	  arise	  as	  a	  consequence	   of	   abortive	   Topoisomerase	   1	   (Top1)	   activity	   consist	   of	   3'-­‐	   and	   5'-­‐	   termini	  covalently	  attached	  to	  Top1	  and	  AMP,	  respectively.	  These	  lesions	  require	  additional	  processing	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by	   the	   tyrosyl-­‐DNA	   phosphodiesterase	   1	   (TDP1)	   as	   well	   as	   Aprataxin	   (APTX).	   RNaseH2-­‐mediated	  excision	  of	  ribonucleotides	  that	  have	  been	  misincorporated	  into	  the	  DNA	  results	  in	  the	  formation	  of	  5'-­‐ribonucleotide	  termini	  that	  might	  also	  require	  APTX	  activity.	  Gap	  filling	  by	  Polβ	  or	  Polδ/ε	  and	  subsequent	  ligation	  by	  LigIIIα	  or	  LigI	  is	  carried	  out	  in	  a	  similar	  fashion	  as	  during	  BER,	  and	  depends	  on	  short-­‐	  or	  long-­‐patch	  subpathway	  choice	  (reviewed	  in	  [138,	  139]).	  	  	  
Double-­‐Strand	  Break	  Repair	  DNA	   double-­‐strand	   breaks	   (DSBs)	   are	   highly	   cytotoxic	   lesions,	   because	   they	   can	   cause	  deleterious	  genomic	  rearrangements.	  Environmental	  factors,	  such	  as	  ionizing	  radiation	  (IR),	  but	  also	   endogenous	   factors,	   like	   reactive	   oxygen	   species	   (ROS)	   or	   cleavage	   by	   cellular	  endonucleases,	  can	  lead	  to	  the	  formation	  of	  DSBs.	  These	  so-­‐called	  two-­‐ended	  DSBs	  may	  trigger	  a	  different	   damage	   response	   as	   compared	   to	   the	   one-­‐ended	  DSBs	   generated	   by	   replication	   fork	  collapse.	  Homologous	  recombination	  (HR)	  and	  non-­‐homologous	  end-­‐joining	  (NHEJ)	  are	  the	  two	  major	  pathways	   that	   act	   to	   repair	  DSBs,	  while	   single-­‐strand	  annealing	   (SSA)	   is	   a	  minor	   repair	  pathway.	  HR	  is	  restricted	  to	  the	  S-­‐	  and	  G2-­‐phase	  of	  the	  cell	  cycle,	  since	  this	  pathway	  requires	  the	  presence	  of	  a	  sister	  chromatid	  for	  error-­‐free	  repair.	  NHEJ	  on	  the	  other	  hand	  is	  active	  throughout	  the	  cell	  cycle,	  but	  it	  is	  rather	  error	  prone	  [89,	  140,	  141].	  	  Phosphorylation	  of	  the	  histone	  H2AX	  (γH2AX)	  spreading	  rapidly	  away	  from	  the	  two-­‐ended	  DSB	   in	   both	   directions	   enables	   the	   recruitment	   of	  DSB	   response	   factors	   [142,	   143].	  MRN	   and	  ATM	   act	   in	   concert	   to	   phosphorylate	   H2AX	   upon	   sensing	   of	   two-­‐ended	   DSBs,	   while	  phosphorylation	  in	  response	  to	  replication	  stress	  is	  dependent	  on	  ATR	  [144].	  	  	  
	  
	  
Fig.11:	   DNA	   double-­‐strand	   break	   (DSB)	   repair	  
mechanisms.	   DSBs	   are	   predominantly	   repaired	   by	  NHEJ	  or	  HR.	  NHEJ	  is	  active	  throughout	  the	  cell	  cycle,	  but	  mainly	  during	  the	  G1	  and	  G2	  phases,	  whereas	  HR	  peaks	  in	  S	  phase	  when	  a	  sister	  chromatid	  is	  available.	  Rapid	   binding	   of	   the	   Ku70/80	   heterodimer	   to	   DNA	  ends	   promotes	   NHEJ	   by	   recruiting	   DNA-­‐PKcs.	   DNA	  ends	   are	   processed	   by	   Artemis,	   followed	   by	  religation	   mediated	   by	   XLF,	   Ligase	   IV	   (Lig4)	   and	  XRCC4.	   Alternatively,	   the	   MRN	   complex,	   which	  competes	   with	   Ku70/80	   for	   binding	   of	   the	   DSB,	  initiates	  resection	  together	  with	  CtIP	  to	  promote	  HR.	  The	   NHEJ	   factor	   53BP1	   antagonizes	   BRCA1	   in	   DSB	  resection.	   Further	   resection	   and	   subsequent	  formation	   of	   RPA-­‐coated	   ssDNA	   stimulates	   ATR	  activation.	  BRCA2	  together	  with	  PALB2	  mediates	  the	  displacement	   of	   RPA	   by	   RAD51,	   allowing	   strand	  invasion	   into	   the	   homologous	   DNA	   template	   and	  second	  end	  capture.	  This	   leads	  to	  the	   formation	  of	  a	  double	   Holliday	   junction,	   which	   is	   processed	   by	  resolvases.	  Finally,	  the	  DNA	  is	  sealed	  by	  ligases	  (from	  Hühn	  et	  al.,	  2013	  [145]).	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Homologous	  Recombination	  HR	   is	   an	   accurate	   DSB	   repair	   pathway	   that	   uses	   the	   homologous	   information	   on	   a	   sister	  chromatid	   as	   a	   template	   for	   repair	   and	   takes	   place	   in	   three	   core	   steps:	   1)	   end	   resection,	   2)	  strand	   invasion	   and	   3)	   resolution.	   The	   MRE11/RAD50/NBS1	   (MRN)	   complex	   initiates	   DSB	  repair	   by	   immediately	   binding	   the	   broken	   ends	   and	   inducing	   endonucleolytic	   cleavage	   of	   the	  DNA	  at	  some	  distance	  from	  the	  DSB	  [146,	  147].	  	  The	   initial	   end	   resection,	   called	   'end	   clipping',	   is	   promoted	   by	   the	   structure-­‐specific	  nucleases	  MRE11	   and	   CtIP,	   leading	   to	   the	   degradation	   of	   about	   20	   base	   pairs	   in	  mammalian	  cells.	   In	   a	   second	   step	   'extensive	   resection'	   is	   achieved	   by	   a	   set	   of	   different	   helicases	   and	  nucleases,	  such	  as	  DNA2,	  BLM,	  WRN,	  CtIP	  and	  EXO1.	  This	  ultimately	   leads	  to	  the	  generation	  of	  single-­‐stranded	  3'	  overhangs	  that	  can	  be	  several	  hundred	  base-­‐pairs	  long.	  The	  ssDNA	  is	  rapidly	  coated	  by	  RPA	  and	  subsequently	  BRCA2	  helps	  to	  replace	  RPA	  with	  the	  RecA	  type	  recombinase	  RAD51	  [148,	  149].	  RAD51	  is	  a	  DNA-­‐dependent	  ATPase	  that	  catalyzes	  strand	  invasion	  in	  search	  of	  a	  homologous	  sequence	  on	  the	  undamaged	  sister	  chromatid	  serving	  as	  a	  template	  for	  the	  DNA	  polymerase	  [150].	  Two	  DNA	  binding	  domains	  within	  RAD51	  mediate	  tethering	  of	  the	  resected	  3'	  ssDNA	  overhang	   to	   the	  donor	   sequence	  with	  minimal	  homology	  of	   approximately	  8	  bp,	  which	  likely	  become	  available	  through	  intrinsic	  'DNA	  breathing'	  especially	  at	  thermally	  more	  unstable	  AT-­‐rich	  regions.	  In	  vitro,	  cooperative	  sliding	  of	  the	  presynaptic	  nucleofilament	  within	  a	  range	  of	  60-­‐300	  bp	  on	  the	  dsDNA	  and	  'intersegmental	  contact	  sampling'	  of	  multiple	  DNA	  regions	  at	  the	  same	   time,	   are	   believed	   to	   mediate	   homology	   identification	   (reviewed	   in	   [151]).	   ChIP	  experiments	  of	  RAD51	  at	  various	  time	  points	  after	  DSB	  induction	  have	  revealed	  that	  homology	  probing	  favors	  intrachromosomal	  recombination	  and	  that	  homology	  search	  is	  mostly	  driven	  by	  spatial	  proximity	  in	  a	  three-­‐dimensional	  setting	  [152].	  In	  S,	  G2	  and	  M	  close	  proximity	  is	  given	  by	  the	  architecture	  of	  the	  replication	  fork,	  sister	  chromatid	  cohesion	  and	  alignment	  of	  homologous	  chromosomes,	   respectively.	   Transient	   chromatin	   opening,	   e.g.	   by	   nucleosome	   shifting	   or	  eviction,	  could	  accelerate	  homology	  probing	  at	  distal	  regions	  [153].	  This	  led	  to	  the	  postulation	  of	  an	   'accelerated	   random	   search	   model',	   stating	   that	   homology	   search	   is	   a	   random	   probing	  mechanism	  that	  is	  accelerated	  by	  simultaneous	  multiple	  contacts	  with	  different	  DNA	  segments,	  sliding	  of	  the	  RAD51-­‐DNA	  filament	  on	  the	  DNA	  and	  induced	  chromatin	  mobility	  [151].	  	  Upon	   invasion,	   a	   so-­‐called	   D-­‐loop	   structure	   is	   formed,	   which	   is	   composed	   of	   the	   ssDNA	  filament	   and	   the	   double	   stranded	   sister	   chromatid.	   The	   D-­‐loop	   is	   converted	   into	   a	   (double)	  Holiday	   junction	   (HJ)	   when	   both	   strands	   have	   paired	   with	   the	   homologous	   sequences	   [154].	  Different	   endonucleases	   resolve	   HJs,	   forming	   either	   crossover	   or	   non-­‐crossover	   products,	  depending	  on	  the	  endonucleolytic	  cleavage	  pattern	  [155,	  156].	  	  BRCA1	  and	  BRCA2	  are	  crucial	  for	  HR	  and	  frequently	  lost	  in	  breast	  cancer.	  While	  BRCA1	  is	  required	  for	  DNA	  end-­‐resection	  and	  the	  regulation	  of	  pathway	  choice,	  as	  well	  as	  recruitment	  of	  downstream	  DNA	  repair	  factors,	  BRCA2	  it	  mediates	  RAD51	  nucleofilament	  formation	  and	  strand	  exchange.	  The	  BRC	  domains	  of	  BRCA2	  are	  required	  to	  disrupt	  self-­‐assembled	  RAD51	  oligomers	  and	   promote	   loading	   of	   RAD51	   in	   monomeric	   form	   onto	   ssDNA.	   The	   C-­‐terminal	   domain	   of	  BRCA2	  promotes	  RAD51	  nucleofilament	  assembly	  and	  participates	  in	  strand	  invasion	  [157-­‐159].	  BRCA1/2	   mutant	   tumors	   display	   an	   obvious	   mutational	   spectrum	   (signature	   3)	   that	   is	  associated	   with	   elevated	   levels	   of	   large	   (longer	   than	   3	   bp)	   insertions	   and	   deletions	   with	  overlapping	  microhomology	  at	  breakpoints.	  Alternative	  non-­‐homologous	  end-­‐joining	  (alt-­‐NHEJ)	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and	   single-­‐strand	   annealing	   (SSA)	   may	   serve	   as	   backup	   pathways	   when	   HR	   is	   impaired	   and	  could	  explain	  this	  mutation	  signature	  [160,	  161].	  Another	   protein	   involved	   in	   HR	   is	   RAD54,	   an	   Snf2/Swi2	   helicase	   family	   member	   that	  stabilizes	  RAD51	  filaments	  with	  homologous	  DNA	  and	  increases	  the	  mobility	  of	  DSBs,	  possibly	  through	   nucleosome	   remodeling.	   Importantly,	   RAD54	   is	   also	   required	   for	   the	   coordinated	  removal	   of	   RAD51	   from	   ssDNA	   while	   extending	   the	   D-­‐loop	   to	   generate	   a	   template	   for	   HR-­‐associated	  DNA	  synthesis	   [162].	  Chromatin	  modifiers,	   such	  as	   INO80	  and	  SWI/SNF,	  as	  well	   as	  DDR	   mediators,	   like	   ATR,	   CHK2	   and	   53BP1,	   are	   likely	   important	   for	   increased	   chromatin	  dynamics	  upon	  DSB	   initiation	   [163,	  164].	   Interestingly,	  ChIP	   signals	  of	   yeast	  Rad51	  and	  γH2A	  overlap,	  suggesting	  that	  γH2AX	  does	  not	  spread	  in	  a	   linear	  fashion	  from	  the	  DSB	  as	  previously	  assumed	  [165].	  	  
Single	  strand	  annealing	  SSA	   is	  a	   subpathway	  of	  HR	   that	  utilizes	   the	  homologous	  sequences	  of	   the	  complementary	  strand	  for	  strand	  annealing,	  instead	  of	  a	  sister	  chromatid	  and	  therefore	  does	  not	  require	  a	  donor	  sequence.	   Upon	   recognition	   of	   the	  DSB	   by	   the	  MRN	   complex,	   extensive	   resection	   occurs	   until	  regions	  of	  homology	  are	  exposed	  on	  either	  side	  of	  the	  DSB.	  These	  homologous	  regions	  are	  then	  paired,	  the	  overhangs	  are	  removed	  and	  the	  ends	  ligated	  [120].	  Since	  the	  SSA	  mechanism	  causes	  loss	  of	  genetic	  material,	   it	   is	  highly	  error-­‐prone.	  In	  contrast	  to	  HR,	  SSA	  does	  not	  require	  strand	  invasion;	   the	   actions	   of	   BRCA2	   and	  RAD51	   are	   therefore	   dispensable	   for	   this	   repair	   pathway.	  Consequently,	   loss	   of	   the	   tumor	   suppressor	   gene	   BRCA2	   stimulates	   the	   use	   of	   SSA	   [166].	   In	  contrast,	   RAD52	   and	   Rad1-­‐Rad10	   (ERCC4-­‐ERCC10)	   are	   involved	   in	   SSA	   in	   mammalian	   cells	  [167]	  and	   thus	   loss	  of	  RAD52	   induced	  synthetic	   lethality	   in	  HR-­‐deficient	  cells	   (BRCA1,	  BRCA2,	  PALB2)	  [161].	  	  
	  
Non-­‐Homologous	  End	  Joining	  At	   times,	   when	   no	   sister	   chromatid	   is	   available,	   as	   during	   G0-­‐	   and	   G1-­‐phases	   of	   the	   cell	  cycle,	  NHEJ	  is	  the	  predominant	  repair	  pathway	  for	  two-­‐ended	  DSBs.	  It	  is	  tightly	  regulated	  due	  to	  its	  error-­‐prone	  nature,	  however,	  its	  activity	  is	  also	  necessary	  for	  biological	  processes,	  e.g.	  during	  V(D)J	   recombination	   and	   class	   switch	   recombination	   (CSR)	   as	   part	   of	   the	   immune	   response.	  Classical	  NHEJ	  (c-­‐NHEJ)	  is	  initiated	  by	  binding	  of	  the	  broken	  ends	  by	  the	  KU70/80	  heterodimer,	  which	  acts	  as	  a	   scaffold,	   recruiting	  DNA-­‐PK	  catalytic	   subunit	   (DNA-­‐PKcs)	   to	  build	   the	  DNA-­‐PK	  complex	   [168,	   169].	   Once	   activated,	   DNA-­‐PK	   phosphorylates	   itself,	   as	   well	   as	   other	   NHEJ	  proteins,	   and	   holds	   the	   broken	   DNA	   ends	   in	   close	   proximity.	   Several	   factors,	   such	   as	   MRN,	  Artemis,	  PNK	  and	  WRN,	  are	  involved	  in	  processing	  of	  the	  broken	  ends	  in	  order	  to	  generate	  blunt	  ends	   that	   are	   ready	   for	   ligation	   [170].	   Processing	   of	   the	   ends	  may	   lead	   to	   loss	   of	   nucleotides;	  NHEJ	  is	  therefore	  an	  error-­‐prone	  pathway.	  Finally,	  rejoining	  of	  the	  DNA	  ends	  is	  accomplished	  by	  XRCC4	  in	  conjunction	  with	  DNA	  ligase	  IV	  [171].	  	  Alternative	  NHEJ	  (alt-­‐NHEJ),	  also	  known	  as	  microhomology-­‐mediated	  end-­‐joining	  (MMEJ),	  is	  a	  less	  efficient	  pathway	  that	  takes	  place	  in	  the	  absence	  of	  KU70/80.	  It	  utilizes	  3-­‐16	  base	  pair	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homologies	  at	  the	  broken	  DNA	  ends	  in	  order	  to	  align	  them	  and	  enable	  re-­‐ligation	  by	  DNA	  ligase	  III	  [172,	  173].	  	  
Pathway	  choice	  The	  choice	  whether	  a	   cell	  uses	  HR	  or	  NHEJ	   to	   repair	   a	  DSB	   is	   tightly	   regulated.	  Cell	   cycle	  dependent	   expression,	   degradation	   and	   posttranslational	   modification	   of	   repair	   factors	   is	  important	  to	  suppress	  HR	  outside	  of	  S-­‐	  and	  G2	  phases	  when	  no	  sister	  chromatid	  is	  available	  for	  faithful	   repair.	   Upon	   DSB	   detection,	   the	   histone	   H2AX	   gets	   phosphorylated,	   marking	  nucleosomes	   over	   megabase	   regions	   flanking	   the	   break	   (however,	   not	   in	   a	   linear	   fashion),	  serving	  as	  a	  platform	  for	  recruitment	  of	  DNA	  signaling	  and	  repair	  proteins	  [174].	  	  A	  major	  determinant,	  dictating	  pathway	  choice	  and	  repair	  outcome,	   is	  DNA	  end-­‐resection.	  Binding	  of	  the	  NHEJ	  factors	  KU70/80	  at	  free	  DNA	  ends	  blocks	  access	  of	  the	  resection	  machinery	  and	  therefore	  inhibits	  HR.	  Similarly,	  53BP1	  prevents	  CtIP	  from	  accessing	  DNA	  ends	  and	  directs	  repair	   through	  canonical	  NHEJ	   (c-­‐NHEJ)	  by	   tethering	  broken	  DNA	  ends	   in	  close	  proximity	  and	  facilitating	   their	   ligation	   in	   a	   process	   termed	   'synapsis'	   [175].	   This	   end-­‐protecting	   function	   of	  53BP1	  depends	  on	  ATM-­‐mediated	  phosphorylation	  and	  promotes	  recruitment	  of	  RIF1,	  PTIP	  and	  the	   nuclease	   Artemis	   [176-­‐179].	   53BP1	   and	   RIF1	   further	   inhibit	   recruitment	   of	   BRCA1	  specifically	   in	  G1	   to	  avoid	  HR	  when	  no	   sister	   chromatid	   is	  present	   [180,	  181].	  Recently,	  REV7	  (also	  known	  as	  MAD2L2)	  was	  shown	  to	  promote	  c-­‐NHEJ	  downstream	  of	  RIF1	  by	  inhibiting	  5'-­‐3'	  end-­‐resection	  [182,	  183].	  Consequently,	  absence	  of	  these	  factors	  increases	  HR	  frequency	  or	  even	  restores	   HR	   in	   certain	   cases.	   This	   is	   important,	   especially	   for	   the	   selective	   treatment	   of	   HR-­‐deficient	   cells	  with	   PARP	   inhibitors,	   because	   restored	  HR	   function	  might	   induce	   resistance	   to	  these	  agents	  [184,	  185].	  	  Conversely,	  NHEJ	  can	  be	  inhibited	  by	  HR,	  for	  instance	  through	  clipping	  KU70/80	  from	  DNA	  ends	   by	  MRN	   and	   CtIP	   [141].	   S-­‐phase-­‐dependent	   phosphorylation	   of	  MRN	   complex	  members	  BRCA1,	   CtIP,	   EXO1	   and	  BLM	  by	   cyclin-­‐dependent	   kinases	   (CDKs)	   and	  ATM	  promotes	   efficient	  end	   resection	   [186,	   187].	   CtIP	   is	   central	   in	   this	   process:	   protein	   levels	   are	   upregulated	   upon	  progression	   through	   S/G2	   and	   CDK-­‐dependent	   phosphorlytion	   promotes	   complex	   formation	  between	   CtIP,	   MRN	   and	   BRCA1	   and	   activates	   resection	   [188,	   189].	   Other	   posttranslational	  modifications	   that	   regulate	   protein	   activity	   are	   acetylation,	   SUMOylation,	   neddylation	   and	  polyribosylation.	   RNF111/UBE2M-­‐dependent	   neddylation	   of	   BRCA1	   for	   instance	   inhibits	   end	  resection,	  while	  poly(ADP-­‐)ribosylation	  of	  BRCA1	  promotes	  resection	  and	  thus	  favors	  HR	  [190,	  191].	  Negative	  regulators	  of	  HR	  are	  helicases,	  such	  as	  Srs2,	  PARI,	  RECQL5,	  BLM,	  FANCJ	  and	  FBH1,	  which	  dismantle	  RAD51	  nucleofilaments	  in	  a	  process	  that	  requires	  ATP	  hydrolysis	  [23,	  35,	  160,	  192-­‐196].	   Additionally,	   D-­‐loops	   can	   be	   displaced	   by	   a	   subset	   of	   helicases,	   such	   as	   RTEL1	   and	  FANCM,	   thereby	   preventing	   crossover	   events	   and	   promoting	   synthesis-­‐dependent	   strand-­‐annealing	   (SDSA)	   [197-­‐199].	   The	   TLS	   polymerase	   Polυ	   also	   acts	   as	   an	   anti-­‐recombinase,	   by	  limiting	  the	  formation	  of	  RAD51	  nucleofilaments	  at	  a	  presynaptic	  step	  [160,	  192].	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Repair	  of	  one-­‐ended	  DSBs	  One-­‐ended	  DSBs	  can	  form	  either	  by	  a	  polymerase	  'run-­‐off'	  at	  a	  SSB,	  as	  discussed	  earlier,	  or	  by	   collapse	   of	   ssDNA	   exposed	   at	   stalled	   replication	   forks.	   Moreover,	   active	   cleavage	   of	   fork	  structures	  by	  endonucleases	  such	  as	  MUS81	  has	  been	  proposed	  to	  be	  required	  for	  fork	  collapse	  and	  leads	  to	  DSBs	  formation	  [200].	  The	  benefit	  of	  such	  an	  action	  could	  be	  to	  generate	  free	  DNA	  ends	  for	  HR-­‐mediated	  strand	  invasion	  and	  replication	  fork	  restart.	  	  Break-­‐induced	  replication	  (BIR)	  is	  the	  proposed	  mechanism	  for	  HR-­‐mediated	  repair	  of	  one-­‐ended	  DSBs	  [201]	  and	  starts	  with	  resection	  of	  the	  free	  DNA	  end,	  creating	  a	  3'	  ssDNA	  overhang.	  RAD51-­‐mediated	   strand	   invasion,	   D-­‐loop	   formation	   and	   eventually	   Holiday	   junction	   (HJ)	  resolution	   allow	   faithful	   repair.	   HR-­‐deficient	   cells	   are	   hypersensitive	   to	   replication	   stress,	   but	  also	   cells	  with	   a	  defect	   in	  NHEJ	  display	   sensitivity,	   implying	  NHEJ	   as	   a	  backup	  mechanism	   for	  replication-­‐dependent	  DSB	  repair	  [75].	  	  
	  
DNA	  damage	  bypass	  Tolerance	  of	  DNA	  lesions	  can	  be	  favored	  under	  certain	  circumstances,	  e.g.	  when	  the	  repair	  process	  would	  interfere	  with	  replication	  and	  cause	  fork	  collapse.	  In	  order	  to	  protect	  the	  genome,	  the	   lesion	   is	   bypassed	   and	   repaired	   later	   on.	   Translesion	   synthesis	   (TLS)	   allows	   replication	  through	   damaged	   sites	   due	   to	   specialized	   DNA	   polymerases,	   which	   have	   more	   flexible	   base	  pairing	  properties	  than	  replicative	  polymerases.	  Their	  active	  pocket	  is	  generally	  larger	  and	  can	  thus	   accommodate	   nucleotides	  with	   certain	  modifications.	   TLS	   polymerases	   are	   characterized	  by	  low	  fidelity,	  lack	  of	  a	  3'	  to	  5'	  exonuclease	  proofreading	  activity	  and	  poor	  processivity,	  as	  they	  incorporate	  only	  a	  very	  limited	  number	  of	  nucleotides.	  	  Arrest	  of	  replication	  at	  a	  lesion	  causes	  uncoupling	  of	  the	  helicase	  from	  the	  replication	  fork	  and	  ssDNA	  accumulation,	  which	   in	   turn	   leads	   to	  monoubiquitylation	  of	  PCNA	  at	   lysine	  164	  by	  the	   E2	   ubiquitin-­‐conjugating	   enzyme	   RAD6	   together	  with	   the	   E3	   ubiquitin	   ligase	   RAD18	   [31,	  202].	   Monoubiqutylation	   of	   PCNA	   serves	   as	   a	   signal	   to	   recruit	   TLS	   polymerases	   via	   direct	  interactions	  with	  the	  ubiquitin-­‐binding	  motif	  (UBM)	  or	  ubiquitin-­‐binding	  zinc	  (UBZ)	  domains	  of	  Y-­‐polymerase	   members	   [203,	   204].	   A	   number	   of	   different	   TLS	   polymerases	   with	   different	  substrate	   specificities	   have	   been	   identified.	   Polη	   is	   required	   for	   bypass	   of	   UV-­‐induced	  cyclobutane	  pyrimidine	  dimers	  [205],	  while	  Polβ	  and	  Polλ	  participate	  in	  the	  accurate	  bypass	  of	  the	  oxidative	  DNA	  lesion	  8-­‐oxoguanine.	  	  	  
Stabilization	  of	  replication	  forks	  Stalled	   replication	   forks	   can	  be	   stable	   for	   several	  hours	   in	   vivo	   [206,	  207],	   indicating	   that	  there	  are	  stabilizing	  factors,	  preventing	  fork	  collapse.	  	  The	   ATR/CHK1-­‐dependent	   S-­‐phase	   checkpoint	   control	   is	   induced	   upon	   RPA	   binding	   to	  ssDNA	   and	   prevents	   late	   origin	   firing	   [208].	   One	   theory	   of	   how	   the	   checkpoint	   stabilizes	  replication	   forks	   suggests	   that	   cell	   cycle	   retardation	   prevents	   continued	   helicase	   unwinding	  [209].	  Another,	  more	  accepted,	   theory	  assumes	   that	   it	   regulates	  HR-­‐mediated	   fork	  remodeling	  for	  which	  several	  models	  have	  been	  proposed.	  These	  are	  described	  here	  briefly	  [74,	  112].	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Template	   switching	  at	  a	   fork	  stalling	   lesion	   involves	  homology	  search	  and	   invasion	  of	   the	  sister	  chromatid	  in	  order	  to	  find	  an	  unperturbed	  template	  to	  continue	  DNA	  synthesis.	  Behind	  the	  lesion,	  the	  invading	  strand	  will	  flip	  back	  to	  its	  original	  template	  strand.	  Another	  model	  suggests	  fork	   reversal,	   characterized	   by	   regression	   of	   stalled	   forks	   and	   re-­‐annealing	   of	   the	   parental	  strands,	   to	   stabilize	   stalled	   forks.	   The	   two	   daughter	   strands	   will	   be	   displaced	   and	   annealed	  creating	   a	   four-­‐way	   junction	   termed	   'chicken-­‐foot'.	   New	   synthesis	   initiated	   at	   the	   daughter	  strands	  and	  branch	  migration	  or	   formation	  of	   a	  double	  HJ	  might	  be	   required	   for	   resolution	  of	  chicken-­‐foot	   structures.	   Helicases,	   especially	   of	   the	   RecQ	   family,	   have	   been	   suggested	   to	   be	  involved	  in	  fork	  stabilization	  and	  remodeling	  [210].	  	  
	  
	  
Fig.12:	  Mechanisms	  of	  replication	  fork	  restart	  and	  collapse.	  a)	  At	  a	  stalled	  replication	   fork	  ATR	  and	   its	  binding	  partner	   ATRIP	   are	   activated	   and	   ATR	   initiates	   a	   signaling	   cascade	   that	   is	   primarily	  mediated	   through	   the	   effector	  kinase	   Chk1.	   Chk1	   activation	   promotes	   fork	   stabilization	   and	   restart,	   while	   inhibiting	   cell	   cycle	   progression	   until	  replication	   is	   completed.	  b)	   Replication	   forks	   that	   are	   stalled	   due	   to	  DNA	   lesions	   (red	   star)	   can	   restart	   replication	  either	  by	  firing	  dormant	  origins,	  repriming	  replication	  behind	  the	  lesion,	  reversing	  the	  fork	  or	  activating	  DNA	  damage	  tolerance	   pathways.	   Key	   intermediates	   are	   illustrated.	   c)	   If	   stalled	   forks	   are	   not	   properly	   stabilized,	   or	   persist	   for	  longer	  periods	  of	  time,	  replication	  forks	  may	  collapse.	  Several	  possibilities	  for	  replication	  fork	  collapse	  are	  presented	  here,	  including	  dissociation	  of	  components	  of	  the	  replisome,	  nucleolytic	  cleavage	  of	  a	  reversed	  or	  stalled	  fork	  (middle	  panels)	  by	  endonucleases	  or	  replication	  run-­‐off	  (modified	  from	  Zeman	  and	  Cimprich,	  2014	  [70]).	  	  	  
 
Replication	  fork	  restart	  Blocked	  replication	  forks	  still	  have	  access	  to	  intact	  replication	  machinery	  and	  synthesis	  may	  simply	   continue	   following	   bypass	   or	   repair	   of	   blocking	   lesions.	   It	   seems	   that	   re-­‐priming	   of	  replication	  is	  a	  common	  event	  on	  the	  lagging	  strand	  due	  to	  the	  constant	  availability	  of	  Okazaki	  fragments.	   Electron	   microscope	   imaging	   has	   revealed	   the	   presence	   of	   ssDNA	   gaps	   behind	  proceeding	   replication	   forks	   in	   both	   leading	   and	   lagging	   strands	  upon	   adduct	   formation	   [211,	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CANCER	  CELL	  METABOLISM	  Cancer	   cells	   are	   dependent	   on	   increased	   metabolic	   rates	   in	   order	   to	   provide	   energy	   to	  support	   the	   rapid	   proliferation	   and	   growth	   rates	   associated	   with	   malignant	   transformation.	  Deregulated	  cellular	  metabolism	  is	  thus	  a	  hallmark	  of	  cancer,	  causing	  increased	  metabolic	  stress	  and	   an	   accumulation	   of	   potentially	   toxic	  metabolic	   intermediates.	   Already	   in	   the	   early	   1900s	  Otto	  Warburg	   observed	   that	   cancer	   cells	   preferably	   use	   glycolysis	   and	   subsequent	   anaerobic	  lactic	   acid	   fermentation	   for	   energy	   production,	   instead	   of	   oxidative	   phosphorylation	   that	  requires	  molecular	  oxygen.	  This	  phenomenon	  was	  is	  thus	  termed	  'Warburg	  effect'.	  However,	  the	  exact	  causes	   for	   this	  metabolic	  switch	  are	  still	  not	   fully	  elucidated.	  Hypoxic	  conditions	   in	  solid	  tumors	  could	  create	  an	  environment	  where	  glycolysis	  is	  a	  necessary	  energy	  supplier.	  But	  even	  in	  conditions	  were	  oxygen	  is	  plentiful,	  glycolytic	  rates	  can	  be	  up	  to	  200-­‐fold	  higher	  in	  cancer	  cells,	  compared	   to	   normal	   tissue.	   Another	   advantage	   of	   using	   glycolysis	   instead	   of	   mitochondrial	  oxidative	  phosphorylation	  is	  the	  decreased	  risk	  of	  inducing	  oxidative	  stress	  through	  production	  of	  reactive	  oxygen	  species	  (ROS),	  which	  are	  generated	  as	  a	  consequence	  of	  electron	  leakage	  from	  the	   respiratory	   chain.	   In	   order	   to	   adapt	   to	   their	   altered	   redox	   state,	   cancer	   cells	   might	   thus	  switch	   their	  metabolism	   to	   glycolysis	   to	  minimize	   the	   endogenous	  production	  of	   toxic	   oxygen	  radicals.	   Glycolysis	   further	   provides	   useful	   intermediate	   metabolites	   that	   are	   necessary	   for	  nucleoside	   and	   amino	   acid	   production,	   which	   are	   required	   for	   proper	   replication	   and	  proliferation	  of	  fast-­‐growing	  cells	  [9].	  Nevertheless,	   elevated	   oxidative	   stress	   was	   observed	   in	   cancer	   cells,	   which	   demands	  adaptation	   to	   avoid	   adverse	   effects,	   such	   as	   oxidative	   damage	   to	   proteins,	   lipids	   and,	   most	  importantly,	  the	  DNA.	  Disturbing	  the	  cellular	  redox	  and	  ROS	  balance	  has	  therefore	  been	  shown	  to	   be	   a	   promising	   strategy	   for	   novel	   and	   more	   selective	   anti-­‐cancer	   treatments	   due	   to	   the	  increased	   dependence	   of	   those	   cells	   on	   the	   ROS	   stress	   response	   [8].	   Naturally,	   this	   includes	  protection	  from	  oxidative	  DNA	  injury	  by	  repair	  and	  prevention	  of	  this	  sort	  of	  damage.	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Fig.13:	  Enhanced	  ROS	  production	  and	  disturbed	  redox	  
balance	   in	   cancer	   cells.	   Due	   to	  metabolic	   abnormalities	  and	   oncogene	   activation,	   cancer	   cells	   exhibit	   increased	  production	   of	   ROS,	   which	   brings	   them	   closer	   to	   a	   toxic	  threshold	  of	  tolerable	  oxidative	  stress	  compared	  to	  normal	  cells.	   In	   order	   to	   cope	   with	   increased	   oxidative	   stress,	  cancer	  cells	  have	  to	  adapt,	  which	  they	  do	  by	  shifting	  their	  redox	  dynamics	  by	  upregulating	  their	  antioxidant	  capacity.	  Cancer	   cells	   are	   thus	  more	   dependent	   on	   the	   antioxidant	  system	  and	  more	  vulnerable	  to	  further	  insult	  by	  ROS.	  This	  phenotype	   may	   be	   exploited	   to	   constitute	   novel	   anti-­‐cancer	  therapy	  (from	  Trachootham	  et	  al.,	  2009	  [9]).	  	  
Oxidative	  stress	  and	  disease	  Reactive	  oxygen	  species	  are	  oxygen	  containing	  reactive	  chemical	  species	  with	  an	  unpaired	  electron,	   such	   as	   superoxide	   anions	   (O2-­‐),	   peroxide	   (O22-­‐),	   nitric	   oxide	   (NO),	   hydroxyl	   radicals	  (OH)	   or	   hydrogen	   peroxide	   (H2O2).	   They	   are	   essential	   for	   biological	   functions	   by	   regulating	  signal	   transduction,	   host	   defense,	   neurotransmission	   and	   vasodilatation	   [216].	   However,	  because	  free	  oxygen	  radicals	  are	  highly	  reactive	  with	  biomolecules,	  including	  proteins,	  lipids	  and	  the	  DNA,	  they	  also	  constitute	  a	  major	  threat	  to	  cellular	  integrity.	  H2O2	  has	  been	  proposed	  to	  play	  an	  important	  role	  in	  disease,	  since	  it	  easily	  diffuses	  through	  biological	  membranes	  [217].	  ROS	  are	  produced	  by	  environmental	  mutagens	  such	  as	   ionizing	  radiation,	  ultraviolet	   light,	  chemotherapeutic	   drugs	   or	   heavy	   metals,	   but	   also	   arise	   from	   normal	   cellular	   metabolism,	   as	  mentioned	   earlier.	   Electron	   leakage	   from	   the	   mitochondrial	   respiratory	   chain,	   β-­‐oxidation	   in	  peroxisomes,	   inflammation,	   prostaglandin	   synthesis	   and	   cytochrome	   P450	   detoxification	  reactions	   are	   just	   a	   few	   examples	   of	   endogenous	   processes	   generating	   oxygen	   radicals	   [218,	  219].	   Aerobic	   organisms	   rely	   on	   oxidative	   phosphorylation	   to	   produce	   energy	   in	   the	   form	   of	  ATP.	  During	  this	  process,	  an	  electron	  is	  transferred	  to	  molecular	  oxygen,	  transiently	  producing	  superoxide	   anion	   radicals.	   The	   cytochrome	   oxidase	   complex	   in	   the	   mitochondrial	   membrane	  then	  ensures	  detoxification	  of	  the	  reactive	  oxygen	  radical	  by	  pairing	  it	  with	  two	  hydrogen	  atoms,	  generating	  a	  water	  molecule.	  However,	  approximately	  1	  -­‐	  5	  %	  of	  the	  electrons	  escape	  from	  the	  electron	   transport	   chain	   complexes	   and	   lead	   to	   the	   formation	   of	   intracellular	  ROS	   [220,	   221].	  The	   exceptionally	   high	   growth	   and	   metabolic	   rates	   of	   cancer	   cells	   correlate	   with	   elevated	  production	  of	  oxygen	  radicals	  and	  have	  been	  associated	  with	  increased	  levels	  of	  oxidative	  stress	  [9].	   A	  variety	  of	  defense	  mechanisms	  have	  evolved	  to	  combat	  the	  harmful	  effects	  of	  intracellular	  ROS.	   However,	   despite	   the	   activity	   of	   detoxifying	   enzymes	   and	   low	   molecular	   weight	  antioxidants,	  oxidative	  DNA	  lesions	  occur	  quite	  frequently	  [222].	  They	  represent	  a	  major	  threat	  not	   only	   causing	   mutagenesis	   and	   carcinogenesis,	   but	   also	   neurodegenerative	   disease	   and	  ageing	   [223-­‐225].	   Increased	   ROS	   production	   is	   frequently	   observed	   in	   cancer	   cells	   at	   an	  advanced	  disease	  stage,	  caused	  by	  an	  activation	  of	  oncogenes	  (such	  as	  Ras,	  Bcr-­‐Abl	  and	  c-­‐Myc),	  aberrant	   metabolism,	   mitochondrial	   dysfunction	   and	   loss	   of	   p53	   activity	   [226,	   227].	   Genetic	  instability	   thus	  drives	   increased	  ROS	  generation,	  which	   in	   turn	   causes	   further	  mutations.	  This	  'vicious	  circle'	  is	  self-­‐potentiating	  and	  promotes	  cancer	  development	  [228].	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Fig.14:	   Oxidative	   stress	   and	   its	   consequences	   for	  
tumor	   development.	   Excessive	   intracellular	   ROS	  accumulation	   can	   induce	   lethal	   damage	   in	   cells	   that	  have	   inadequate	   stress	   response	   or	   adaptation	  mechanisms.	   Persistent	   oxidative	   stress	   may	   induce	  an	   adaptive	   response	   in	   cancer	   cells,	   such	   as	  activation	   of	   redox-­‐sensitive	   transcription	   factors	  (NF-­‐kB	   and	   Nrf2)	   promoting	   expression	   of	   ROS-­‐scavenging	   enzymes	   (superoxide	   dismutase	   and	  glutathione),	   elevated	   levels	   of	   pro-­‐survival	   factors	  (BCL2	  and	  MCL1),	  and	  inhibition	  of	  cell	  death	  factors	  (caspases).	   DNA	  mutations	   induced	   by	   RPS	   promote	  genomic	   instability,	   which	   provides	   an	   additional	  mechanism	  for	  stress	  adaptation.	  These	  events	  enable	  survival	   of	   cells	   with	   high	   levels	   of	   ROS	   (from	  Trachootham	  et	  al.,	  2009	  [9]).	  	  	  
Antioxidants	  Cancer	  cells	  have	  the	  ability	  to	  acquire	  adaptive	  mechanisms	  to	  counteract	  the	  toxic	  effects	  of	  elevated	  levels	  of	  ROS	  through	  increased	  genomic	  instability.	  High	  selective	  pressure	  enriches	  the	  population	  of	   cells	   that	  are	   capable	  of	   stress	  adaptation,	   for	   instance	  by	   induction	  of	  ROS-­‐scavenging	  systems,	  promotion	  of	  cell-­‐survival	  or	  DNA	  repair	  pathways	  [228].	  	  The	   three	   major	   groups	   of	   enzymatic	   antioxidants	   are	   superoxide	   dismutases	   (SOD),	  catalases	  and	  peroxidases.	  SOD1	  and	  SOD2	  initiate	  detoxification	  of	  superoxide	  anions	  into	  less	  toxic	  H2O2	  and	  O2	  [229].	  H2O2	  is	  further	  detoxified	  to	  water	  by	  catalases,	  which	  are	  localized	  in	  peroxisomes	   and	   cytosol.	   Similarly,	   glutathione	   peroxidases	   are	   able	   to	   reduce	   free	   H2O2	   to	  water	  via	  oxidation	  of	  a	  selenocysteine	  residue	  of	   two	  reduced	  monomeric	  glutathiones	  (GSH)	  by	  H2O2,	   leading	   to	   the	  production	  of	  a	  glutathione	  disulfide	   (GS-­‐SG)	  and	   two	  water	  molecules	  [229].	  	  Additionally	   to	   those	   enzymatic	  ROS-­‐detoxifiers,	   a	   number	   of	   non-­‐enzymatic	   antioxidants	  exist,	   including	   vitamins	   (e.g.	   A,	   C,	   E),	   organo-­‐sulfur	   components	   (e.g.	   glutathione),	   coenzyme	  Q10,	   enzyme-­‐bound	  minerals	   (e.g.	   zinc,	   selenium),	   carotenoids,	   nitrogen	   compounds	   (e.g.	   uric	  acid),	  phenolic	  acids	  and	  flavonoids	  [230].	  Redox	  adaptation	  also	   involves	   activation	  of	   redox-­‐sensitive	   transcription	   factors,	   such	  as	  NF-­‐κB,	   Nrf2,	   c-­‐Jun	   and	   HIF-­‐1,	   which	   among	   others	   drive	   expression	   of	   the	   antioxidants	   SOD,	  catalase,	   thioredoxin	   and	   glutathione	   (GSH).	   Other	   transcription	   factors	   sensitive	   to	   redox	  imbalances	  induce	  the	  expression	  of	  cell-­‐survival	  molecules,	  such	  as	  anti-­‐apoptotic	  BCL2	  family	  members	  and	  proteins	  involved	  in	  the	  AKT	  survival	  pathway.	  Due	   to	   the	   elevated	   ROS	   production	   and	   altered	   redox	   states,	   cancer	   cells	   are	   likely	   in	   a	  state	  close	  to	  the	  cytotoxic	  threshold	  of	  oxidative	  stress.	  They	  are	  therefore	  more	  dependent	  on	  cellular	  antioxidants	  and	  oxidative	  stress-­‐evading	  systems	   than	  normal	  cells	  and	  consequently	  more	  vulnerable	  to	   further	  ROS	  insult.	  Exploiting	  this	  phenotype,	  which	   is	  shared	  among	  most	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cancers,	  to	  induce	  the	  preferential	  death	  of	  cancer	  cell	  was	  proposed	  already	  ten	  years	  ago	  as	  an	  anti-­‐cancer	  strategy	  and	  shown	  to	  be	  feasible	  in	  experimental	  systems	  [8,	  231,	  232].	  	  However,	  in	   order	   to	   achieve	   therapeutic	   selectivity	   and	   overcome	   drug	   resistance,	   it	   is	   important	   to	  induce	  oxidative	  stress	  and	  simultaneously	  abrogate	  the	  redox	  adaptation	  mechanisms	  of	  cancer	  cells	  [228].	  	  	  





Fig.15:	  Structure	  of	  base-­‐pairs	  containing	  guanine	  
(dG)	   and	   8-­‐oxoguanine	   (dOG).	   G	   normally	   base	  pairs	  with	  C,	  while	  T	  base	  pairs	  with	  A.	  8-­‐oxoguanine	  is	  generated	  by	  the	  addition	  of	  an	  oxo-­‐group	  at	  C8	  and	  a	  NH-­‐group	   at	   N7	   of	   G,	   facilitating	   base-­‐pairing	  with	  both	  C	   (anti-­‐configuration)	  and	  A	   (syn-­‐configuration)	  (from	  David	  et	  al.,	  2007	  [126]).	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8-­‐oxoguanine	  8-­‐oxoguanine	  (GO)	   is	   the	  best	  studied	  oxidative	  DNA	  lesion	  because	  of	   its	  high	  abundance,	  stability	  and	  mutagenicity.	  In	  normal	  cells	  roughly	  103	  lesions	  arise	  per	  cell	  per	  day	  under	  steady	  state	  conditions.	  This	  number	  of	   lesions	  can	  be	  two	  orders	  of	  magnitude	  higher	   in	  cancer	  cells	  and	  also	  serves	  as	  a	  good	  biomarker	  for	  oxidative	  stress	  [217,	  239,	  240].	  GO	   can	   base	   pair	   not	   only	   with	   cytosine,	   but	   also	   with	   adenine	   when	   it	   adopts	   a	   syn	  conformation.	  This	  Hoogsteen	  base	  pairing	  of	  GO(syn)/A(anti)	  is	  mediated	  by	  a	  hydrogen	  bridge	  bond	  between	  the	  hydrogen	  atom	  on	  N7	  and	  the	  oxo-­‐group	  on	  C6	  of	  the	  purine	  and	  specifically	  induces	   A:T	   à	   C:G	   transversions	   [241].	   Replicative	   polymerases	   efficiently	   bypass	   GO	   and	  preferentially	   incorporate	  A	  opposite	   them	  [242-­‐246].	  Base	  pairing	  of	  GO(anti)	  with	  C	   leads	   to	  distortions	  in	  the	  template	  strand	  and	  also	  in	  the	  polymerase.	  This	  prevents	  further	  interactions	  of	  the	  next	  template	  base	  with	  the	  pre-­‐insertion	  site	  of	  the	  polymerase,	  thus	  creating	  problems	  for	   the	   elongation	   from	   a	   GO/C	   pair	   [245].	   The	   geometry	   of	   a	   GO(syn)/A(anti)	   mispair	   in	   the	  minor	  groove	  mimics	  a	  T/A	  base	  pair	  without	  causing	  distortions.	  It	  is	  therefore	  not	  recognized	  by	  the	  proofreading	  activity	  of	  the	  polymerase	  and	  easily	  elongated.	  Nevertheless,	  bypass	  of	  GO	  was	   shown	   to	   be	   80%	   accurate	   in	   vivo	   [242].	   A	   polymerase	   switch	   from	   replicative	   TLS	  polymerases	  Polλ	  or	  Polη	  was	  shown	  to	  mediate	  correct	  bypass	  of	  GO.	  In	  the	  presence	  of	  PCNA	  and	   RPA,	   Polλ	   incorporates	   C	   with	   1200-­‐fold	   higher	   efficiency	   than	   A	   and	   polη	   with	   68-­‐fold	  higher	   efficiency	   [247-­‐250].	   However,	   some	   GO(syn)/A(anti)	   mispairs	   are	   formed	   in	   genomic	  DNA	   anyways	   and	   the	   misincorporated	   adenine	   is	   excised	   by	   the	   DNA	   glycosylase	   MYH	   to	  prevent	  G:C	  à	  T:A	  transversions.	  OGG1	  on	  the	  other	  hand	  is	  a	  glycosylase	  that	  removes	  GO	  that	  is	  base	  paired	  with	  a	  cytosine,	  thus	  preventing	  T:A	  à	  G:C	  transversions.	  Crucial	  for	  efficient	  sensing	  and	  removal	  of	  oxidative	  damage	  in	  nuclear	  and	  mitochondrial	  DNA	  is	  also	  the	  tumor	  suppressor	  p53.	  Loss	  of	  functional	  p53	  is	  associated	  with	  increased	  ROS,	  a	  disturbed	   redox	   balance	   and	   increased	   mutagenesis,	   which	   correlates	   with	   tumor	  aggressiveness	  and	  poor	  prognosis	  [251,	  252].	  	  	  
Damage	  prevention	  and	  base	  excision	  repair	  of	  8-­‐oxoguanine	  As	  mentioned	  earlier,	  base	  excision	  repair	  (BER)	  is	  involved	  in	  the	  repair	  of	  oxidative	  DNA	  lesions,	   such	   as	   8-­‐oxoguanine	   (GO).	   As	   a	   first	   line	   of	   defense,	   the	   hydrolase	   MTH1	   prevents	  incorporation	  of	  the	  oxidized	  nucleotide	  precursor	  8-­‐oxo-­‐dGTP	  into	  the	  DNA	  during	  replication	  by	  its	  degradation	  to	  8-­‐oxo-­‐dGMP	  [253].	  Oxidized	  guanines	  in	  the	  DNA	  that	  are	  paired	  with	  C	  are	  recognized	  by	  the	  glycosylase	  OGG1,	  followed	  by	  short-­‐patch	  BER	  with	  Polβ	  [254].	  MYH	  initiates	  repair	   of	   GO/A	  mispairs	   that	   are	   formed	  when	   GOs	   are	   not	   repaired	   before	   another	   round	   of	  replication	  and	  A	  is	  misincorporated	  opposite	  GO	  by	  a	  polymerase.	  Upon	  excision	  of	  the	  adenine	  and	  further	  processing	  by	  BER,	  the	  original	  GO/C	  mispair	  is	  regenerated	  [255],	  which	  now	  serves	  as	   a	   substrate	   for	   OGG1	   again.	   Polλ	   together	   with	   PCNA	   and	   RPA	   were	   shown	   to	   accurately	  participate	  in	  MYH-­‐initiated	  repair	  via	  long-­‐patch	  BER	  [255,	  256].	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Fig.16:	  MYH-­‐initiated	  BER	  of	  A:GO	   lesions.	  ROS	   can	  attack	  guanines	   in	   the	  DNA,	   leading	   to	   the	   formation	  of	  C:GO	  base	  pairs.	  Left:	  OGG1	  excises	  the	  GO	  and	  uses	  its	  lyase	  activity	  to	  incise	  the	  AP-­‐site	  by	  β-­‐elimination,	  which	  gives	  rise	  to	  a	  3′ddR5P	  and	  a	  5′P	  group.	  APE1	  removes	  the	  3′	  sugar	  phosphate,	  generating	  a	  1	  nucleotide	  gap	  with	  a	  3′OH	  and	  a	  5′P.	  Polβ	   then	   inserts	  a	  G	  opposite	   the	   templating	  C	   in	   this	  SP-­‐BER	  pathway.	  XRCC1/DNA	   ligase	   I	   ligate	   the	  DNA	  to	  restore	  an	  intact,	  correctly	  base-­‐paired	  DNA.	  Middle:	  If	  C:GO	  base	  pairs	  are	  not	  recognized	  prior	  to	  S-­‐phase	  by	  OGG1,	  or	  they	  arise	  through	  oxidation	  during	  S-­‐phase,	  the	  replicative	  polymerases	  will	  often	  mis-­‐incorporate	  an	  A	  opposite	  GO,	  giving	  rise	   to	  A:	  GO	  mispairs,	  which	  will	   lead	  to	  a	  CG→AT	  transversions,	   if	  not	  repaired	  before	  another	  round	  of	  replication.	  Right:	  MYH	  (MUTYH)	  recognizes	  A:GO	  base	  pairs	  and	  excises	  the	  wrong	  A.	  The	  resulting	  AP	  site	  is	  further	  processed	  by	  APE1,	  generating	  a	  1	  nt	  gap	  with	  3′OH	  and	  5′dRP	  moieties.	  	  Polλ	  incorporates	  the	  correct	  C	  opposite	  GO	  in	  collaboration	  with	  the	  cofactors	  PCNA	  and	  RPA	  and	  FEN1	  cleaves	  the	  5′	  flap.	  Finally,	  DNA	  ligase	  I	  seals	  the	  gap	  to	  yield	  an	  intact	  C:GO	  containing	  double-­‐stranded	  DNA,	  which	  is	  is	  then	  again	  substrate	  for	  OGG1-­‐mediated	  removal	  of	  the	  GO	  (modified	  from	  Markkanen	  et	  al.,	  2013	  [257]).	  	  
OGG1	  OGG1	  is	  a	  bifunctional	  glycosylase	  with	  an	  AP	  lyase	  activity	  that	  allows	  generation	  of	  DNA	  nicks	  via	  β-­‐elimination.	  However,	  the	  intrinsic	  lyase	  activity	  of	  OGG1	  is	  rather	  weak	  (half	  of	  the	  glycosylase	  activity	  and	  therefore	  rate	   limiting)	  and	  can	  be	  stimulated	  by	  the	  addition	  of	  APE1	  [128,	   258].	  Human	  OGG1	   represents	   the	   functional	   analog	   of	   the	   bacterial	   Fpg	   enzyme	   and	   is	  responsible	   for	   the	   excision	   of	   GO	   opposite	   C	   as	   well	   as	   the	   removal	   of	   other	   oxidized	  pyrimidines	  or	  ring-­‐fragmented	  purines,	  such	  as	  fapy-­‐G	  [259,	  260].	  	  While	   OGG1	   knock-­‐out	   in	   S.	   cerevisiae	   leads	   to	   mutagenesis	   in	   the	   form	   of	   G	   to	   T	  transversions,	   OGG1	   null	  mice	   have	   only	  mildly	   increased	  mutation	   rates	   and	   do	   not	   develop	  malignancies	  [261,	  262].	  This	  may	  be	  due	  to	  the	  activity	  of	  MYH,	  acting	  as	  a	  'backup'	  pathway	  to	  avoid	  mutations.	  However,	  MYH	  activity	  alone	  does	  not	  eliminate	  GO	  in	  the	  genome,	  it	  is	  thus	  not	  surprising	  to	  find	  elevated	  levels	  of	  GO	  in	  the	  DNA	  of	  OGG1	  knock-­‐out	  mice.	  Mutations	  in	  the	  human	  OGG1	  gene	  were	  identified	  in	  lung	  and	  kidney	  cancer;	  however,	  it	  is	  still	  unknown	  whether	  they	  contributed	  to	  cancer	  development	  [263-­‐265].	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MYH	  As	  guardian	  of	   the	  genome,	  MYH	  prevents	   the	  persistence	  of	  GO/A	  mispairs	  and	   therefore	  mutagenesis.	  Indeed,	  the	  levels	  of	  GO	  were	  increased	  in	  cells	  derived	  from	  MYH	  knock-­‐out	  mice	  [266]	   and	   enhanced	   spontaneous	  mutagenesis	   was	   observed	   in	  mouse	   embryonic	   fibroblasts	  (MEFs)	  [256,	  267].	  	  Mutations	  in	  MYH	  have	  been	  shown	  to	  be	  associated	  with	  a	  novel	  cancer	  syndrome	  named	  MYH-­‐associated	   polyposis	   (MAP)	   [268].	   Patients	   suffering	   from	   this	   disease	   show	   multiple	  colorectal	   adenomas	   and	   carcinomas,	   which	   display	   high	   proportions	   of	   somatic	   G:C	   to	   T:A	  transversions	  in	  their	  APC	  gene.	  This	  mutation	  footprint	  is	  characteristic	  for	  deficiency	  in	  mutY,	  the	   homolog	   of	   human	  MYH	   in	  E.	   coli.	   Heterozygous	  MYH	  missense	  mutations	  Tyr179Cys	   and	  Gly396Asp	   (referring	   to	   the	   longest	  MYH	   transcript	  NM_00128425.1)	  were	   identified	   in	   these	  patients	   and	   it	   was	   shown	   that	   corresponding	   mutations	   in	   E.	   coli	   mutY	   caused	   decreased	  activity	  of	  those	  mutants	  on	  GO/A	  and	  G/A	  substrates	  [268].	  Collectively,	   these	  results	   indicate	  that	  mutations	  in	  MYH	   lead	  to	  the	  G	  to	  T	  transversion	  signature	  in	  APC,	  which	  in	  turn	  caused	  a	  cancer	   phenotype	   that	   is	   similar	   to	   inherited	   familial	   adenomatous	   polyposis	   (FAP),	   a	   cancer	  caused	  by	  inherited	  APC	  gene	  mutations.	  	  The	   above-­‐mentioned	   missense	   variants	   Tyr179Cys	   and	   Gly396Asp	   include	   residues,	  involved	   in	   GO	   recognition	   [269,	   270].	   Other	   variants	   identified	   in	   MAP	   patients	   all	   showed	  defects	   in	   GO/A	   repair	   [271-­‐275].	   Germline	   mutations	   in	  MYH	   are	   inherited	   in	   an	   autosomal	  recessive	  manner	  and	  cause	  predominantly	  colorectal	  polyposis,	  possibly	  due	  to	  the	  exposure	  of	  the	  large	  bowel	  to	  high	  levels	  of	  oxidative	  stress.	  The	  APC	  gene	  is	  especially	  susceptible	  to	  G	  to	  T	  transversions	   that	   predominantly	   affect	   GAA	   sites	   in	   MAP	   patients	   [268]	   due	   to	   their	   high	  abundance	   in	  APC,	   which	   contains	   211.	   Furthermore,	   G	   to	   T	  mutations	   in	   GAA	   sites	   generate	  stop	  codons	  and	  therefore	  frequently	  lead	  to	  the	  inactivation	  of	  APC	  in	  the	  absence	  of	  MYH.	  Since	  defects	  in	  MYH	  ultimately	  cause	  APC	  mutations	  that	  are	  the	  underlying	  cause	  for	  the	  polyposis	  phenotype	   FAP,	   both	  MYH	   and	  APC	   genes	   need	   to	   be	   sequenced	   in	   order	   to	   provide	   the	   right	  prognosis	  and	  distinguish	  FAP	  from	  MAP.	  	  Posttranslational	  modifications	  were	  shown	  to	  affect	  the	  function	  of	  MYH.	  Shrimp	  alkaline	  phosphatase	   (SAP)	   treatment	   of	   native	   MYH	   present	   in	   human	   cell	   extracts	   decreased	   the	  activity	  of	  the	  protein,	  indicating	  that	  phosphorylation	  is	  crucial	  for	  proper	  MYH	  function	  [276].	  Similarly,	  human	  colorectal	  cancer	  cell	  extracts	  lacking	  MYH	  mutations	  but	  displaying	  defective	  GO/A	  repair	  showed	  enhanced	  repair	  efficiency	  upon	  treatment	  with	  protein	  kinase	  C	  or	  A	  (PKC	  or	  PKA)	  as	  well	  as	  casein	  kinase	  II	  [277].	  Ser524	  is	  located	  in	  the	  GO	  recognition	  domain	  within	  the	   PCNA	   binding	   region	   of	   MYH	   and	   can	   be	   phosphorylated	   [278].	   In	   addition	   to	  phosphorylation,	  MYH	  can	  undergo	  ubiquitylation	  by	  the	  E3	  ligase	  Mule	  in	  between	  amino	  acids	  475	  and	  535	  [279].	  	  	  
MTH1	  As	  mentioned	   earlier,	   free	   nucleotides	   are	   highly	   susceptible	   to	   oxidation	   by	   ROS,	   which	  underlines	   the	   necessity	   to	   sanitize	   the	   precursor	   pool	   to	   avoid	   incorporation	   of	   damaged	  nucleotides	   into	   DNA	   during	   replication.	   Several	   enzymes	   belonging	   to	   the	   Nucleoside	  
Diphosphatase	   linked	   to	  another	  moiety	  X	   (NUDIX)	   family	  are	  specialized	   to	  degrade	  oxidized	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nucleotides	  and	  control	  the	  intracellular	  levels	  of	  other	  potentially	  toxic	  metabolic	  intermediates	  and	  signaling	  compounds.	  They	  were	  thus	  described	  as	  ‘housecleaning’	  enzymes	  [280].	  The	  free	  nucleotide	   pool	   is	   especially	   susceptible	   to	   oxidation,	   as	   it	   is	   not	   protected	   by	   the	   complex	  chromatin	   structure	   like	   genomic	   DNA	   [281].	   In	   order	   to	   avoid	   spontaneous	   mutagenesis,	  prevention	  of	  DNA	  damage,	  through	  elimination	  of	  damaged	  nucleotides,	  may	  therefore	  be	  even	  more	  important	  and	  efficient	  than	  DNA	  repair	  itself.	  The	  first	  mammalian	  Nudix	  family	  member	  was	  named	  MutT	  homolog	  1	  (MTH1)	  because	  of	  its	   functional	   similarity	   to	   the	   E.	   coli	   MutT	   protein.	   MutT	   degrades	   the	   oxidized	   purine	  nucleotide	  triphosphates	  8-­‐oxo-­‐dGTP,	  2-­‐OH-­‐dATP	  and	  8-­‐oxo-­‐dATP	  to	  their	  monophosphates	  and	  PPi,	   preventing	   their	   incorporation	   into	   DNA	   [253]	   [236].	  MutT-­‐defective	  E.	   coli	   strains	   show	  100	   to	  10000-­‐fold	   increase	   in	  spontaneous	  G:C	   to	  T:A	   transversions,	  highlighting	   the	  essential	  role	  in	  removal	  of	  oxidized	  dATPs	  [282].	  The	  actions	  of	  OGG1	  and	  MYH,	  as	  well	  as	  their	  bacterial	  homologs,	  may	  attribute	  for	  the	  lack	  of	  G:C	  to	  T:A	  transversions	  induced	  by	  GO.	  The	  degradation	  product	  of	  MutT,	  8-­‐oxo-­‐dGMP,	  is	  not	  suitable	  for	  DNA	  synthesis,	  because	  the	  cellular	  guanylate	  kinase	  cannot	  utilize	  8-­‐oxo-­‐dG-­‐containing	  nucleotides	  as	  substrates	  [283].	  	  In	  human	  cells,	  seven	  different	  MTH1	  splice	  variants	  were	  identified	  that	  encode	  mainly	  an	  18	   kDa	   transcript,	   present	   predominantly	   in	   the	   cytoplasm	   and	   mitochondria.	   They	   display	  similar	   enzymatic	   activity	   towards	   8-­‐oxo-­‐(d)GTP,	   8-­‐oxo-­‐(d)ATP	   and	   2-­‐oxo-­‐(d)ATP,	   which	   has	  been	   shown	   to	   reduce	   H2O2-­‐induced	   mitochondrial	   dysfunction	   and	   cell	   death	   [216].	  Furthermore,	   Rai	   et	   al.	   reported	   that	   impaired	  MTH1	   expression	   induces	   cellular	   senescence,	  mainly	  through	  the	  p53	  tumor	  suppressor	  pathway	  and	  defects	  in	  DNA	  replication	  [236].	  MTH1-­‐null	  mice	   show	  a	  predisposition	   to	  develop	   tumors	   in	   lungs,	   liver	   and	   stomach	  and	   cells	   from	  these	  animals	  are	  sensitive	   to	  H2O2	   treatment	   [284].	  Furthermore,	   increased	  MTH1	  expression	  was	   observed	   in	   several	   tumors	   (kidney,	   lung	   and	   brain)	   and	   a	   polymorphic	   MTH1	   variant	  (V83M)	  has	  been	  associated	  with	  increased	  frequency	  of	  stomach	  cancer	  [285].	  Together,	  these	  observations	   indicate	   a	   crucial	   role	   of	   MTH1	   in	   preventing	   spontaneous	   mutagenesis	   and	  tumorigenesis	  caused	  by	  oxygen-­‐induced	  DNA	  damage	  [286].	  	  In	   2014,	   a	   novel	   MTH1	   inhibitor	   has	   been	   developed	   that	   seems	   to	   selectively	   eradicate	  cancer	  cells,	  while	  leaving	  normal	  cells	  unaffected	  [8,	  287].	  Inhibition	  of	  MTH1	  was	  suggested	  as	  a	   potential	   therapeutic	   approach	   to	   selectively	   target	   a	   broad	   range	   of	   tumors	   that	   rely	   on	  clearance	   of	   oxidized	   nucleotide	   precursors	   to	   prevent	   oxidative	   DNA	   damage,	   a	   concept	  referred	  to	  as	  'cancer	  phenotypic	  lethality'.	  MTH1	  was	  described	  as	  a	  'non-­‐oncogene	  addiction'	  target,	  because	  it	  is	  not	  a	  typical	  oncogene,	  but	  indispensable	  for	  cancer	  cell	  survival	  due	  to	  the	  necessity	   of	   cancer	   cells	   to	   adapt	   to	   enhanced	   intracellular	   oxidative	   stress	   and	   redox	  imbalances.	  The	  applicability	  of	  this	  approach	  in	  the	  clinic	  remains	  to	  be	  tested	  in	  the	  future.	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Fig.17:	   Mutagenesis	   induced	   by	  
oxidative	   DNA	   damage	   and	   its	  
repair	   mechanisms	   in	   mammalian	  
cells.	  8-­‐oxo-­‐dG	  and	  2-­‐oxo-­‐dA	  can	  form	  relatively	   stable	   base	   pairs	   with	   A	   or	  G,	  respectively.	  This	  can	  lead	  to	  A:T	  à	  C:G	   and	   G:C	   à	   T:A	   transversion	  mutations.	   MTH1	   effectively	  hydrolyzes	   2-­‐OH-­‐dATP	   and	   8-­‐oxo-­‐dGTP	   from	   the	   nucleotide	   precursor	  pool.	  The	  glycosylase	  OGG1	  excises	  8-­‐oxo-­‐dG	  and	  2-­‐oxo-­‐dA	  directly	  from	  the	  DNA,	   while	   MYH/MUTYH	   removes	   A	  that	   has	   been	   incorporated	   opposite	  8-­‐oxo-­‐dG	   in	   the	   template	   (from	  Tsuzuki	  et	  al.,	  2007	  [286]).	  
Other	  Nudix	  hydrolase	  family	  members	  	  Besides	   the	   above-­‐mentioned	  MTH1,	   21	   other	   hydrolases	   of	   the	   Nudix	   family	   have	   been	  identified	  with	   different	   substrate	   specificities.	  MTH2	   is	   also	   an	   8-­‐oxo-­‐dGTPase,	  which	   is	   less	  selective	   for	   oxidized	   nucleotides	   than	   MTH1	   and	   its	   expression	   in	   mutT-­‐deficient	   E.	   coli	  significantly	  reduces	  the	  spontaneous	  mutation	  frequency	  [288].	  In	  contrast	  to	  MTH1	  and	  MTH2,	  NUDT5	   is	   a	  Nudix	   enzyme	   that	   preferentially	   hydrolyzes	   the	  oxidized	   guanine	  diphosphate	  8-­‐oxo-­‐dGDP	  [289].	  8-­‐oxo-­‐dGTP-­‐induced	  mutation	  rates	  were	  shown	  to	  be	  significantly	   increased	  upon	  NUDT5	  depletion	  [241]	  and	  expression	  of	  NUDT5	  in	  mutT-­‐deficient	  E.	  coli	  mutant	  cells	  was	  sufficient	  to	  decrease	  the	  spontaneous	  mutation	  frequency	  to	  normal	  levels	  [289].	  The	  fact	  that	  8-­‐oxo-­‐dGTP	  and	  8-­‐oxo-­‐dGDP	  are	  interconvertible	  within	  the	  cell	  (through	  the	  actions	  of	  the	  nucleotide	  diphosphate	  kinase	  and	  the	  nucleotide	  triphosphatase)	  [289]	  explains	  the	  necessity	  to	  remove	  both	  oxidized	  nucleotides	  to	  efficiently	  eliminate	  all	  potentially	  harmful	  DNA	   precursors	   from	   the	   cell.	   The	   involvement	   of	   several	   proteins	   in	   clearance	   of	   oxidized	  nucleotides	   underscores	   the	   fundamental	   importance	   of	   avoiding	   oxidative	   DNA	   damage	   in	  eukaryotic	  cells.	  Furthermore,	  they	  prevent	  transcriptional	  errors	  and	  mistranslation	  of	  proteins	  by	  detoxifying	   the	  precursor	  pool	   to	  avoid	   incorporation	  of	  modified	  nucleotides	   into	   the	  RNA	  transcript	  [290].	  The	   catalytic	   reaction	   by	   NUDIX	   proteins	   is	   dependent	   on	   the	   conserved	   23-­‐amino	   acid	  motif	   (Nudix	   box),	   Gx5Ex5[UA]xREx2EExGU	   (U	   representing	   an	   aliphatic,	   hydrophobic	   residue)	  that	   is	   located	   in	   a	   loop-­‐helix-­‐loop	   structure.	   Conserved	  Glu	   residues	   in	   the	   core	   of	   the	  motif,	  REx2EE,	  are	  essential	   for	  binding	  of	  divalent	  cations	  (in	  most	  cases	  Mg2+)	   that	  are	  required	  for	  the	  enzymatic	  activity.	  Some	  NUDIX	  family	  members	  are	  known	  to	  degrade	  ADP-­‐sugars,	  such	  as	  ADP-­‐Ribose.	  Free	  ADPR	  mono-­‐	  and	  polymers	  constitute	  a	  major	  threat	  to	  cellular	  integrity	  due	  to	  their	  reactivity	  with	   proteins	   and	   the	   involvement	   in	   Ca2+-­‐signaling,	   and	   their	   clearance	   is	   important	   for	  balanced	  metabolism.	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Fig.18:	  Schematic	  presentation	  of	  the	  degradation	  
of	  deoxyribonucleotides	  containing	  8-­‐oxo-­‐dG	  from	  
the	   nucleotide	   precursor	   pool.	   8-­‐oxo-­‐dGTP	   and	   8-­‐oxo-­‐dGDP	   are	   interconvertible	   in	   the	   cell	   by	   the	  activity	  of	   the	  nucleoside	  diphosphate	  kinase	   (a)	  and	  nucleoside	  triphosphatase	  (b).	  Misincorporation	  of	  8-­‐oxo-­‐dGTP	  into	  the	  DNA	  during	  replication	  can	  lead	  to	  spontaneous	   mutations.	   MTH1	   hydrolyzes	   8-­‐oxo-­‐dGTP,	   while	   NUDT5	   degrades	   8-­‐oxo-­‐dGDP	   to	   8-­‐oxo-­‐dGMP,	   which	   is	   not	   suitable	   for	   DNA	   replication.	  MTH1	   is	   inhibited	   by	   8-­‐oxo-­‐dGDP,	   NUDT5	   therefore	  indirectly	  promotes	  the	  activity	  of	  MTH1	  by	  degrading	  its	  inhibitor	  (modified	  from	  Sanada	  et	  al.,	  2011	  [291]).	  	  	  	  
ADP-­‐RIBOSE	  METABOLISM	  ADP-­‐ribosylation	   is	   a	   posttranslational	   modification	   of	   proteins,	   which	   is	   of	   central	  importance	   for	   genomic	   stability	   [292]	   and	   a	   wide	   variety	   of	   other	   biological	   processes,	  including	   transcriptional	   regulation,	   [293],	   chromatin	   dynamics,	   centromere	   function	   [294],	  telomere	  length	  [295],	  cell	  cycle	  regulation	  and	  apoptosis	  [296].	  ADP-­‐ribosylation	  is	  carried	  out	  by	  ADP-­‐ribosyltransferases	  and	  a	  subclass	  of	  sirtuins	  (writers),	  sensed	  by	  proteins	  with	  specific	  binding	  modules	  (readers)	  and	  removed	  by	  ADP-­‐ribosylhydrolases	  (erasers)	  [297].	  	  	  
ADP-­‐Ribosylation	  (writers)	  Eighteen	  different	  human	  enzymes	  with	  ADP-­‐ribosylation	  activity	  have	  been	  identified	  thus	  far	   and	   a	  new	  nomenclature	  was	  proposed	  due	   to	   their	   differential	   activity	   in	  mono-­‐	   or	   poly-­‐ADP-­‐ribosylation	   (MARylation	   or	   PARylation):	   ADP-­‐ribosyltransferase	   Diphteria	   toxin-­‐like	  (ARTD)	  [298,	  299].	  However,	  for	  simplicity	  I	  will	  continue	  to	  make	  use	  of	  the	  old	  nomenclature	  for	   poly(ADP-­‐ribose)polymerases	   (PARPs)	   throughout	   this	   thesis.	   MARylated	   proteins	   are	  primarily	   found	  outside	   the	  nucleus,	  while	  PARylation	   is	  mostly	  observed	  on	  nuclear	  proteins,	  but	  both	  act	  as	  scaffolds	  for	  the	  recruitment	  of	  proteins	  during	  complex	  formation	  [300].	  	  Amongst	   poly-­‐ADP-­‐ribosyltransferases	   (PARP)	   family	   members,	   PARP1	   is	   the	   most	  abundant	  one	  sharing	  overlapping	  functions	  with	  the	  related	  protein	  PARP2	  in	  response	  to	  DNA	  damage.	  Other	  proteins	  with	  the	  ability	   to	  carry	  out	  PARylation	  are	   the	  tankyrases	  (TNKS1/2)	  involved	  in	  signaling,	  telomere	  length	  regulation	  and	  vesicle	  trafficking	  [301,	  302].	  Members	   of	   the	   prominent	   sirtuin	   (SIRT)	   family	   are	   mono-­‐ADP-­‐ribosyltransferases	  (MARTs)	   that	   transfer	  mono-­‐ADPR	   to	   histones	   [303,	   304]	   and	  may	  be	   involved	   in	  DSB	   repair	  and	   BER	   [305].	   Mono-­‐ADP-­‐ribosylation	   could	   regulate	   DNA	   repair	   and	   cell	   proliferation	   by	  serving	  as	  a	  marker	  for	  the	  severity	  of	  the	  damage	  and	  regulating	  the	  pathway	  choice	  for	  repair	  [306].	   For	   further	   information	   on	   enzymatic	   and	   non-­‐enzymatic	   ADP-­‐ribosylation	   reactions,	   I	  would	  like	  to	  refer	  to	  comprehensive	  reviews	  by	  Hassa	  et	  al.,	  2006	  and	  Diefenbach	  and	  Buerkle,	  2005	  [306,	  307].	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NAD+	  metabolism	  The	   oxidized	   form	   of	   nicotinamide	   adenine	   dinucleotide	   (NAD+)	   serves	   as	   the	   source	   for	  mono-­‐ADP-­‐ribose,	  the	  building	  block	  for	  PAR.	  Hydrolysis	  of	  the	  high-­‐energy	  bond	  between	  the	  nicotinamide	  and	  the	  ribose	  moieties	  of	  NAD+	  produces	  free	  energy	  (-­‐34.3	  kJ/mol),	  which	  is	   in	  turn	  used	  for	  enzymatic	  ADP-­‐ribosylation	  of	  proteins	  [306].	  	  NAD+	  is	  not	  only	  required	  for	  the	  formation	  of	  (poly-­‐)ADP-­‐ribose,	  but	  it	  is	  also	  an	  essential	  cofactor	   for	   the	   generation	   of	   energy	   in	   form	   of	   ATP.	   Hence,	   excessive	   PARP1	   activation	   in	  response	   to	   high	   levels	   of	  DNA	  damage	   can	   lead	   to	   a	   severe	   and	   irreversible	   depletion	   of	   the	  NAD+	   pool	   and	   induce	   cell	   death	   due	   to	   ATP	   depletion	   and	   energy	   failure	   [308,	   309].	  Intracellular	  NAD+	  levels	  actually	  decrease	  to	  10	  –	  20%	  of	  their	  normal	  levels	  within	  5	  –	  15	  min	  upon	  exposure	  of	  cells	  to	  high	  doses	  of	  DNA-­‐damaging	  agents	  [310].	  Efficient	  recycling	  of	  ADPR	  and	   maintenance	   of	   balanced	   NAD+	   pools	   are	   thus	   crucial	   for	   energy	   homeostasis	   and	   cell	  viability.	  
	  
Interactions	  with	  ADP-­‐Ribose	  (readers)	  Regulatory	   functions	   of	   ADP-­‐ribosylation	   are	   mainly	   carried	   out	   by	   noncovalent	  interactions	   of	   'readers'	  with	  ADP-­‐ribose-­‐modified	   proteins	   via	   four	   distinct	   binding	   domains.	  The	  PAR-­‐binding	  domain	  (PBD)	  is	  found	  in	  many	  DNA	  repair	  proteins	  and	  is	  composed	  of	  a	  20-­‐amino-­‐acid-­‐long	   stretch	   of	   basic	   and	   hydrophobic	   residues,	   specifically	   recognizing	   long	   and	  branched	  PAR	  chains.	  PAR-­‐binding	  Zinc-­‐Finger	  Domains	   (PBZ)	   contain	  a	   zinc	   ion,	   coordinated	  by	  two	  cysteine	  and	  two	  histidine	  residues	  and	  are	  only	  found	  in	  three	  human	  proteins	  involved	  in	  DNA	  break	  repair	  (APLF),	  checkpoint	  regulation	  (CHFR)	  and	  PAR	  metabolism	  (SNM1A).	  The	  globular	  WWE	  domain	  is	  defined	  by	  two	  tryptophan	  and	  one	  glutamate	  residue	  and	  found	  in	  E3	  ubiquitin	   ligases	   as	  well	   as	   some	  ARTD	   family	  members.	  Macrodomains	   are	   highly	   conserved	  globular	   motifs	   with	   130	   -­‐	   190	   amino	   acids	   in	   length	   and	   are	   involved	   in	   many	   different	  processes	  (comprehensively	  reviewed	  in	  [297]).	  	  	  
ADP-­‐Ribosylhydrolases	  (erasers)	  	  (Poly-­‐)ADP-­‐ribosylation	   is	   a	   reversible	   protein	  modification	   that	   is	   removed	   rapidly	   and	  efficiently	   by	   ADP-­‐ribosylhydrolases,	   reducing	   the	   half-­‐life	   of	   PAR	   to	   only	   a	   few	   minutes.	  Poly(ADP-­‐ribose)	  glycohydrolase	  (PARG)	  is	  the	  major	  enzyme	  responsible	  for	  the	  degradation	  of	  PAR	  chains,	  forming	  both	  free	  ADPR	  polymers	  and	  monomers	  [311].	  It	  hydrolyzes	  the	  glycosidic	  ribose-­‐ribose	  bonds	  both	  exo-­‐	  and	  endonucleolytically.	  However,	  due	  to	  steric	  hindrance	  PARG	  is	  not	  able	  to	  cleave	  protein-­‐bound	  ADP-­‐ribose,	  leaving	  behind	  MARylated	  proteins.	  Alternative	  splicing	   gives	   rise	   to	   several	   different	   PARG	   proteins	   with	   different	   subcellular	   localizations	  (nuclear,	   cytoplasmic	   and	   mitochondrial)	   and	   length	   [312].	   ADP-­‐ribosylhydrolase	   family	  members	  (ARH1-­‐3)	  are	  structurally	  distinct	  from	  PARG	  and	  display	  distinct	  specificities	  towards	  ADP-­‐ribosylated	   targets;	   they	   are	   found	   primarily	   in	   the	   cytosolic	   fraction.	   Furthermore,	  macrodomain-­‐containing	  hydrolases	  are	  recruited	  to	  DNA	  damage	  sites	  and	  some	  of	  them	  were	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shown	  to	  possess	  a	  novel	  glutamate-­‐specific-­‐mono-­‐ADP-­‐ribosylhydrolase	  activity,	  removing	  the	  last	  ADP-­‐ribose	  unit	  from	  glutamate	  residues	  [297].	  A	   rapid	   turnover	   of	   nuclear	   PAR,	   synthesized	   in	   response	   to	   cellular	   stress,	   may	  consequently	  lead	  to	  the	  accumulation	  of	  intracellular	  ADPR	  units.	  A	  large	  increase	  of	  free	  ADPR	  can	  be	  toxic	  to	  cells,	  because	  it	  contains	  reactive	  aldehyde	  groups,	  which	  mediate	  non-­‐enzymatic	  glycation	  of	  proteins	  on	  N-­‐terminal	  lysyl	  amino	  acid	  groups	  and	  cysteinyl	  thiols	  [306].	  Glycation	  and	   glycoxidation	   are	   protein	   modifications	   that	   can	   cause	   substantial	   damage	   to	   long-­‐lived	  proteins	  and	  lead	  to	  loss	  of	  function.	  It	  is	  therefore	  of	  great	  importance	  to	  maintain	  a	  balanced	  pool	  of	  NAD+	  as	  well	  as	  ADPR	  mono-­‐	  and	  polymers	  to	  reduce	  cellular	  toxicity	  induced	  by	  these	  metabolites.	  	  	  
	  
Fig.19:	   Schematic	   view	   of	  
(poly)ADP-­‐ribose	   metabolism.	  PARP1	   hydrolyzes	   NAD+	   to	   attach	  ADPR	   units	   to	   the	   target	   proteins.	  Negatively	   charged	   ADP-­‐ribose	  polymers	  have	  a	  short	  half-­‐lives	  due	  to	  the	   activity	   of	   poly(ADP-­‐ribose)	  glycohydrolase	   (PARG)	   that	   is	  activated	  in	  response	  to	  an	  increasing	  levels	  of	  PAR.	  PARG	  cleaves	  glycosidic	  bonds	   between	   ADP-­‐ribose	   subunits	  endo-­‐	   and	   exonucleolytically.	   Free	  ADPR	   units	   can	   be	   cleaved	   by	   the	  Nudix	  hydrolase	  NUDT5	  to	  Adenosine-­‐mono-­‐phosphate	   (AMP)	   and	   Ribose-­‐5’-­‐Phosphate	   (R5’P)	   (from	  Rouleau	   et	  
al.,	  2004	  [313]).	  
	  
PARP1	  As	  mentioned	  earlier,	  PARP1	  is	  a	  poly(ADP-­‐ribose)polymerase	  that	  is	  activated	  by	  binding	  to	  DNA	  strand	  breaks	  and	  catalyzes	  the	  transfer	  of	  ADP-­‐ribose	  units	  onto	  itself	  and	  other	  target	  proteins	   [314].	   In	   fact,	   in	  response	   to	  DNA	  damage	  90%	  of	  PAR	   is	  synthesized	  by	  PARP1.	  PAR	  chains	   serve	  as	  a	  platform	   to	   recruit	  proteins	   involved	   in	  DNA	  damage	   recognition	  and	   repair	  and	  binding	  of	  PARP1	  to	  SSB	  intermediates	  protects	  those	  from	  further	  damage.	  Because	  of	  the	  negative	  charge	  of	  ADP-­‐ribose	  units,	  automodification	  of	  PARP1	  itself	  leads	  to	  its	  repulsion	  from	  the	  negatively	  charged	  DNA,	  making	  the	  interaction	  of	  PARP1	  with	  DNA	  a	  transient	  and	  highly	  dynamic	  process.	  Despite	   its	   role	   in	   DNA	   damage	   control,	   PARP1	   has	   multiple	   other	   functions,	   including	  chromatin	   remodeling,	   transcription	   regulation	   and	   the	   response	   to	   a	   wide	   range	   of	   cellular	  signals	  and	  stresses,	  such	  as	  oxidative,	  oncogenic,	  genomic	  or	  inflammatory	  stress	  [315].	  It	  is	  a	  highly	   abundant	   nuclear	   protein,	   which	   contains	   several	   structural	   and	   functional	   domains.	  Three	   zinc	   finger	  motifs	   in	   the	   amino-­‐terminus	  mediate	  DNA	  binding,	  while	   the	   central	   BRCT	  domain	  allows	  automodification	  and	  thus	  interaction	  with	  other	  proteins.	  The	  WGR	  (Tryp-­‐Gly-­‐
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Arg)	  motif	  seems	  to	  be	  important	  for	  inter-­‐domain	  communications,	  while	  the	  carboxy-­‐terminal	  catalytic	  domain	  is	  required	  for	  NAD+	  binding	  to	  the	  highly	  conserved	  signature	  (Sig)	  motif	  and	  controls	   PAR	   catalysis	   [316].	   The	  PARP	   regulatory	   domain	   (PRD)	   interacts	  with	   the	   substrate	  binding	  site	  and	  controls	  branching	  of	  PAR	  chains	  [317].	  The	  versatile	  roles	  of	  PARP1	  are	  mainly	  carried	   out	   via	   posttranslational	  modification	   of	   acceptor	   proteins	   to	  modulate	   their	   function,	  change	   of	   interaction	   partners	   by	   automodification	   and	   PAR-­‐independent	   interactions	   via	   the	  BRCT	  domain.	  It	  thus	  seems	  to	  act	  as	  a	  scaffold	  protein,	  which	  can	  be	  modified	  additionally	  by	  phosphorylation,	  acetylation,	  ubiquitylation	  and	  SUMOylation	  that	   further	  broaden	   its	  mode	  of	  action.	  	  
PARP1	  in	  base-­‐excision	  repair	  A	  role	  for	  PARP1	  in	  BER	  was	  first	  anticipated	  when	  it	  became	  evident	  that	  PARP1	  knock-­‐out	  mice,	   which	   display	   no	   overt	   phenotype	   under	   normal	   conditions,	   are	   sensitive	   to	   treatment	  with	   monofunctional	   alkylating	   agents	   and	   γ-­‐irradiation	   causing	   DNA	   damage,	   which	   is	  recognized	  by	  BER	  [318,	  319].	  Importantly,	  it	  was	  shown	  that	  PARP1	  is	  able	  to	  bind	  AP-­‐sites	  and	  nicks	   that	   are	   transiently	   generated	   by	   initial	   base-­‐excision	   repair	   steps	   [320].	   These	  observations	   challenged	   the	   'passing	   the	   baton'	   model	   of	   BER,	   which	   described	   a	   well-­‐coordinated	   process,	   during	   which	   single-­‐strand	   intermediates	   are	   passed	   on	   from	   one	   BER	  enzyme	   to	   the	   next,	   avoiding	   accessibility	   to	   other	   factors.	   Furthermore,	   it	   was	   shown	   that	  PARP1	   interacts	   physically	   and	   functionally	  with	   key	  BER	   factors,	   such	   as	  OGG1,	   XRCC1	   [321,	  322],	  DNA	  Ligase	  III	  and	  polymerase-­‐β	  [323].	  Due	   to	   these	   results,	   a	   'two-­‐step'	   BER	   model	   was	   proposed	   [320],	   claiming	   that	   PARP1	  transiently	   binds	   and	   protects	   nicks	   generated	   by	   the	   BER	   glycosylase	   and	   APE1	   [324,	   325].	  Activation	  of	  PARP1	  upon	  binding	  to	  the	  nick	  triggers	  automodification	  and	  therefore	  generates	  a	   'recruiting	  platform'	   for	  XRCC1,	  Polβ	  and	  DNA	  LigIII	  at	   the	  site	  of	  damage.	  At	   the	  same	  time,	  excessive	  PARylation	   leads	   to	   repulsion	  of	  PARP1	   from	   the	  DNA,	  which	   allows	   accessibility	   of	  downstream	  BER	  enzymes	  to	  complete	  the	  repair	  process.	  PARP1	  thus	  seems	  to	  stimulate	  BER	  [320,	   323,	   326]	   and	   accelerates	   SSBR	   [327],	   but	   it	   is	   not	   absolutely	   required	   for	   these	   repair	  processes	   [328].	   This	   is	   highlighted	   by	   the	   fact	   that	   PARP1	   knock-­‐out	   mice	   display	   no	   overt	  phenotype	  under	  normal	  conditions,	  while	  APE1,	  Polβ	  and	  XRCC1	  knock-­‐out	  mice	  are	  not	  viable	  [329-­‐331].	  Furthermore,	  alkylation-­‐induced	  repair	  of	  SSBs	  is	  not	  affected	  by	  PARP1	  status	  [328]	  and	   SSB-­‐containing	   plasmids	   are	   repaired	   with	   the	   same	   efficiency	   in	   cell	   extracts	   with	   and	  without	  PARP1	  [314].	  However,	  it	  has	  been	  proposed	  that	  PARP1	  activity	  may	  be	  an	  important	  'sensor'	  for	  the	  recognition	  and	  accelerated	  repair	  of	  'direct'	  SSBs	  that	  arise	  in	  the	  context	  of	  the	  complex	  chromatin	  environment	  [139].	  Furthermore,	  recruitment	  of	  the	  important	  BER	  scaffold	  factor	  XRCC1	  to	  the	  site	  of	  the	  lesion	  stimulates	  repair	  about	  5-­‐fold	  [332].	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Fig.20:	  Base-­‐excision	  repair	  (BER)	  is	  a	  distinct	  from	  DNA	  single-­‐strand	  break	  (SSB)	  repair	  in	  mammalian	  cells.	  
A)	  SSB	  repair:	  PARP1	  binds	  with	  high	  affinity	  to	  SSBs	  and	  is	  thus	  amongst	  the	  first	  proteins	  binding	  the	  lesion.	  In	  turn	  it	  recruits	  factors	  involved	  in	  end	  processing	  and	  ligation.	  B)	  Two-­‐step	  BER	  model:	  Small	  base	  lesions	  are	  recognized	  and	  excised	  by	  different	  DNA	  glycosylases	  (Gly),	  before	  incision	  of	  the	  DNA	  by	  the	  AP-­‐endonuclease	  (APE).	  SSBs	  are	  left	  unprotected	  and	  recognized	   in	  a	   separate	  process	  by	  PARP1	   to	   initiate	  SSB	  repair.	  C)	  One-­‐step	  BER	  model:	  The	  glycosylase	  removes	  the	  damaged	  base	  just	  before	  APE	  incision	  and	  already	  interacts	  with	  other	  proteins	  involved	  in	  the	  early	   incision	  step.	  The	  half-­‐life	  of	   the	  SSB	   intermediate	   is	  very	  short	  and	  rapidly	   ligated	  by	  short-­‐patch	  repair,	  switching	  to	  long-­‐patch	  repair	  in	  case	  of	  ligation	  difficulty.	  PARP1	  is	  not	  directly	  involved	  in	  BER,	  but	  can	  transiently	  bind	   the	   SSB	   intermediate.	  When	   PARP1	   activity	   is	   inhibited,	   it	   gets	   trapped	   on	   the	   SSB	   intermediate	   preventing	  ligation	  (modified	  from	  Helleday,	  2011	  [326]).	  	  	  
PARP1	  in	  double-­‐strand	  break	  repair	  PARP1	   has	   been	   implicated	   in	   the	   repair	   of	   DSBs,	   as	   PARylation	   is	   thought	   to	   recruit	  appropriate	  repair	  factors	  to	  the	  site	  of	  the	  lesion	  [4].	  Additionally,	  PARP1	  activity	  is	  important	  for	  resolution	  of	  stalled	  replication	  forks.	  It	  binds	  to	  stalled	  forks	  and	  mediates	  fork	  reversal	  as	  well	  as	  recruitment	  of	  MRE11	  to	  allow	  processing	  and	  fork	  restart	  [213].	  Further,	  PARP1	  seems	  to	  inhibit	  toxic	  NHEJ	  events	  at	  collapsed	  replication	  forks	  [139].	  	  Despite	  the	  ability	  of	  PARP1	  to	  bind	  DSBs	  its	  role	  in	  classical	  NHEJ	  is	  still	  not	  clear.	  PARP1	  and	   KU/DNA-­‐PK	   physically	   interact	   [333]	   and	   modify	   each	   other	   by	   PARylation	   and	  phosphorylation,	   respectively	   [334,	   335].	   Furthermore,	   PARP1	   seems	   to	   be	   required	   for	  alternative	  NHEJ,	   a	   pathway	   that	   takes	   over	   in	   the	   absence	   of	  KU70/80	   and	   independently	   of	  DNA-­‐PK	   and	   XRCC4-­‐LigIV	   [263].	   Together	   with	   XRCC1,	   PARP1	   may	   promote	   end-­‐joining	  (synapsis)	  of	  the	  broken	  DNA	  ends	  and	  recruitment	  of	  LigIII	  to	  facilitate	  final	  ligation	  [336].	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PARP1	  INHIBITION	  AND	  SYNTHETIC	  LETHALITY	  The	   concept	   of	   synthetic	   lethality	   is	   based	   on	   the	   redundancy	   of	   certain	   pathways	   that	  normally	   serve	   as	   backup	   pathways	   for	   one	   another	   and	   thus	   both	   need	   to	   be	   deactivated	   to	  induce	   cell	   death.	   The	   clinical	   applicability	   of	   this	   approach	  was	   nicely	   shown	  more	   than	   ten	  years	  ago,	  when	  it	  became	  evident	  that	  BRCA1-­‐	  or	  BRCA2-­‐deficient	  tumors	  are	  specifically	  killed	  by	  PARP	  inhibitors	  in	  the	  absence	  of	  additional	  exogenous	  DNA	  damaging	  agents	  [2,	  3].	  Due	  to	  the	   specific	   toxicity	   of	   this	   treatment	   to	   BRCA	   mutated	   cancer	   cells	   with	   deficiency	   in	  homologous	  recombination,	  side	  effects	  should	  be	  very	  much	  reduced	  compared	  to	  conventional	  chemotherapeutics.	  The	  first	  PARP	  inhibitors	  were	  NAD+	  analogs	  that	  compete	  with	  NAD+	  for	  its	  binding	   pocket	   [337].	   The	   biggest	   challenges	   were	   then	   to	   develop	   inhibitors	   with	   better	  substrate	  specificity,	  especially	  due	  to	  the	  high	  sequence	  similarity	  of	  the	  PARP	  family	  members.	  The	  mode	   of	   action	   of	   PARP	   inhibitors	   in	   homologous	   recombination	   (HR)	   deficient	   cells	  was	  proposed	  to	  be	  mediated	  through	  the	  role	  of	  PARP1	  in	  single-­‐strand	  break	  repair	  (SSBR).	  It	  was	  shown	  that	  PARP1	  promotes	  BER	  by	  recruiting	  downstream	  repair	  factors,	  such	  as	  XRCC1,	  Polβ	  and	  LigIII.	  Upon	  PARP1	  inhibition	  this	  pathway	  is	  thought	  to	  be	  interrupted,	  leading	  to	  an	  accumulation	   of	   SSBs	   that	   collapse	   into	   DNA	   double-­‐strand	   breaks	   (DSBs)	   when	   they	   are	  encountered	  by	  the	  replication	  machinery.	  These	  highly	  cytotoxic	  lesions	  are	  normally	  repaired	  by	  HR	  during	  S-­‐	  and	  G2-­‐phases	  of	   the	  cell	   cycle.	  However,	   in	   the	  absence	  of	  BRCA1	  or	  BRCA2,	  homologous	   recombination	   is	   impaired	   and	   cells	   undergo	   apoptosis	   due	   to	   the	   high	   loads	   of	  DNA	   damage	   [2,	   3].	   Additionally,	   it	   was	   shown	   that	   HR-­‐deficient	   cells	   treated	   with	   PARP	  inhibitors	  induce	  non-­‐homologous	  end-­‐joining	  joining	  (NHEJ)	  to	  repair	  DNA	  DSBs.	  This	  pathway	  is	  error	  prone	  and	  can	  cause	  genomic	  instability,	  which	  ultimately	  also	  leads	  to	  cell	  death	  [338].	  	  	  	  
	  
Fig.21:	   Models	   for	   synthetic	   lethality	   between	   PARP	   and	   BRCA.	   A)	   SSB	   replication	   run-­‐off	   model.	   PARP1	   is	  involved	  in	  the	  repair	  of	  SSBs.	  In	  the	  presence	  of	  a	  PARP	  inhibitor,	  SSBs	  may	  persist	  and	  collapse	  during	  an	  encounter	  with	  the	  replication	  fork	  into	  a	  one-­‐ended	  DSB.	  BRCA-­‐defective	  cancer	  cells	  lack	  HR	  and	  are	  thus	  unable	  to	  repair	  the	  resulting	  DSBs	  in	  an	  accurate	  manner,	  leading	  to	  toxicity.	  B)	  PARP1	  trapping	  model.	  PARP	  inhibitors	  trap	  PARP1	  onto	  SSBs	  that	  have	  formed	  spontaneously	  or	  arise	  as	  intermediates	  during	  BER.	  PARP1-­‐DNA	  complexes	  may	  present	  an	  obstacle	  to	  replication	  that	  require	  HR	  for	  repair	  (modified	  from	  Helleday,	  2011	  [326]).	  	   Surprisingly,	   siRNA-­‐mediated	   knock-­‐down	   of	   PARP1	   in	   BRCA-­‐deficient	   cells	   is	   less	   toxic	  compared	  to	  PARP1	  inhibition	  in	  the	  same	  cells	  [2].	  Furthermore,	  depletion	  of	  PARP1	  does	  not	  affect	   alkylation-­‐induced	   SSB	   repair	   [328]	   and	  knock-­‐down	  of	   the	   essential	  BER	   factor	  XRCC1	  does	  not	  kill	  BRCA2-­‐deficient	  ovarian	  cancer	  cells	  [338].	  Collectively,	  these	  experimental	  results	  led	   to	   the	   proposal	   of	   the	   so-­‐called	   'trapping	   model',	   which	   suggests	   that	   PARP1	   inhibition	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allows	  binding	  of	  the	  enzyme	  to	  SSBs,	  but	  prevents	  its	  automodification	  and	  thus	  repulsion	  from	  the	  DNA.	  PARP1	  would	   therefore	  be	   trapped	  on	  the	  SSB	  and	  could	  be	  converted	  to	  even	  more	  toxic	  lesions	  during	  replication	  and	  other	  processes	  [326],	  which	  require	  HR	  activity	  for	  faithful	  repair.	   According	   to	   the	   'trapping	   model',	   PARP1	   levels	   in	   tumor	   cells	   would	   increase	   the	  effectiveness	  of	  PARP	   inhibitors,	  while	   the	  original	  model	  would	  state	   the	  opposite.	  A	  detailed	  understanding	  of	  the	  exact	  mechanism	  will	  be	  important	  for	  personalized	  medicine.	  It	  has	  been	  proposed	  that	  PARP	  inhibitors	  may	  also	  be	  effective	  at	  killing	  cells	  proficient	  in	  BRCA1/2,	  possibly	  through	  processes	  unrelated	  to	  DNA	  repair	  [339,	  340].	  	  
PARP1	  inhibitors	  in	  the	  clinic	  Following	  the	  discovery	  that	  PARP	  inhibitors	  are	  highly	  cytotoxic	  in	  BRCA-­‐deficient	  cancer	  cells	  [2,	  3],	  first	  clinical	  trials	  were	  initiated	  using	  the	  PARP	  inhibitor	  Olaparib	  in	  ovarian	  cancer	  patients	  with	   inherited	  BRCA1	  or	  BRCA2	  mutations	   [341].	   In	  2014	  Lynparza™	   (containing	   the	  PARP	  inhibitor	  Olaparib)	  was	  finally	  licensed	  in	  the	  European	  Union	  as	  well	  as	  the	  United	  States	  as	   first-­‐in-­‐class	   treatment	   for	   maintenance	   monotherapy	   of	   patients	   with	   platinum-­‐sensitive	  relapsed	   BRCA-­‐mutated	   high-­‐grade	   serous	   epithelial	   ovarian,	   fallopian	   tube	   or	   primary	  peritoneal	   cancers.	   The	  most	   common	   adverse	   events	   associated	  with	   Olaparib	  monotherapy	  were	  rather	  mild	  and	  include	  nausea,	  vomiting,	  fatigue	  and	  anemia.	  In	  recent	  years,	  research	  has	  focused	  on	  the	  identification	  of	  other	  gene	  mutations	  that	  are	  sensitive	  to	  PARP	  inhibitors.	  Worthwhile	  to	  mention	  here	  are	  synthetic	  lethal	  interactions	  with	  PTEN,	   a	   tumor	   suppressor	   gene	   that	   is	   frequently	  mutated	   in	   prostate,	   endometrial,	   skin	   and	  brain	   tumors	   and	   causes	   HR-­‐deficiency	   [342,	   343].	   MRE11-­‐deficiency	   also	   causes	   HR-­‐defects	  and	  was	  shown	  to	  induce	  PARP	  inhibitor	  sensitivity	  in	  microsatellite	  unstable	  colorectal	  cancer	  cells	   [344].	   Interestingly,	   defects	   in	   cell	   cycle	   regulators	   such	   as	   ATM	   also	   leads	   to	   PARP	  inhibitor	  sensitivity	  [345].	  This	  is	  quite	  interesting,	  as	  synthetic	  lethal	  interactions	  with	  cell	  cycle	  regulators	   in	   combination	   with	   other	   DNA	   repair	   pathways	   could	   be	   envisioned	   and	   ATM	  inhibitors	  are	  currently	  under	  investigation	  as	  novel	  cancer	  therapeutics.	  PARP	   inhibitors	   were	   also	   tested	   in	   various	   clinical	   trials	   as	   combination	   therapy	  approaches	   with	   DNA	   damage	   inducing	   drugs,	   such	   as	   alkylating	   agents,	   topoisomerase	   I	  inhibitors,	  platinum	  drugs,	  radiation,	  nucleoside	  analogs	  or	  antimetabolites.	  The	  concept	  behind	  these	   treatment	   modalities	   is	   to	   generate	   a	   high	   amount	   of	   DNA	   lesions	   that	   require	   PARP1	  activity	  and	  even	  exceed	  the	  repair	  capacity	  of	  HR-­‐competent	  cells.	  	  
PARP	  inhibitor	  resistance	  A	  major	  problem	  of	  PARP1	  inhibitors	  and	  many	  other	  drugs	   is	  resistance	  that	   is	  often	  the	  consequence	  of	   the	  high	  mutation	  rate	  of	  malignant	  cells	  and	  their	  ability	   to	  adapt	  to	  different	  environmental	   challenges.	   Several	   molecular	   mechanisms	   for	   (adapted)	   resistance	   to	   PARP1	  inhibitors	  were	   reported	   in	  pre-­‐clinical	   and	  clinical	   settings.	  Elegant	   studies	  by	  Edwards	  et	  al.	  identified	   secondary	   mutations	   in	   BRCA2	   that	   restored	   the	   open	   reading	   frame	   through	  intragenic	  deletions,	  which	  re-­‐activated	  HR	  ability	  in	  CAPAN1	  cells	  [346].	  Later,	  several	  studies	  showed	  that	  also	  loss	  of	  important	  factors	  involved	  in	  NHEJ,	  such	  as	  53BP1	  and	  REV7,	  can	  lead	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  INTRODUCTION	  
	  
	  _______________________________________________________________________________________________________________________________________	  51	  
to	   PARP	   inhibitor	   resistance	   in	   HR-­‐deficient	   cells	   by	   partial	   restoration	   of	   functional	   HR,	   e.g.	  through	   alternative	   loading	   of	   Rad51	   onto	   ssDNA	   and	   promotion	   of	   end	   resection	   [182,	   183,	  347].	   Furthermore,	   inhibition	   of	   NHEJ	   prevents	   deleterious	   genomic	   rearrangements	   and	  therefore	   reduces	   the	   toxicity	   of	   PARP	   inhibitors.	   Another	   mechanism	   by	   which	   cancer	   cells	  achieve	   drug	   resistance	   is	   through	   upregulation	   of	   multidrug	   resistance	   (MDR)	   transporters,	  such	  as	  P-­‐glycoproteins,	  that	  effectively	  reduce	  the	  intracellular	  availability	  of	  xenobiotics	  [348].	  With	   regard	   to	   personalized	   medicine,	   it	   will	   be	   crucial	   to	   identify	   further	   resistance	  mechanisms	  to	  avoid	  treatment	  of	  patients	  who	  will	  likely	  not	  respond	  to	  the	  treatment	  due	  to	  specific	   mutations	   or	   gene	   expression	   profiles.	   Novel	   approaches	   further	   aim	   at	   overcoming	  drug	   resistance	   to	   be	   able	   to	   make	   use	   of	   the	   tremendous	   therapeutic	   potential	   of	   PARP	  inhibitors.	   One	   strategy	   is	   for	   instance	   to	   generate	   inhibitors	   that	   are	   not	   targeted	   by	   MDR-­‐transporters	  like	  AZD2461.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  AIMS	  
	  	  
	  _______________________________________________________________________________________________________________________________________	  52	  
AIMS	  
	   A	  detailed	   understanding	   of	   genome	   stability	   and	   the	   underlying	   repair	  mechanisms	   that	  prevent	  mutagenesis	  is	  crucial	  in	  the	  field	  of	  oncology.	  Endogenous	  DNA	  damage	  is	  emerging	  as	  an	  abundant	  and	   important	  source	  of	  DNA	   lesions,	  which	  substantially	  contribute	   to	   the	  onset	  and	  progression	  of	  cancer.	  Furthermore,	  germline	  or	  somatic	  mutations	  in	  DNA	  repair	  genes	  are	  found	   in	   a	   subset	   of	   tumors,	   leaving	   them	   more	   dependent	   on	   backup	   repair	   pathways	   to	  support	   cell	   survival.	  This	   concept	  has	  been	  exploited	   in	   cancer	   therapy,	   in	  an	  attempt	   to	   find	  novel	  synthetic	  lethal	  interactions	  of	  different	  DNA	  repair	  pathways.	  	  	  The	  first	  aim	  of	  this	  thesis	  was	  to	  further	  investigate	  and	  unravel	  the	  basis	  of	  a	  well-­‐known	  synthetic	   lethal	   interaction	   between	   PARP	   inhibitors	   and	   homologous	   recombination	   (HR)	  deficiency.	   PARP	   inhibitors	   prevent	   efficient	   repair	   of	   single-­‐strand	   breaks	   (SSBs),	   which	   are	  converted	   into	   even	   more	   toxic	   lesions	   that	   require	   HR	   for	   accurate	   repair.	   We	   argued	   that	  endogenous	  stress,	  primarily	  oxidative	  DNA	  damage,	   contributes	   to	  PARP	   inhibitor	  sensitivity.	  Our	  research	  focused	  on	  one	  particular	  lesion,	  8-­‐oxo-­‐guanine	  (GO),	  that	  can	  mispair	  with	  adenine	  (A)	   to	   give	   rise	   to	   GO:A	   mismatches.	   The	   base-­‐excision	   repair	   pathway,	   initiated	   by	   the	   DNA	  glycosylase	  MYH,	  addresses	  these	  particular	   lesions	  and	   leads	  to	  the	  accumulation	  of	   transient	  SSBs,	   which	   potentially	   trigger	   PARP	   activation.	   We	   therefore	   set	   out	   to	   test	   whether	   this	  particular	  repair	  pathway	  contributes	  to	  PARP	  inhibitor	  activity	  in	  HR-­‐defective	  cells.	  	  Another	   aspect	   of	   this	   thesis	   focused	   on	   elucidating	   the	   role	   of	   ATAD5,	   a	   putative	   DNA	  repair	   factor,	   in	   DNA	   damage	   prevention	   in	   mammalian	   cells.	   We	   aimed	   at	   unraveling	   its	  requirement	   as	   a	   proposed	   PCNA	   unloader	   for	   the	   maintenance	   of	   genome	   stability	   and	   to	  uncover	   other	   functions	   of	   ATAD5	   in	   DNA	   metabolism.	   Furthermore,	   we	   hypothesized	   that	  ATAD5	   may	   be	   involved	   in	   DNA	   replication	   and	   therefore	   carried	   out	   a	   series	   of	   DNA	   fibre	  experiments	  to	  test	  this	  experimentally.	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Oxidative) DNA) damage) repair) initiated) by) MYH) contributes) to) PARP) inhibitor)
sensitivity)in)HR>deficient)cells)!Marie'Christine!Weller,!Simone!Repmann,!Josef!Jiricny!!
Institute( of( Molecular( Cancer( Research( of( the( University( of( Zurich( and( the( ETH( Zurich,(
Winterthurerstrasse(190,(8057(Zurich,(Switzerland(!!Abstract!Homologous! recombination! (HR)'deficient! cells,! such! as! BRCA1'! or! BRCA2'mutated!breast! and! ovarian! cancer! cells,! are! intrinsically! sensitive! to! poly(ADP'ribose)polymerase! (PARP)! inhibition! '! a! concept! that! is! generally! referred! to! as!synthetic! lethality! (1,2).! This! hypersensitivity! to! PARP! inhibitors,! such! as! Olaparib,! is!thought! to! result! from! accumulation! of! DNA! single'strand! breaks! (SSBs),! which! are!converted! into! deleterious! double'strand! breaks! (DSBs)! during! encounters! with! the!replication!machinery!(1,2).!HR'defective!cells!treated!with!PARP!inhibitors!rely!on!the!error'prone! non'homologous! end'joining! (NHEJ)! pathway! for! DSB! repair,! leading! to!elevated!levels!of!genomic!instability!and!cytotoxicity!(3).!However,!the!initial!source!of!DNA! lesions! that! require! PARP! activity! for! their! repair! still! remains! speculative.! We!hypothesized! that! one! such! source! might! be! SSB'intermediates! generated! during! the!processing! of! endogenous! oxidative! DNA! damage! by! base! excision! repair! (BER).!Particularly,! we! asked! whether! processing! of! potentially! mutagenic! 8'oxo'guanine!(GO)/A!mispairs!by!the!DNA!glycosylase!MYH!could!contribute!to!Olaparib!sensitivity!in!HR'defective!cells.!Here!we!show!that!siRNA'mediated!depletion!of!MYH!in!BRCA1'!or!RAD51'depleted! cells! partially! rescues! Olaparib! sensitivity! and! DNA! strand! break!accumulation!in!several!different!cancer!cell!lines.!Collectively,!our!results!indicate!that!MYH'induced! processing! of! oxidative! DNA! damage! contributes! to! PARP! inhibitor!sensitivity!of!HR'defective!cells.!!!!Introduction!BRCA1'! and!BRCA2'deficient! cells! are! highly! sensitive! to! treatment!with! inhibitors! of!poly(ADP'ribose)polymerase! (PARP)! (1,2).! BRCA1! and! BRCA2! are! important! tumor!suppressor!genes! involved! in!homologous!recombination!(HR)!repair! (reviewed! in!(4'6)),! a!pathway!required! for!efficient!and!accurate! repair!of!DNA!double'strand!breaks!(DSBs).! DSBs! are! highly! cytotoxic! lesions! due! to! their! potential! to! cause! genomic!rearrangements!and! their!ability! to! trigger!cell! cycle!arrest!or!apoptosis.!PARP'1! is!an!enzyme! with! a! variety! of! different! functions! in! DNA! metabolism,! one! being! its!involvement! in!single'strand!break!repair! (SSBR),!a! sub'pathway!of! the!base'excision'repair! (BER)! pathway.! PARP'1! accelerates! global! SSBR! to! facilitate! fast! and! efficient!repair!of!single'strand!breaks!(SSBs),!which!are!the!most!common!lesions! in!cells! that!can! arise! from! direct! attack! of! the! DNA,! abortive! activity! of! topoisomerase! 1! or! as!normal! intermediates! of! BER! (7).! Upon! binding! to! DNA! strand! breaks,! PARP'1! is!activated!and!catalyzes!the!synthesis!of!long!chains!of!poly(ADP'ribose)!(PAR)!on!itself!and!other!acceptor!proteins! (8'10).!Using!small!molecule! inhibitors! it!was!shown!that!global!PARP!inhibition!dramatically!slows!down!DNA!strand!break!repair!(11'15).!The! mode! of! action! of! PARP! inhibitors! was! thus! proposed! to! be! attributed! to! an!accumulation! of! DNA! SSBs,! which! are! converted! into! deleterious! DSBs! as! a! result! of!encounters!with!the!replication!machinery!(reviewed!in!(16'20)).!HR'deficient!cells!are!incapable! of! faithful! repair! of! these! lesions! and! rely! on! the! more! error'prone! non'homologous! end'joining! (NHEJ)! pathway,! which! may! lead! to! chromosomal!rearrangements,!genomic!instability!and!cell!death.!However,!the!initial!sources!of!SSBs,!which!require!PARP!activity!in!cells!that!have!not!been!exposed!to!DNA!damaging!!
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agents,(still(remains(a(matter(of(speculation.(Intracellular(oxidative(stress(may(be(one(of(the(main(contributors(of(cellular(SSB(accumulation,(due(to(the(fact(that(normal(cellular(metabolism( can( generate( intracellular( reactive( oxygen( species( (ROS),( which( readily(attack(proteins,( lipids(and(the(DNA((21,22).(One(of(the(most(frequent(and(wellHstudied(oxidative(DNA(lesions(is(7,8HdihydroH8HoxoHguanine((8HoxoHG(or(GO)(with(a(steadyHstate(level( of( 103( lesions( per( cell( in( normal( tissues( (21,23,24).( Frequently,( adenine( is( misHincorporated(opposite(GO(by( replicative(polymerases,( leading( to( the( formation(of(GO:A(mispairs,(which( can( give( rise( to(G:C( to(T:A( transversion(mutations(when(not( repaired(before(subsequent(rounds(of(replication((25).(These(lesions(are(primarily(eliminated(by(BER,( which( is( initiated( by( the( DNA( glycosylases( MYH( and( OGG1( (26).( While( OGG1(removes(GO(paired(with(C,(MYH(excises(adenines(that(have(misHpaired(with(GO(in(order(to(allow(subsequent(repair(by(OGG1(to(restore( the(correct(G:C(pair( (24).( Interestingly,(these( glycosylases( have( a( different(mode( of( action:( OGG1( initiates( a( short( patch( BER(reaction( in(which(Polβ( fills(a(oneHnucleotide(gap( that( is( later(sealed(by( the(DNA( ligase(III/XRCC1(complex.(MYH,(on(the(other(hand,(induces(long(patch(BER(that(is(coordinated(by(proliferating(cell(nuclear(antigen((PCNA)(and(replication(protein(A((RPA).(Following(lesion(bypass(by(Polλ,(which(preferentially( incorporates(dCTP(opposite(GO((27H29)( the(flap( endonuclease( 1( (FEN1)( is( recruited( by(PCNA( to( remove( the( 5'HsingleHstrand(DNA((ssDNA)( flap,(allowing(DNA( ligase( I( to( seal( the(nick( (29).(The(resulting(GO:C(pair( is,( as(mentioned(earlier,(a( substrate( for(OGG1.(Both(repair(events(create( transient(SSBs( that(may( require( PARP( activity( for( global( BER.( This( may( be( important,( especially( in( the(context(of(chromatin,(where(repair(proteins(need(to(be(attracted(specifically(and(rapidly(to(the(site(of(the(lesion.(PARP1(may(thus(help(to(facilitate(recruitment(of(repair(factors(to( sites( of( DNA( damage( that( are( difficult( to( access( in( the( complex( chromatin(environment.((Furthermore,(cancer(cells(presumably(display(elevated(levels(of(oxidative(stress,(due(to(oncogene( activation,( enhanced( cell( growth( and( altered( metabolism( (21).( We( thus(reasoned( that( processing( of( DNA( lesions( induced( by( endogenous( oxidative( stress(require(PARP(activity(for(efficient(repair(and(thus(induce(sensitivity(in(an(HRHdeficient(background.(Indeed,(we(show(that(MYH(knockHdown(partially(rescues(Olaparib(toxicity(in(BRCAH(or(Rad51Hdepleted(cells.(Furthermore,(we(observed(reduced(amounts(of(SSBs(and(DSBs(when(MYH(and(BRCA1(or(MYH(and(Rad51(were(coHdepleted,(suggesting(that(processing( of( potentially( mutagenic( GO:A( misHpairs( by( MYH( generates( transient( SSBs(that(contribute(to(PARP(inhibitor(sensitivity(in(HRHdefective(cancer(cells.(((Material(and(Methods(
!
Antibodies*for*Western*Blot*Rabbit( αH53BP1( (Santa( Cruz( Biotechnology,( 1:1000),( mouse( αHBRCA1( (Santa( Cruz(Biotechnology,( 1:100),(mouse(αHCtIP( (Santa( Cruz(Biotechnology,(D4,( 1:250),(mouse(αHLamin(B1((Abcam,(ab16048,(1:100),(mouse(αHMYH((Abcam,(ab(55551,(1:333),(rabbit(αHOGG1((Abcam,(ab124741,(1:10000),(rabbit(αHRad51((Santa(Cruz(Biotechnology,(scH293,(1:1000),(rabbit(αHRNaseH2((GeneTex,(GTX85020,(1:1000),(mouse(αHRPA2((Calbiochem,(1:50),( and( rabbit( αHpRPA2( (SerH4/SerH8,( Bethyl( Laboratories,( 1:500)( were( used.(Horseradish( peroxidase( (HRP)Hconjugated( secondary( antiHmouse( and( antiHrabbit(antibodies((GE(Healthcare)(were(used(at(a(dilution(of(1:5000.(((
Cell*culture*A2780( cells( were( grown( in( DMEM( (GIBCO)( supplemented( with( 5%( TetHOff( FCS,(streptomycin/penicillin( (100( U/ml),( blasticidin( and( puromycin.( HCT116( cells( and(HCT116(+(Chromosome(3(cells(were(grown(in(McCoy's(medium((GIBCO)(supplemented(with(10%(FCS(and(streptomycin/penicillin((100(U/ml).(((
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siRNA&transfection&&Cells%were% seeded% to%approximately%30350%%confluency%and% transfected%with%40%pmol%siRNA% oligonucleotides% using% Lipofectamine% RNAiMAX™% (Invitrogen)% according% to%manufacturer's%instructions.%The%medium%was%refreshed%20%hours%post3transfection%and%cells%re3seeded%for%48h%after%transfection.%The%following%oligonucleotide%sequences%were%applied:%%Luciferase%(siLuc)%5'3CGUACGCGGAAUACUUCGA33'%(Microsynth,%Switzerland),%%MYH%5'3UCACAUCAAGCUGACAUAUCAAGUA33'%(Microsynth,%Switzerland),%%BRCA1%5'3ACCAUACAGCUUCAUAAAUAA33'%(Microsynth,%Switzerland),%%RAD51%5'3GAGCUUGACAAACUACUUC33'%(Microsynth,%Switzerland),%%RNaseH2%5'3GGACUUGGAUACUGAUUAU33'%(Microsynth,%Switzerland).%%OGG1%SMART%pool%(4968,%M300514730330005,%Dharmacon)%consisting%of:%%5'3GAUCAAGUAUGGACACUGA33',%5'3AGAGGUGGCUCAGAAAUUC33',%%5'3GGUUCUGCCUUCUGGACAA33'%and%5'3GGAGCAAAGUCCUGCACAC33'%%%
CellTiter2Blue®&cell&viability&assay&For%viability%assays,%cells%were%seeded%in%triplicates%in%963well%plates%at%a%density%of%750%(A2780),%1000%(HCT116%and%HCT116+3)%and%2000%(SUM149PT)%per%well%48%hours%after%siRNA% transfection.% 24% hours% after% seeding,% the% cells% were% treated% with% the% indicated%concentrations%of%Olaparib.%Treatment%with%Olaparib%was%performed%continuously%for%72%or% 96% hours,% as% indicated.% Cell% viability% was% measured% with% the% CellTiter3Blue®% Cell%Viability% Assay% (Promega)% according% to% the% manufacturer's% instructions.% Fluorescence%(560Ex/590Em% nm),% an% indicator% of% metabolic% activity,% was% measured% 436% hours% after%addition%of%CellTiter3Blue®%reagent.%Whole% cell% extracts% for% Western% blot% analysis% were% prepared% on% the% day% of% the% drug%treatment,%using%2x%Laemmli%buffer%(120%mM%Tris3HCl%[pH%6.8],%4%%SDS,%20%%glycerol).%%
Immunofluorescence&Cells%were% cultured%on% glass% coverslips% and%24%h%post% seeding% cells%were% treated%with%10µM%Olaparib%for%24%hours.%Subsequently,%cells%were%fixed%with%3.7%%formaldehyde%for%10min%at%room%temperature%(RT)%and%permeabilized%using%0.2%%(v/v)%Triton3X3100% in%PBS%for%5min%at%RT.%After%blocking%with%5%mg/ml%BSA%in%PBS%for%30min%at%RT,%cells%were%incubated%with%the%primary%antibody%diluted%in%blocking%solution%for%1.5%h%at%RT:%mouse%α3BRCA1%(Santa%Cruz;%1:100).%Slides%were%washed%with%PBS%two%times%10%min%and%then%incubated% for% 1% hour% at% RT% with% according% secondary% antibody% in% blocking% solution:%alexa3488% conjugated% goat% anti3mouse% IgG% (Invitrogen;% 1:1000).% After% washing% twice%with% PBS% for% 10% min% and% rinsing% the% slides% once% quickly% in% ddH2O,% coverslips% were%mounted% on% Vectashield% with% 4’63diamidino323phenylindole% (DAPI)% (Vector%Laboratories).% Images% were% captured% with% an% Olympus% IX81% fluorescence%microscope%and%at%least%50%cells%were%analyzed%in%each%of%three%independent%experiments.%%%
Chromatin2binding&Assay&Chromatin%fractionation%was%adapted%from%the%previously%described%protocol%described%in%(30).%Briefly,%cells%were%harvested%and%incubated%in%buffer%A%(10%mM%HEPES%pH%7.9,%10%mM%KCl,% 1.5%mM%MgCl2,% 0.34%M% sucrose,% 10%%glycerol,% 1%mM%DTT,% 1%mg/ml%digitonin,%Roche% complete% protease% inhibitor% cocktail% and% addition% of% phosphatase% inhibitors:% 1%mM%NaVO3%and%10%mM%NaF)%on%ice%for%12%min.%Nuclei%were%washed%twice%with%PBS%and%chromatin3bound%proteins%were% extracted%using% 2x% Laemmli% buffer% (120%mM%Tris3HCl%[pH%6.8],%4%%SDS,%20%%glycerol).%Samples%were%sonicated% for%25%seconds%at%amplitude%72,% 50% cycles% (Bandelin% Sonoplus% GM70)% and% subsequently% prepared% for%western% blot%analysis.%%%%
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  RESULTS	  	  
	  ____________________________________________________________________________________________________________________	  56	  
	  
	  
Alkaline(Comet(Assay(The$ CometAssay®$ kit$ from$ Trevigen®$ was$ used$ as$ described$ per$ manufacturer's$protocol.$ Briefly,$ 48$ h$ after$ transfection$ with$ siRNA$ cells$ were$ reDseeded$ into$ 10$ cm$dishes$ and$ exposed$ to$ 10$ µM$ Olaparib$ for$ 24$ h$ the$ following$ day.$ Cells$ were$ reDsuspended$ in$ iceDcold$PBS$at$a$ concentration$of$2$x$105$ cells/ml,$ embedded$ in$molten$LMAgarose$at$a$ratio$of$1:10$and$spread$on$CometSlides™.$The$slides$were$immersed$in$4°C$ Lysis$ Solution$ for$ 30D60$ min$ before$ exposure$ to$ Alkaline$ Unwinding$ Solution$(pH>13)$for$20$min$at$RT$and$electrophoresis$at$21$V$for$30$min.$Subsequently,$slides$were$washed$twice$in$dH2O$and$once$in$70%$ethanol,$dried$at$37°C$for$10D15$min$and$stained$ with$ SYBR®$ Green$ for$ 30$ min.$ Images$ were$ captured$ with$ an$ Olympus$ IX81$fluorescence$ microscope$ and$ at$ least$ 60$ cells$ were$ analyzed$ in$ each$ of$ three$independent$experiments.$$$
Pulsed(Field(Gel(Electrophoresis(Pulsed$ field$ gel$ electrophoresis$ was$ performed$ as$ described$ previously$ (31).$ Briefly,$cells$were$ transfected$with$ siRNA$ in$ 6Dwell$ format,$ reDseeded$ into$ 10$ cm$dishes$ 48$h$after$transfection$and$treated$the$day$after$with$10$μM$Olaparib$for$24h.$Cells$were$then$harvested$ by$ trypsinization$ and$ agarose$ plugs$ were$ generated$ containing$ 250000$cells/plug.$ Quantifications$ were$ performed$ using$ ImageJ$ software,$ and$ graphs$generated$using$GraphPad$Prism.$$
Growth(curves(A2780$ cells$ were$ transfected$ with$ siRNA$ and$ 72h$ after$ transfection,$ cells$ were$ reDseeded$ into$ 12Dwell$ plates$ at$ a$ concentration$ of$ 20000$ cells/well.$ The$ following$ day$cells$were$ treated$with$ 10$ μM$Olaparib$ for$ the$ indicated$ time$points.$ Cells$were$ then$counted$and$absolute$number$of$cells$was$calculated.$$
FACS(Analysis(72$hours$after$siRNA$transfection,$ cells$were$ treated$with$Olaparib$at$10$μM$ for$24$h.$Cells$were$ then$collected,$washed$once$with$PBS$and$subsequently$ fixed$by$dropDwise$addition$of$iceDcold$80%$ethanol.$For$samples$preparation,$cells$were$washed$once$with$PBS$and$stained$with$25$μg/ml$propidium$iodide$(Fluka)$supplemented$with$100$μg/ml$RNaseA$(Sigma)$for$30min$at$RT.$Samples$were$analyzed$on$a$Cyan$ADP$flow$cytometer$(Beckman$Coulter)$fitted$with$Summit$software$v4.3$(Beckman$Coulter).$$$$Results$$
MYH?depletion(partially(rescues(toxicity(of(BRCA1?depleted(and(?deficient(cells(towards(the(
PARP(inhibitor(Olaparib(PARP$inhibitors$are$a$novel$class$of$anticancer$drugs$used$for$the$treatment$of$BRCA1D$or$ BRCA2Ddeficient$ breast$ and$ ovarian$ tumors$ that$ display$ a$ defect$ in$ homologous$recombination$(HR).$It$is$believed$that$the$toxicity$of$these$agents$in$HRDdefective$cells$is$mediated$through$an$accumulation$of$DNA$single$strand$breaks,$which$are$converted$to$ deleterious$ double$ strand$ breaks$ as$ a$ result$ of$ encounters$ with$ the$ replication$machinery.$ In$order$ to$ investigate$ the$origin$of$ the$causal$single$strand$breaks$(SSBs),$we$investigated$the$involvement$of$a$specific$DNA$glycosylase$MYH,$which$is$crucial$for$the$ repair$ of$ 8DoxoDguanine$ (GO)$ lesions$ that$ are$ paired$ with$ adenine$ (A)$ (29).$ MYH$recognizes$GO:A$pairs$and$excises$the$misincorporated$adenine$to$prevent$mutagenesis$(29,32,33).$Here$we$show$that$simultaneous$siRNADmediated$knockDdown$of$MYH$and$BRCA1$partially$ rescues$ the$ sensitivity$ of$A2780$ovarian$ carcinoma$ cells$ to$ the$PARP$inhibitor$Olaparib,$as$compared$to$cells$depleted$of$BRCA1$alone$(Fig.$1$A).$The$knockDdown$efficiency$of$BRCA1$and$MYH$is$shown$by$Western$Blot$analysis$(Fig.$1$B)$and$
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BRCA1&depletion/ is/ additionally/ confirmed/ by/ immunofluorescence/ imaging/ (Fig./ 1/C&D)./ Notably,/ BRCA1/ forms/ nuclear/ foci/ upon/ high&dose/ Olaparib/ treatment,/ which/underscores/the/requirement/for/HR/activity/in/cells/exposed/to/PARP/inhibitors.///

































siMYH + siBRCA1 

































Fig.1:/MYH* co-depletion* partially* rescues* Olaparib* sensitivity* of* BRCA1-depleted* A2780*
ovarian*carcinoma*cells.*A)/Cell/Titer/Blue/survival/assay/of/A2780/cells/transfected/with/siRNA/targeting/MYH,/ BRCA1/ or/ a/ combination/ of/ both/ treated/with/ increasing/ doses/ of/ Olaparib/ for/72h./The/survival/of/untreated/cells/was/set/to/100%./Error/bars/represent/SD/(n/=/3)./B)/Western/Blot/analysis/of/BRCA1/and/MYH/knock&down/efficiencies./C)/Immunofluorescence/imaging/using/anti&BRCA1/ antibody/ and/ 4’6&diamidino&2&phenylindole/ (DAPI)/ upon/ treatment/ of/ siRNA&transfected/cells/with/10/µM/Olaparib/for/24h./D)/Quantification/of/BRCA1/positive/cells/(>/10/foci/per/nucleus)/depleted/of/MYH,/BRCA1/alone/or/in/combination.///To/test/whether/the/observed/phenotype/is/a/general/one,/we/depleted/BRCA1/and/MYH/in/ combination/with/ BRCA1/ in/ several/ different/ cancer/ cell/ lines/ (Fig./ 2)./ Similarly/ to/A2780/cells,/MYH/and/BRCA1/co&depletion/reduces/Olaparib/toxicity/in/mismatch/repair&deficient/HCT116/colon/cancer/cells/as/well/as/HCT116/cells/complemented/with/part/of/chromosome/3/ (HCT116/+/ 3)/ (Fig./ 2/A),/ in/which/mismatch/ repair/ (MMR)/ is/ restored/(34)./It/thus/appears/that/the/cellular/MMR/status/does/not/influence/the/involvement/of/oxidative/DNA/damage/repair/by/MYH/on/PARP/inhibitor/sensitivity/in/BRCA1&depleted/cells./ This/ is/ an/ interesting/ observation,/ because/ it/ was/ shown/ that/ not/ only/ base&excision&repair/(BER),/but/also/the/MMR/machinery/can/recognize/and/process/oxidative/DNA/damage/(35&37)./Notably,/MMR&deficient/cells/(HCT116)/reacted/in/general/slightly/more/ sensitive/ to/ Olaparib/ treatment/ when/ compared/ to/ their/ MMR&proficient/counterparts/ (HCT116+3)./ This/ was/ already/ observed/ previously/ (38),/ however,/ the/exact/mechanism/ for/ this/ is/ still/ unclear./ In/ addition,/we/were/ able/ to/ recapitulate/ the/MYH&dependent/ rescue/ phenotype/ in/ U2&OS/ ovarian/ sarcoma/ cells/ (data/ not/ shown)./Collectively,/these/results/suggest/that/MYH&dependent/BER/of/GO:A/lesions/contributes/to/Olaparib/sensitivity/ in/a/variety/of/different/cancer/cell/ lines/ that/display/a/defect/ in/BRCA1.//
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and' BRCA1-deficient' cell' lines.' A)! Cell! Titer! Blue! survival! assays! of!MMR5deficient! HCT116!colon! cancer! cells! and! MMR5proficient! HCT116! cells! that! were! complemented! with! part! of!chromosome! 3! (HCT116! +! 3).! Cells! were! transfected! with! siRNA! targeting! MYH,! BRCA1! or! a!combination!of!both!and!treated!with!increasing!doses!of!Olaparib!for!72h.!Survival!of!untreated!cells!was! set! to!100%.!Data!are! represented!as!mean!±!SD! (n!=!2)!B)!Western!Blot! analysis!of!MYH!knock5down!efficiency!in!HCT116!and!HCT116!+!3!cells.!!!!
MYH$depletion-rescues-SSB-and-DSB-accumulation-in-Olaparib-exposed-cells-The!toxicity!of!PARP!inhibitors!is!thought!to!arise!from!an!accumulation!of!DNA!breaks!that!cannot!be!repaired!faithfully!in!cells!lacking!functional!HR.!We!therefore!monitored!DNA! strand! break! accumulation! at! single! cell! level! using! an! alkaline! comet! assay.! In!agreement! with! our! hypothesis,! compared! to! BRCA1! depletion! alone,! we! observed! a!marked! reduction! of! DNA! breaks! upon! MYH! and! BRCA1! co5depletion! in! A2780! cells!treated!with!10!µM!Olaparib!for!24!hours!(Fig.!3!A&B).!Next,!we!made!use!of!the!pulse!field! gel! electrophoresis! (PFGE)! technique! to! specifically! quantify! DNA! double! strand!breaks.!Also!here!we!found!significantly!reduced!levels!of!DSBs!in!MYH!and!BRCA1!co5depleted! samples!upon!exposure! to!Olaparib! (Fig.! 3!C&D).!Notably,!MYH5depletion!by!itself!also!seems!to!reduce!the!amount!of!SSBs!and!DSBs!in!genomic!DNA!compared!to!control!cells!(siLuc),!although!to!a!slightly!lower!degree!than!in!BRCA1!co5depleted!cells.!Collectively,! these! results! suggest! that!MYH5initiated! repair! of! oxidative! DNA! damage!creates! transient! SSBs,! which! likely! require! functional! PARP! activity! for! repair.! As! a!result! of! PARP! inhibition! by! Olaparib,! these! SSBs! accumulate! in! the! genome! and!eventually!collapse!into!deleterious!DSBs,!which!cannot!be!repaired!faithfully!in!BRCA15deficient!cells.!!!
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Fig.3:!MYH* depletion* partially* reduces* DNA* strand* breaks* upon* Olaparib* treatment* of*
BRCA1Ddepleted* A2780* cells.* A&B)! Representative! images! and! quantification! of! three!independent! Alkaline! Comet! experiments! in! A2780! cells! depleted! of! MYH,! BRCA1! or! a!combination! of! both! treated! with! 10! µM! Olaparib! for! 24h.! Relative! Tail! Moment! (%)! was!normalized! to! siBRCA1! samples,! which! was! set! to! 100%.! C&D)! Representative! image! and!quantification! of! three! independent! Pulse! Field! Gel! Electrophoresis! (PFGE)! experiments! in!A2780! cells! upon! Olaparib! treatment! (10! µM)! for! 24h.! Relative! amount! of! DSBs! (%)! was!normalized! to! siBRCA1! samples,! which! was! set! to! 100%.! M+B:! cells! transfected! with! a!combination!of!siRNA!targeting!MYH!and!BRCA1.!!!
MYH$depletion-leads-to-PARP-inhibitor-resistance-in-HR$deficient-cells-Besides! BRCA1! and! BRCA2,! also! other! factors! involved! in! homologous! recombination!were!shown!to!induce!synthetic!lethality!together!with!PARP!inhibitors.!In!order!to!test,!whether!the!reduced!sensitivity!and!genomic!instability!upon!MYH!depletion!is!due!to!a!general!defect!in!HR,!we!repeated!the!above[mentioned!experiments!in!Rad51[depleted!and!MYH! +! Rad51! co[depleted! A2780! cells! and! were! able! to! recapitulate! the! results!obtained! previously! using! siRNA! targeting! BRCA1.! Loss! of! MYH! leads! to! Olaparib!resistance,!and!reduces!the!accumulation!of!SSBs!as!well!as!DSBs!in!genomic!DNA!in!a!Rad51[deficient!background!(Fig.!4!A[F).!!!
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Fig.4:!MYH*co-depletion*partially*rescues*Olaparib*sensitivity*of*HR-deficient*A2780*cells.*A)!Cell!Titer!Blue!survival!assays!of!A2780!cells!depleted!of!MYH,!Rad51!or!a!combination!of!both!treated!with! increasing!doses!of!Olaparib! for!96h.!B)!Western!Blot!analysis!of!MYH!and!Rad51!knockMdown! efficiencies! in! whole! cell! extracts! (WCE)! and! chromatin! enriched! samples.! C&D)!Representative! images! and! quantification! of! one! Alkaline! Comet! experiment! in! A2780! cells!treated! with! 10! µM! Olaparib! for! 24h.! Relative! Tail! Moment! (%)! was! normalized! to! siRad51!sample,! which! was! set! to! 100%.! E&F)! Representative! image! and! quantification! of! three!independent!Pulse!Field!Gel!Electrophoresis! (PFGE)!experiments! in!A2780!cells!upon!Olaparib!treatment!(10!µM)!for!24h.!Smear!in!the!lower!part!of!the!gel!represent!smaller!DNA!fragments,!induced! by! genome! fragmentation! during! apoptosis.! Relative! amount! of! DSBs! (%)! was!normalized! to! siRad51! samples,! which! was! set! to! 100%.! M+R:! cells! transfected! with! a!combination!of!siRNA!targeting!MYH!and!Rad51.!!
!
Loss!of!MYH!does!not!lead!to!growth!defects!in!Rad518depleted!A2780!cells!To! rule! out! that! proliferation! defects! are! responsible! for! the! aboveMmentioned! MYHMinduced! rescue! of! Olaparib! toxicity,! we! investigated! growth! patterns! and! cell! cycle!distribution! of! siRNAMdepleted! cells.! Although! Rad51! knockMdown! reduces! overall!growth! rates! in!mockMtreated!A2780! cells,! additional!MYH!depletion! does! not! further!reduce!or!accelerate!the!observed!growth!retardation!(Fig.!5!A).!In!accordance!with!this!phenotype,! knockMdown! of! Rad51,! independently! of! MYH! status,! increases! the!population!of!cells!in!G2!phase!of!the!cell!cycle!(Fig.!5!B&C).!Furthermore,!MYH!knockMdown! had! no! effect! on! growth! rates! or! cell! cycle! distribution! in! Rad51Mdepleted! cells!that!were!exposed!to!the!PARP!inhibitor!Olaparib!(Fig.!5!DMF).!!!!
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depleted'A2780'cells.'A)!After!seeding!20000!cells!on!Day!0,!the!total!number!of!control!cells!was!counted!over!the!course!of!six!days.!B&C)!Representative!images!of!cell!cycle!profiles!after!Propidium! Iodide! staining! and! quantification! of! cells! in! the! different! cell! cycle! stages,!respectively.!DFF)!Growth! curve,!FACS!profiles! and!quantification!of! cells! in!different! cell! cycle!stages!upon!Olaparib!treatment!at!10!µM!for!24!hours!to!five!days.!!!!
PARP1%trapping%on%endogenous%DNA%lesions%mediates%Olaparib%toxicity!Trapping!of!PARP1!and!PARP2!on!DNA!after!lesion!recognition!was!proposed!to!be!the!major!mechanism!mediating! toxicity! of! several! different! clinical! PARP! inhibitors! (39).!According! to! this! hypothesis,! inhibition! of! PARP! by! a! certain! class! of! small! molecule!inhibitors! prevents! automodification,! which! is! characterized! by! synthesis! of! highly!negatively! charged! polyFADPFribose! (PAR)! polymers! on! itself! and! other! acceptor!proteins! upon! DNA! damage! binding.! These! PARP! poisons! thus! interfere! with! the!repulsion!of!the!protein!from!DNA!and!it!was!shown!that!trapped!PARPFDNA!complexes!are! more! cytotoxic! than! the! original! SSBs! (39).! Our! results! confirm! this! hypothesis.!Compared!to!siRNAFmediated!knockFdown!of!PARP1!alone,!loss!of!BRCA1!together!with!PARP1! yielded! about! 80%! survival! of! untreated! control! cells! (Fig.! 6! A).! Additionally,!compared!to!BRCA1Fdepletion,!simultaneous!knockFdown!of!BRCA1!and!PARP1!leads!to!reduced! Olaparib! sensitivity! (Fig.! 6! B),! suggesting! that! the! absence! of! PARP1! confers!Olaparib! resistance! because! no! PARPFDNA! complexes!will! be! formed.! KnockFdown! of!MYH!in!this!background!did!not!result!in!any!additional!effects!on!cell!viability!in!control!or! Olaparib! treated! cells! (Fig.! 6! A&D).! Although! we! cannot! strictly! rule! out! a!contribution! of! PARP2! or! PARP3,! which! are! also! inhibited! by! Olaparib,! it! seems! that!trapping! of! the! protein! on! DNA! at! least! partially! contributes! to! its! phenotype! in! our!system.!!!!!
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Fig.6:' PARP1' depletion' reduces' Olaparib' toxicity' in' BRCA1>depleted' A2780' cells.' A)!Seeding!efficiencies!of!A2780!cells!depleted!of!PARP1!alone!or!in!combination!with!MYH!and/or!BRCA1! as! measured! in! untreated! populations! of! two! independent! Cell! Titer! Blue! survival!experiments.!The!survival!of!siPARP1Itransfected!cells!was!set!to!100%.!Error!bars!represent!SD!(n!=!2).!B)!Cell!Titer!Blue!survival!assay!shows!reduced!Olaparib!toxicity!upon!PARP1!and!BRCA1!coIdepletion.!The!survival!of!untreated!cells!was!set!to!100%.!Error!bars!represent!SD!(n!=!2).!!C)!Western! Blot! analysis! of! PARP1! and!MYH! knockIdown! efficiencies.! D)! Cell! Titer! Blue! survival!assay!of!PARP1Idepleted!A2780!cells!treated!with!increasing!concentrations!of!Olaparib!for!72h.!The!survival!of!untreated!cells!was!set!to!100%.!Error!bars!represent!SD!(n!=!3).!!!!
RNaseH2(mediated- excision- of- genomic- rNTPs- does- not- contribute- to- PARP- inhibitor-
sensitivity-Ribonucleotides! (rNTPs)! are! frequently! misincorporated! into! the! DNA! by! replicative!polymerases!under!physiological! conditions! and! are! likely! the!most! abundant! form!of!DNA!damage! in! the! genome! (40,41).! They! are! about! 100000Ifold!more! susceptible! to!spontaneous!hydrolysis! than!deoxynucleotides!due! to! the!additional! reactive!hydroxyl!group!at!the!2'!position!of!the!ribose!sugar!(42),!which!is!why!processing!of!such!lesions!by! ribonuclease! (RNase)! H2! is! required! to! preserve! genomic! stability! (43).! We! thus!reasoned! that! RNaseH2Imediated! removal! of! genomic! rNTPs! could! be! another!mechanism!contributing!to!PARP!inhibitor!toxicity!in!HRIdeficient!cells.!In!order!to!test!this,!we!knockedIdown!RNaseH2!together!with!BRCA1,!but!found!that!these!cells!are!as!sensitive! to! PARP! inhibitor! treatment! as! BRCA1Idepleted! A2780! cells! (Fig.! 7! A).! CoIdepletion! of! RNaseH2! and! BRCA1! also! resulted! in! even! further! increased! DSB!accumulation! upon! exposure! to! Olaparib! (Fig.! 7! C),! suggesting! that! spontaneous!hydrolysis!of! rNTPs! leads! to!enhanced!genomic! instability! in! the!absence!of!RNaseH2.!These!results!also!imply!that,!unlike!MYHIinduced!BER!of!GO:A!!baseIpairs,!processing!of!rNTPs!by!RNaseH2!does!not!generate!transient!repair!intermediates!that!require!PARP!activity.! This! highlights! that! processing! only! of! a! specific! subset! of! endogenous! DNA!lesions!induces!PARP!inhibitor!sensitivity!in!HRIdeficient!cells,!which!likely!depends!on!the!molecular!repair!mechanism.!!
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Fig.7:! RNaseH2! co1depletion! does! not! rescue! Olaparib! sensitivity! of! BRCA11depleted!
A2780! cells.!A)!Cell!Titer!Blue!survival!assays!of!A2780!cells! transfected!with!siRNA!targeting!RNaseH2,! BRCA1! or! a! combination! of! both! treated!with! increasing! doses! of! Olaparib! for! 72h.!Survival!of!control!cells!was!set!to!100%.!Data!are!represented!as!mean!±!SD!(n!=!2)!B)!Western!Blot! analysis! of! MYH! knockQdown! efficiency.! C)! Cell! Titer! Blue! survival! assays! A2780! cells!transfected!with! siRNA! targeting!RNaseH2,!BRCA1!and!MYH!or!a! combination!of! those! treated!with! increasing!doses! of!Olaparib! for! 72h.!D)!Representative! image! of! PFGE! analysis! to! detect!DSBs!in!response!to!treatment!with!10!µM!Olaparib!for!24h.!
!
!!Discussion!The!use!of!PARP!inhibitors!to!specifically!target!BRCA1!or!BRCA2!deficient!ovarian!and!breast! cancer! cells! is! currently! tested! in! clinical! trials.! Olaparib! is! the! first! PARP!inhibitor!that!was!approved!for!clinical!use.!It!is!authorized!as!fourthQline!treatment!for!advanced!BRCAQmutated!ovarian!cancer.!However,!(acquired)!resistance!to!these!small!molecule!PARP! inhibitors!has! already!been!proposed! to!be! a!major!obstacle,! affecting!their! efficacy! and! clinical! outcome.! For! instance,! increased! drug! efflux! by!overexpression! of!multiQdrug! resistance! (MDR)! transporters! or! reduced! expression! of!PARP1! may! diminish! the! efficacy! of! Olaparib! and! other! PARP! inhibitors! (44).!Furthermore,!secondary!mutations!that!restore!functional!BRCA1!or!BRCA2!proteins,!as!well!as!inhibition!of!the!NHEJ!pathway!due!to!mutations!or!loss!of!53BP1!or!Rev7!(also!known! as! MAD2L2)! can! reactivate! HR,! rendering! cells! insensitive! to! PARP! inhibitor!treatment! (3,44Q48).! We! hypothesized! that! loss! of! other! factors,! which! normally!contribute! to! PARP! inhibitor! sensitivity! in! HRQdeficient! cells,! could! lead! to! drug!resistance.! Likely! candidates! appeared! DNA! repair! proteins,! which! are! involved! in!processing! of! endogenous! DNA! damage.! We! focused! on! oxidative! lesions! due! to! the!increased!levels!of!ROS!in!cancer!cells!and!found!that!loss!of!the!BER!glycosylase!MYH,!which!is!crucial!for!the!repair!of!potentially!mutagenic!GO:A!baseQpairs,!partially!inhibits!Olaparib!toxicity!in!HRQdeficient!cells.!Our!results!indicate!that!MYHQdepletion!reduces!the!number!of!transient!SSBs,!which!are!normally!generated!by!the!combined!actions!of!MYH!and!APE1!upon!excision!of!misincorporated!adenines!opposite!GO!and!subsequent!cleavage! of! the! sugarQphosphate! backbone! of! the! DNA.! PARP1! may! recognize! these!transient!repair!intermediates!and!facilitate!fast!and!efficient!repair.!Inhibition!of!PARP!will!consequently! interfere!with!the!repair!process!and!lead!to!their!collapse!into!oneQended! DSBs! or! induce! the! formation! of! DNAQPARP! complexes,! which! are! highly!cytotoxic.! Our! results! highlight! the! importance! of! oxidative! DNA! damage! repair!initiation!for!the!efficacy!of!PARP!inhibitors!in!HRQdeficient!cells.!These!findings!could!
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have%important%implications%for%personalized%medicine,%considering%that%the%application%of% PARP% inhibitors% in% hypoxic% tumor% regions% might% be% ineffective% due% to% reduced%oxidative% pressure% and% therefore% reduced% number% of% oxidative% DNA% lesions% that% may%contribute% to% PARP% activation.% Furthermore,% one%may% envision% that% low% expression% or%mutation% of% MYH% in% tumors,% such% as% MYHDassociated% polyposis% (MAP),% could% lead% to%PARP%inhibitor%resistance%and%therefore%serve%as%a%suitable%prognostic%biomarker%in%the%clinic.% However,% detailed% bioinformatic% analysis% of% patient% data% will% be% required% to%confirm%this%hypothesis%in%the%future.%%Besides% oxidative% DNA% damage,% also% other% types% of% endogenous% DNA% damage% could%potentially% contribute% to% PARP% inhibitor% toxicity% in% HRDdeficient% cells.% Specifically,% we%investigated%ribonucleotide%processing%by%RNaseH2%due%to%the%vast%abundance%of%rNTPs%in%genomic%DNA.%However,%we%found%that%knockDdown%of%this%enzyme%had%no%protective%effect% towards% survival% and% DSB% accumulation% upon% Olaparib% treatment% in% BRCA1Ddepleted%cells.%This%emphasizes%that%different%endogenous%DNA%lesions%are%repaired%by%distinct%mechanisms,% which% likely% do% not% all% trigger% PARP% activation% and% can% thus% be%neglected% regarding% the% efficacy% of% PARP% inhibitor% therapy.% However,% considering% the%variety%of%different%endogenous% lesions,% the%question% raises,%whether%also%other% repair%factors,%besides%MYH,%could%contribute%to%PARP%inhibitor%sensitivity.%This%will%be%part%of%our%future%investigations.%%%References%%1.% Farmer,%H.,%McCabe,%N.,%Lord,%C.%J.,%Tutt,%A.%N.,%Johnson,%D.%A.,%Richardson,%T.%B.,%Santarosa,%M.,%Dillon,%K.%J.,%Hickson,%I.,%Knights,%C.,%Martin,%N.%M.,%Jackson,%S.%P.,%Smith,%G.%C.,%and%Ashworth,%A.%(2005)%Targeting%the%DNA%repair%defect%in%BRCA%mutant%cells%as%a%therapeutic%strategy.%Nature%434,%917D921%2.% Bryant,%H.%E.,%Schultz,%N.,%Thomas,%H.%D.,%Parker,%K.%M.,%Flower,%D.,%Lopez,%E.,%Kyle,%S.,%Meuth,%M.,%Curtin,%N.%J.,%and%Helleday,%T.%(2005)%Specific%killing%of%BRCA2Ddeficient%tumours%with%inhibitors%of%poly(ADPDribose)%polymerase.%Nature%434,%913D917%3.% Jaspers,%J.%E.,%Kersbergen,%A.,%Boon,%U.,%Sol,%W.,%van%Deemter,%L.,%Zander,%S.%A.,%Drost,%R.,%Wientjens,%E.,%Ji,%J.,%Aly,%A.,%Doroshow,%J.%H.,%Cranston,%A.,%Martin,%N.%M.,%Lau,%A.,%O'Connor,%M.%J.,%Ganesan,%S.,%Borst,%P.,%Jonkers,%J.,%and%Rottenberg,%S.%(2013)%Loss%of%53BP1%causes%PARP%inhibitor%resistance%in%Brca1Dmutated%mouse%mammary%tumors.%Cancer*Discov%3,%68D81%4.% Boulton,%S.%J.%(2006)%Cellular%functions%of%the%BRCA%tumourDsuppressor%proteins.%
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Institute( of( Molecular( Cancer( Research( of( the( University( of( Zurich( and( the( ETH( Zurich,(
Winterthurerstrasse(190,(8057(Zurich,(Switzerland(!!Abstract!Elg1! (Enhanced! level! of! genome! instability)! has! been! described! as! a! suppressor! of!genome! instability! in! yeast,! however,! very! little! is! known! about! its! human! homolog!ATAD5.! Both! are! constituents! of! alternative! replication! factor! complexes! (aRFC),! in!which! they! replace! the! large! subunit! RFC1! to! associate! with! the! four! small! subunits!RFC2'5! [1,! 2].! Due! to! accumulation! of! PCNA! and! ubiquitylated! PCNA! on! DNA! upon!depletion!of!Elg1!and!ATAD5,!both!aRFC!complexes,!Elg1/RFC2'5!and!ATAD5/RFC2'5,!have!been!proposed!to!act!as!PCNA!unloaders!in!yeast!and!human!cells,!respectively.!As!PCNA! plays! a! central! role! in! orchestrating! DNA! replication! and! repair! events! [3],! its!controlled! removal! from! DNA! may! be! crucial! to! maintain! genome! integrity.!Interestingly,!Elg1'!as!well!as!ATAD5'deficient!cells!display!hypersensitivity! to!certain!DNA! damaging! agents! [4,! 5].! These! results! demonstrate! that! Elg1! and! ATAD5! are!involved!in!DNA!repair!and!may!prevent!mutagenesis!in!response!to!DNA!damage.!!We!set!out! to!elucidate! the!role!of!human!ATAD5! in!genome!maintenance,! specifically!focusing! on! its! basic! biological! function! in! DNA! metabolism.! In! order! to! do! so,! we!investigated! replication! and! repair! in! ATAD5'depleted! human! cells! under! native!conditions! and! upon! exposure! to! DNA! damaging! agents.! Similarly! to! yeast! [4,! 5],! we!found!hypersensitivity!of!ATAD5'deficient!cells!towards!DNA!alkylating!agents,!such!as!MNNG!and!MMS.!Furthermore,!ATAD5'depleted!cells!were!sensitive! to! treatment!with!the! DNA! crosslinking! agent! MMC! and! the! PARP1! inhibitor! Olaparib.! Notably,! the!enhanced!sensitivity!to!DNA!damaging!agents!correlated!with!an!accumulation!of!DNA!double'strand! breaks! or! apoptosis,! demonstrating! that! ATAD5! is! indeed! required! to!maintain! genome! integrity.! In! addition,! we! confirm! an! accumulation! of! PCNA! and!PCNAub!on!chromatin!upon!ATAD5!depletion;!however,!this!did!not!lead!to!any!defect!in!replication,!suggesting!that!ATAD5!is!not!involved!in!replication!per(se.!Collectively,!our!data! confirm! a! role! for! the! human! ATAD5! in! genome!maintenance! upon! exposure! to!DNA! damaging! agents.! However,! thus! far! we! were! not! able! to! prove! whether! its!molecular!function!is!to!unload!PCNA!or!PCNAub!from!DNA!to!protect!the!genome.!!!!Introduction!Our! genome! is! constantly! exposed! to! a! variety! of! endogenous! and! exogenous! DNA!damaging!agents!that!may!cause!mutations!if!not!corrected!before!replication.!In!order!to! protect! the! genetic! material! from! mutagenesis,! a! network! of! repair! pathways! has!evolved.!A!novel!factor!involved!in!maintaining!genome!stability!was!identified!in!yeast!genetic!screens!and!named!Enhanced! level!of!genome! instability! (Elg1)! [2,!4,!6].!Yeast!strains! lacking! Elg1! (Δelg1)! are! hypersensitive! to! certain! DNA! damaging! agents! and!exhibit! increased! levels! of! (gross)! chromosomal! rearrangements,! as! well! as!recombination! events! [4,! 7].! Additionally,! Elg1!was! shown! to! be! involved! in! telomere!maintenance,! sister! chromatid! cohesion! and! DNA! replication! [6,! 8,! 9].! However,! its!precise! function! in! DNA! repair,! especially! its! role! in! maintaining! genome! stability! in!human!cells,!still!remains!elusive.!!Elg1,!like!its!human!homolog!ATAD5,!is!part!of!an!alternative!replication!factor!C!(RFC)!complex!that!is!composed!of!five!subunits!Elg1/RFC2'5!or!ATAD5/RFC2'5,!respectively![1,! 2,! 4].! Elg1! or! ATAD5! replace! the! large! subunit! RFC1! of! the! canonical! RFC!(RFC1/RFC2'5)!complex!that!loads!proliferating!cell!nuclear!antigen!(PCNA)!onto!DNA!
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at#primer)template#junctions#to#facilitate#replication#[10].#RFC1#can#also#be#replaced#by#two#other#proteins,#namely#Rad17#(RAD24#in#human#cells)#or#Ctf18.#Rad17/RFC2)5#and#Ctf18/RFC2)5#are#involved#in#Rad9)Rad1)Hus1#(9)1)1)#complex#loading#at#sites#of#DNA#damage# [11]# and# sister# chromatid# cohesion# [12],# respectively.# The# Elg1/RFC2)5# and#ATAD5/RFC2)5# complexes# seem# to# be# required# for# the# unloading# of# PCNA# from#chromatin# in#yeast# as#well# as# in#human#cells# [13,#14].#Direct#biochemical# evidence# for#such#a# function# is# still#missing,#but# in#yeast# this#hypothesis#was# supported#by# the# fact#that# purified# Elg1/RFC2)5# is# able# to# unload# PCNA# from# chromatin# extracted# from# an#Elg1)deficient# yeast# strain# [13].# Recent# evidence# also# suggests# that# Elg1/RFC2)5# is#required# for# global# PCNA# unloading# after# Okazaki# fragment# ligation# throughout# the#genome# [15],# rather# than# solely# from# specific# unloading# at# sites# of# DNA# damage# or#cohesion.#In#human#cells,# indirect#evidence#was#provided#by#experiments#showing#that#PCNA#accumulates#on#DNA#in#the#absence#of#ATAD5#[14,#16].#Furthermore,#the#lifespan#of#active#replication#factories#on#DNA#was#extended#even#into#G2#phase#of#the#cell#cycle#[14].#ATAD5#was#proposed#to#maintain#low#levels#of#ubiquitinylated#PCNA#on#chromatin#by# recruiting# ubiquitin)specific# protease# 1# (USP1)# and# its# associated# factor# (UAF1)# to#ubiquitinylated# PCNA# [16].# Interestingly,# ubiquitylation# of# PCNA# is# required# for#translesion# synthesis# (TLS)# over# certain# DNA# lesions# [17].# Removal# of# PCNAub# from#chromatin#by#ATAD5#may#therefore#inhibit#error#prone#TLS#and#promote#more#accurate#repair#pathways.##Despite#the#advances#in#the#field,#the#exact#molecular#role#of#ATAD5#in#DNA#metabolism#is#still#unclear.#It#also#remains#enigmatic#how#removal#of#PCNA#or#PCNAub#contributes#to#maintain#genome#stability.#The#aim#of#this#study#was#thus#to#assess#the#role(s)#of#human#ATAD5# in#DNA#repair#and#replication,#especially#with# respect# to# its#potential# role#as#a#PCNA#unloader.#Our#results#confirm#that#ATAD5)deficient#cells#are#hypersensitive# to#a#subset#of#DNA#damaging#agents#and#accumulate#more#strand#breaks#upon#exposure#to#those#drugs.#Despite#the#accumulation#of#PCNA#and#PCNAub#on#chromatin,#replication#is#not# affected# by# ATAD5# depletion,# irrespective# of# whether# the# genome# is# intact# or#damaged.# Further# experiments# are# required# to# clarify# whether# unloading# of# PCNA# or#PCNAub# is# the#main# function# of# ATAD5# and# how# exactly# unloading# of# PCNA# promotes#genome#stability.####Material#and#Methods##
Cell$culture$and$shRNA1mediated$downregulation$of$ATAD5$A2780#cells#were#stably#transfected#with#two#different#expression#plasmids#containing#shRNAs# targeting# ATAD5# (1)6,# targeting# a# sequence# in# exon# 2:# 5')CUGACGAUGUACAAGAUAAUA)3'# and# 15)3,# targeting# a# sequence# in# the# 3'UTR:# 5')GUAUAUUUCUCGAUGUACA)3').#Cells#were#grown#in#DMEM#(Gibco),#complemented#with#5%# Tet)approved# fetal# calf# serum# (FCS,# Sigma),# penicillin# (100# U/ml,# Gibco)# and#streptomycin# (100#µg/ml,# Gibco),# Blasticidin# S# (10#mg/ml,# InvivoGen)# and#Puromycin#(10#mg/ml)#at#37°C#in#a#6%#CO2#humidified#atmosphere.#For#induction#of#ATAD5#knock)down,#cells#were#exposed#to#100#ng/ml#doxycycline#(Clontech)#for#at#least#four#days.#HEK293# TRex# FlpIN# cells# were# cultivated# in# DMEM,# supplemented# with# 10%# FCS#(Gibco),#Blasticidin#S#(10#mg/ml,#InvivoGen)#and#Puromycin#(10#mg/ml)#at#37°C#in#a#6%#CO2#humidified#atmosphere.#Knock)down#of#endogenous#PCNA#or#ATAD5#was#achieved#by#addition#of#100#ng/ml#doxycycline#(Clontech)#to#the#cell#culture#medium#for#at#least#three#days.##
Western$Blot$SDS# lysates#were# prepared# using# 2x# Laemmli# Buffer# (4%# SDS,# 20%# glycerol,# 120#mM#Tris# pH# 6.8)# and# boiled# for# 5# min# at# 95°C# before# sonication# (20# sec,# 50# cycles,# 70%#amplitude;#Bandelin#Sonoplus#GM70).#Protein#concentration#was#determined#using#the#
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Lowry&assay:&3&µl&sample&were&diluted&in&97&µl&H2O&and&incubated&for&10&min&with&1&ml&of& a& 50:1& mixture& of& Solution& A& (2%& Na2CO3& in& 0.1& N& NaOH)& and& Solution& B& (0.5%&CuSO4.5H2O& in& 1%& sodium& citrate).& 100& µl& of& a& Folin&Ciocalteau's& phenol& reagent&(Sigma)&and&H2O&dilution&(1:2)&were&added&to&the&mixture&and&incubated&for&1h&at&room&temperature& (RT).& Absorbance& was& measured& at& 750& nm& (VarianSCary& 50& Scan&spectrophotometer)& and& protein& concentration& calculated& according& to& a& calibration&curve&using&increasing&concentrations&of&a&BSA&standard.&&25S50&µg&protein&were&supplemented&with&5x&Loading&Buffer&(0.25&M&Tris&pH&6.8,&50%&glycerol,&8%&SDS,&0.5&mM&DTT,&0.1%&bromphenol&blue)&and&separated&according&to&size&on&acylamide&gels& (6%&for&ATAD5)&using& the&Mini&TransSBlot&Electrophoretic&Transfer&Cell&(BioRad)&in&10%&SDSSbuffer&at&100&V.&Proteins&were&transferred&in&Transfer&Buffer&(25& mM& Tris,& 192& mM& glycine,& 10%& methanol)& overnight& at& 4°C& to& a& HybondSP&Polyvinylidene& fluoride& (PVDF)& membrane& (Amersham& Pharmacia& Biotech)& that& was&previously& activated& in& 100%&methanol.& Membranes& were& blocked& in& 5%& nonSfat& dry&milk&in&1x&TBSST&(20&mM&TrisSHCl&pH&7.4,&150&nM&NaCl&and&0.1%&TweenS20)&for&at&least&30&min&at&roomtemperature&(RT)&before&incubation&with&primary&antibodies&overnight&at&4°C& in&5%&milk,&washing&3x&with&TBSST&and& subsequent& incubation&with& secondary&antibodies&(horseradish&peroxidase&(HP)Sconjugated&sheep&antiSmouse&or&donkey&antiSrabbit&IgG,&GE&Healthcare)&for&1h&at&RT.&After&three&washes&in&TBSST,&membranes&were&incubated& for& 1& min& with& WesternBright™& Chemiluminescent& Detection& Reagent&(Advansta)&(800&µl&H2O&mixed&with&200&µl&of&both&reagents)&and&analyzed&with&a&Fusion&Solo&(Vilber&Lourmat).&
!
Clonogenic!survival!assays!Four& days& after& exposure& to& doxycycline& (100& ng/ml),& cells& were& seeded& into& 6Swell&plates&at&a& concentration&of&300&cells&per&well,&prior& to& treatment&with&DNA&damaging&agents&the&following&morning.&For&MNNG,&cells&were&preStreated&with&O6Sbenzylguanine&(O6SBG)& for& 1& h& at& 10& µM,& before& addition& of&MNNG& for& the& remaining& duration& of& the&experiment.&Cells&were&exposed&to&mitomycin&C&(MMC)&or&hydroxyurea&(HU)&for&48&h&or&24&h,&respectively,&before&washing&out&the&drug&1x&with&PBS&and&subsequent&addition&of&normal& cell& culture&medium& for& the& remaining& duration& of& the& experiment.& Cells&were&continuously& treated& with& Olaparib,& camptothecin& (CPT),& TMPyP4& (Santa& Cruz)& and&S2T1S6OTD&(kind&gift&of&K.&Nagasawa).&Colonies& were& stained& 10& days& after& exposure& to& the& drug& with& 0.5%& Crystal& Violet&(MERCK)& in& 20%& ethanol& and& depicted& as& relative& survival& fraction& (%)& compared& to&control&cells&(set&to&100%&survival)&using&GraphPad&Prism&6.&&&
Pulse!Field!Gel!Electrophoresis!Assay!Cells& were& cultivated& with& or& without& 100& ng/ml& doxycycline& for& at& least& four& days&before&seeding&in&10&cm&dishes&to&reach&60%&confluence&on&the&day&of&the&treatment.&For&MNNG& treatment,& cells& were& preSexposed& to& 10& µM& O6SBG& and& then& treated& with& the&indicated&concentrations&of&MNNG&for&24&h,&48&h&or&96&h.&Cells&were&treated&with&0.5&µM&MMC& for& 96& h,& 2& µM&Olaparib& for& 24& h& or& 50& nM& camptothecin& (CPT)& for& 24& h.& At& the&indicated& time& points,& the& supernatant& was& collected& and& cells& were& harvested& by&trypsinization.& Cells& were& pelleted,& washed&with& PBS& and& counted& using& the& Countess&Automated& Cell& Counter& (Invitrogen)& and& 0.4%& Trypan& Blue& stain& (Invitrogen).& For&preparation&of&one&plug,&250'000&cells&were&transferred&to&a&new&tube,&spun&down&and&resuspended& in& 50& µl& PBS.& Subsequently,& cells& were& embedded& in& 1.5%& low& melting&agarose& (Sea& Plaque& GTG& Agarose,& Lonza)& at& 50°C,& pipetted& into& CHEF& plug& molds&(BioRad)& and& subsequently& incubated& in& Lysis& Buffer& (100& mM& EDTA& pH& 8.0,& 0.2%&Sodium&Deoxycholate,&1%&Sodium&Lauryl&Sarcosine,&20&mg/ml&Proteinase&K,&Applichem)&for&36S72&h&at&37°C.&After&washing&3x&for&30min&with&5&ml&washing&buffer&(20&mM&TrisSHCl,& 50&mM&EDTA&pH&8.0),& plugs&were& loaded& in&wells& of& a& 0.9%&Pulse& Field&Certified&Agarose&gel&(BioRad)&in&0.5%&TBE&buffer.&Electrophoresis&was&carried&out&in&a&CHEFSDR&
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III"Pulse"Field"Gel"Electrophoresis"System"(BioRad)"at"14°C:"block"I:"switch"time"30E18"s,"run" time"9" h," angle" 120°," voltage" gradient" 5.5"V/cm;" block" II:" switch" time"18E9" s," run"time"6"h,"angle"117°,"voltage"gradient"4.5"V/cm;"block"III:"switch"time"9E5"s,"run"time"6"h,"angle"112°,"voltage"gradient"4"V/cm."Gels"were"stained" in"0.5%"TBE"buffer" containing"0.5" µg/ml" Ethidium" bromide" (Sigma)" and" analyzed" on" an" Alpha" Innotech" imaging"system."""
Alkaline(Comet(Assay(Alkaline"Comet"Assays"were"performed"as"described"in"CometAssay®"(Trevigen)."Briefly,"cells"were"preEexposed" to"doxycycline" for" at" least" four"days"prior" to" treatment"with"3"mM"MMC"for"1"h."Samples"termed" 'recovery'"were"subsequently"washed"with"PBS"and"cultured"for"4"more"hours"in"normal"cell"culture"medium"before"trypsinization."Cells"(at"a"concentration"of"1x105/ml)"were"embedded"in"molten"LMAgarose"(Trevigen)"at"37°C"(ratio" 1:10" (v/v))" and" 50" µl" of" this" suspension" were" immediately" pipetted" onto"CometSlides™."Slides"were"chilled"for"10"min"at"4°C"before"immersion"in"Lysis"Solution"(Trevigen)" for" 30E60" min" at" 4°C" and" subsequent" irradiation" with" 5" Gy" to" enhance"background" levels" of" '%" comet" tail" DNA'." DNA" was" unwound" in" Alkaline" Unwinding"Solution," pH>13" (300" mM" NaOH," 1" mM" EDTA)" for" 20" min" at" 4°C" in" the" dark" and"electrophoresis"was"performed"at"21"V"for"30"min"in"a"CometAssay®"ES"unit"in"850"ml"chilled"Alkaline"Electrophoresis" Solution," pH>13" (300"mM"NaOH," 1"mM"EDTA)." Slides"were"washed" twice" in" dH2O" for" 5"min" each," then" once" in" 70%" ethanol," before" drying"completely"at"37°C"and"staining"with"SYBR®"Green"for"30"min"at"RT."Again,"slides"were"rinsed" quickly" in" dH2O" and" dried" completely" prior" to" analysis" on" a" Olympus" IX81"fluorescence"microscope.""
RNA(interference(Cells"were"transfected"at"a"densitiy"of"30E50%"using"RNAiMAX"(Invitrogen)"according"to"manufacturer's" instructions." For" 6Ewell" plates," 30" pmol" siRNA" (siATAD5" 15E3:" 5'EGUAUAUUUCUCGAUGUACAE3')"were"diluted"in"250"µl"OptiMEM"(Invitrogen)"and"mixed"well"with"250"µl"OptiMEM"supplemented"with"4"µl"RNAiMAX"transfection"reagent."After"incubation" at" RT" for" 15" min," the" mixture" was" added" dropEbyEdrop" to" the" cells" and"incubated"for"at"least"72"h.""""
Immunofluorescence(Cells" grown" on" cover" slides" were" washed" once" with" PBS" and" soluble" proteins" were"removed"by"incubation"with"Preextraction"Buffer"(25"mM"Hepes"pH"7.4,"50"mM"NaCl,"1"mM" EDTA," 3" mM" MgCl2," 300" mM" Sucrose" and" 0.5%" TritonEXE100)" for" 5" min" at" 4°C"(chromatinEbound"protein"fraction"is"retained)."Subsequently,"cells"were"washed"twice"with"iceEcold"PBS"and"fixed"in"3.7%"formaldehyde"(Sigma)"for"10"min"at"RT."Slides"were"then" washed" 3x" with" PBS" before" blocking" in" 5%" BSA" in" PBS" for" 30" min" at" RT" and"subsequent" incubation" with" primary" antibodies" in" blocking" solution" at" 4°C" overnight"(γH2AX:"1:500,"rabbit"polyclonal,"Cell"Signaling;"PCNA"scE56:"1:100,"mouse"monoclonal,"Santa" Cruz)." Cells" were" washed" again" 3x" with" PBS," incubated" with" appropriate"secondary"antibodies"in"blocking"solution"(FITCEconjugated"antiErabbit"antibody,"1:500,"Sigma" and" TREconjugated" antiEmouse" antibody," 1:500," Abcam)" for" 1" h" at" RT," washed"twice"with"PBS,"once"with"ddH2O"and"mounted"on"microscope"slides"(Thermo"Scientific)"with" Vectashield" mounting" medium" containing" DAPI" (Vector" Laboratories)." After"sealing," images" were" taken" at" a" 60x" magnification" on" an" Olympus" IX81" fluorescence"microscope."""
FACS(Analysis(Asynchronous" cell" population" treated"with" or"without" doxycycline" for" four" days"were"grown" in" 6Ewell" plates" to" reach" 70%" confluency" before" harvesting" by" trypsinization."Cells"were"pelleted,"washed"once"with"iceEcold"PBS"and"fixed"with"80%"ethanol"prior"to"
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staining'with'100'µg/ml'Propidium'Iodide'(Sigma)'in'PBS'supplemented'with'20'µg/ml'RNase'A'(Sigma)' for'30min'at'RT.'The'Cyan'ADP9'Flow'Cytometer'(Beckman'Coulter)'was'used'and'DNA'content'in'different'cell'cycle'phases'quantified'using'Summit'v4.3.01'software.'For' cell' synchronization' experiments,' cells' were' arrested' in' G1' phase' by' double'thymidine'block'(DTB).'Briefly,'2'mM'thymidine'(SynGen'Inc.)'was'added'to'cells'grown'at'a'confluence'of'60%.'16h'later,'thymidine'was'washed'out'with'PBS'(3x),'cells'were'released' into' medium' without' thymidine' for' 8' h' and' then' thymidine' (at' a' final'concentration'of'2'mM)'was'added'again' for' another'16'h.'One'hour'after' the' second'release,'10'µM'O6Xbenzylguanine'(O6XBG)'was'added,'cells'were'washed'3x'with'PBS'and'released'into'normal'medium'supplemented'with'1'µM'MNNG'and'10'µM'O6XBG.'At'the'indicated' time'points' cells'were'harvested'and' stained' for'FACS'analysis' as'described'above.''
Chromatin*extraction*Cells'were'treated'as'described'above'in'the'FACS'analysis'cell'synchronization'section,'prior'to'chromatin'extraction.'Briefly,'1.5'Million'cells'per'10'cm'dish'were'washed'once'with'iceXcold'PBS'before'incubation'with'Preextraction'Buffer'(25'mM'Hepes'pH'7.4,'50'mM' NaCl,' 1' mM' EDTA,' 3' mM' MgCl2,' 300' mM' Sucrose,' 0.5%' TritonXXX100' and' 1x'complete,' EDTAXfree' Roche' protease' inhibitor' cocktail)' for' 12'min' at' 4°C.' Cells' were'washed'again'2x'with'PBS'and'afterwards'scraped'in'100'µl'Laemmli'Buffer,'boiled'for'5min'at'95°C'and'sonicated'for'25'sec'(50'cycles,'70%'amplitude).'Protein'concentration'was'assessed'by'Lowry'assay'and'Western'Blot'performed'as'previously'described.'''
DNA*Fibre*Assay*Cells'were'grown'in'6Xwell'plates'to'70%'confluence'before'treatment'or'labeling'with'nucleoside'analogs'as'indicated.'4'µl'CldU'(5'mg/ml,'Sigma)'were'added'to'cells'grown'in'2.5'ml'medium'and' incubated' for'30'min' if'not'otherwise'stated.'CldU'was'washed'out'with' equilibrated'medium'and' replaced'by'medium'containing'1'mM' IdU' (Sigma)'for' another'30'min,' or' as' indicated.' Subsequently,' cells'were'washed'3x'with' iceXcold'PBS,'scraped'and'2'µl'of'a'cell'suspension'containing'1*106'cells/ml'were'pipetted'onto'a'glass'slide'(Super'Frost'Plus,'MenzelXGlaser).'Slides'were'dried'for'approximately'4'min'until''sticky','before'swirling'cells'in'7'µl'Lysis'Buffer'(200'mM'TrisXHCl'pH'7.4,'50'mM'EDTA,' 0.5%' SDS)' and' incubation' for' another'minute.' Subsequently,' slides'were' tilted'slightly'to' let'drops'run'down'slowly,'airXdried'and'fixed'in'methanol/acetic'acid'(3:1)'for'10'min'at'RT.'Slides'were'again'airXdried'and'stored'at'4°C.'Prior'to'staining,'slides'were' reXhydrated'with'PBS' twice' for'3'min,'DNA'was'denatured' in'2.5'M'HCl' for'1'h,'washed' 5x' in' PBS' for' 3'min' each' and' immersed' in' blocking' solution' (2%' BSA,' 0.1%'Tween' 20,' 1x' PBS;' 0.22' µm' filtered)' for' 40' min.' After' incubation' with' primary'antibodies'diluted'in'blocking'solution'(rat'antiXBrdU/CldU,'1:500,'Abcam;'mouse'antiXBrdU/IdU,'1:100,'Becton'Dickinson)'for'2.5'h'at'RT,'slides'were'washed'5x'3'min'in'PBS'supplemented' with' 0.2%' TweenX20' (PBSXT)' and' washed' once' briefly' in' blocking'solution.'Subsequently,' slides'were' incubated'with'secondary'antibodies' (antiXrat'Cy3,'1:300,'Jackson'Immuno'Research;'antiXmouse'Alexa'488,'1:300,'Molecular'Probes)'for'1'h'at'RT,'washed'5x'with'PBSXT' for'3'min'each'and'mounted'with'Vectashield'without'DAPI' (Vector' Laboratories).' DNA' fibre' tracks' were' analyzed' on' an' Olympus' IX81'fluorescence'microscope' and' track' length' determined' using' ImageJ' software.' At' least'100'fibres'were'analyzed'per'experiment'and'graphs'generated'using'GraphPad'Prism'6'of'at'least'two'independent'biological'replicates.''
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ATAD5%deficient-cells-are-hypersensitive-to-DNA-damaging-agents-Elg1' was' initially' identified' as' a' suppressor' of' genomic' instability' in' yeast' genetic'screens'[4,'5].' In'order'to'test'whether'the'mammalian'homolog,'ATAD5,'has'a'similar'protective'function'in'human'cells,'we'performed'clonogenic'survival'experiments'using'different'DNA'damaging' compounds'with'various'modes'of' action.'These' assays'were'performed' in' a' doxycyclineFinducible' A2780' ovarian' carcinoma' cell' lines' that' stably'harbor' two' different' shRNAs' targeting' ATAD5.' Cells' were' cultured' in' the' absence' or'presence'of'doxycycline'(Dox)'for'at'least'four'days'to'downregulate'the'protein'prior'to'treatment' with' the' indicated' drugs' (Fig.' 1' A).' We' detected' sensitivity' of' ATAD5Fdepleted'human'cells' to' the'methylating'DNA'agent'MNNG'only'when'cells'have'been'preFexposed' to' the' O6FMethylguanineFDNAFMethyltransferase' (MGMT)' inhibitor' O6Fbenzylguanine' (O6FBG)' (Fig.' 1' B).' MGMT' is' a' DNA' repair' enzyme' that' catalyzes' the'transfer'of'methyl'groups'from'DNA'bases'onto'itself'and'thereby'inactivates'itself.'The'fact' that' ATAD5Fdeficient' cells' are' only' sensitive' to'MNNG' treatment'when'MGMT' is'inhibited'led'us'to'the'assumption'that'ATAD5'may'be'linked'to'mismatch'repair'(MMR),'which'acts'on'certain'methylated'DNA'bases,'especially'when'they'persist'in'the'genome'and'give'rise'to'mispairs'during'replication.''Furthermore,' we' observed' that' A2780' cells' depleted' of' ATAD5' are' hypersensitive' to'mitomycin'C'(MMC),'an'interstrand'crosslinking'reagent,'and'Olaparib,'a'PARP'inhibitor'(Fig.'1'C&D).'These'results'hint'towards'a'role'of'ATAD5'in'homologous'recombination'(HR),' since' HR' is' ultimately' required' for' accurate' repair' of' interstrand' crosslinks.'Olaparib'inhibits'the'singleFstrand'break'(SSB)'repair'enzyme'PARP1'and'thus'induces'persistent' DNA' SSBs,' which' may,' upon' encounters' with' the' replication' machinery,'collapse' into' doubleFstrand' breaks' (DSBs)' that' also' require' HR' for' accurate' repair.'However,' doubleFstrand' break' reporter' assays' using' ATAD5Fdepleted' cells' were'inconclusive'and'varied'on'the'siRNA'sequence'(data'not'shown).'We'therefore'cannot'conclude'that'ATAD5'has'a'direct'role'in'HR.''In' contrast,' knockFdown' of' ATAD5' had' no' effect' on' survival' of' cells' treated' with'replication'inhibitors'camptothecin'(CPT)'and'hydroxyurea'(HU),'or'the'G4Fquadruplex'stabilizers'TMPyP4'and'S2T'(Fig.'1'EFH),'or'hydrogen'peroxide'(H2O2,'data'not'shown),'which' induces' oxidative' DNA' damage' and' strand' breaks.' Collectively,' these' results'suggest' that' ATAD5' is' important' for' the' maintenance' of' genome' stability' upon'induction' of' different' DNA' lesions,' however,' it' may' not' be' directly' involved' in'replication'or'telomere'maintenance.''
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Fig.1! A)! Representative! Western! Blot! of! doxycycline7inducible! ATAD5! knock7down! in! stable!clones!of!A2780!cells!harboring!either!shRNAs!176!and!1573.!B)!Clonogenic!survival!experiments!using!A2780!shATAD5!(1573)!cells!pre7treated!with!10!µM!O67BG!for!1h!before!addition!of!MNNG!at!the!indicated!concentrations!for!the!remaining!time!of!the!experiment!(10!days).!C)!Clonogenic!survival!experiment!using!A2780!shATAD5!(176)!cells!treated!with!the!indicated!concentrations!of!mitomycin!C!(MMC)!for!48h.!D)!Clonogenic!survival!experiment!using!A2780!shATAD5!(176)!cells!continuously!treated!with!the! indicated!concentrations!of!Olaparib.!E)!Clonogenic!survival!experiment! using! A2780! shATAD5! (176)! cells! continuosly! treated! with! the! indicated!concentrations!of!camptothecin!(CPT).!F)!Clonogenic!survival!experiment!using!A2780!shATAD5!(176)!cells!treated!with!the!indicated!concentrations!of!hydroxyurea!(HU)!for!24h.!G)!Clonogenic!survival! experiment! using! A2780! shATAD5! (176)! cells! continuosly! treated! with! the! indicated!concentrations!of!TMPyP4.!H)!Clonogenic!survival!experiment!using!A2780!shATAD5!(176)!cells!continuously! treated! with! the! indicated! concentrations! of! S2T176OTD.! Depicted! are!representative! results! obtained! from! at! least! two! independent! experiments! performed! in!triplicates.!!
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DNA$ damaging$ agents$ cause$ slightly$ increased$ accumulation$ of$ DNA$ strand$ breaks$ in$
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Fig.2$ A)$ Representative$ image$ of$ a$ Pulse$ Field$ Gel$ Electrophoresis$ (PFGE)$ assay$ of$ A2780$shATAD5$(146)$cells$pre4treated$with$10$µM$O64BG$before$addition$of$1$µM$MNNG$for$24h,$48h$or$72h.$B)$PFGE$of$A2780$shATAD5$(146)$cells$using$either$10$µM$O64BG$and$0.5$µM$MNNG$or$0.5$µM$MMC$for$96h.$C)$PFGE$of$A2780$shATAD5$(146$and$1543)$cells$treated$with$2$µM$Olaparib$for$24h.$ D)$ PFGE$ of$ A2780$ shATAD5$ (146$ and$ 1543)$ cells$ treated$ with$ 50$ nM$ CPT$ for$ 24h.$ E)$Representative$ images$of$comets$ in$an$Alkaline$Comet$Assay$upon$ treatment$with$MMC$ for$1h$and$subsequent$recovery$for$4h.$Cells$were$additionally$irradiated$using$5$Gy.$F)$Quantification$of$at$least$60$comets$per$experiment$of$an$Alkaline$Comet$Assay$(error$bars$represent$standard$deviations$(SD)$calculated$from$the$average$'%$Tail$DNA'$of$two$independent$experiments).$$
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Using&the&Alkaline&Comet&Assay&we&wanted&to&confirm&on&a&single&cell&level&that&ATAD5;deficient& cells& have& difficulties& to& repair& DNA& strand& breaks& induced& by& certain& DNA&damaging&agents.&The&alkaline&conditions&allow&to&visualize&not&only&DSBs&but&also&SSBs&in&genomic&DNA.&MMC&treatment&and&recovery&therefrom&indeed&had&a&mild&effect&on&the&percentage& of& comet& tail& DNA& in& ATAD5;depleted& cells& (Fig.& 2& E&F).& MMC& induces&interstrand&crosslinks&(ICLs)&and&therefore&reduces&the&mobility&of&DNA&molecules&in&an&electric& field.& Consequently,& more& DNA&will& remain& immobile& and& stay& in& the& nucleus&represented&by&the&comet&head.&Processing&of&ICLs&during&repair&subsequently&leads&to&the& restoration& of& the& background& tail& DNA& amount.& Our& experiments& show& that& the&recovery& from& ICLs& induced&by&MMC& is& abolished&or& delayed& in&ATAD5;deficient& cells.&However,& further& experiments& are& required& in& order& to& confirm& this& conclusion,&especially&analysis&of&longer&recovery&times&after&exposure&to&MMC&and&different&doses&of& the&drug.&Additionally,& it&would&be& interesting& to& investigate& the&effect&of&other&DNA&damaging& drugs& in& comet& assays& to& confirm& that& DNA& repair& is& indeed& affected& in&ATAD5;depleted&cells.&&&&&
ATAD5% depletion% causes% retention% of% PCNA(ub)% on% chromatin% and% a% delay% in% S>phase%
progression%It& has& already&been&proposed& a& few&years& ago& that&Elg1& and&ATAD5& function& as&PCNA&unloaders,& most& likely& together& with& the& small& RFC2;5& subunits& [2,& 16].& However,&biochemical& assays& that&would& provide& experimental& evidence& for& this& hypothesis& are&still& lacking,& presumably& due& to& missing& co;factors& or& posttranslational& modifications.&More&recently,&a&role&for&Elg1&and&ATAD5&as&PCNA&unloaders&has&been&strengthened&by&data& showing& that& purified& Elg1/RFC2;5& can& indeed& unload& PCNA& from& chromatin&extracted& from& a& Δelg1& yeast& strain& [13].& Furthermore,& depletion& of& ATAD5& causes&retention&of&PCNA&on&DNA&and&prolonged&lifespan&of&replication&factories&into&G2&phase&of& the&cell&cycle& in&human&cells& [14].&To&test&whether&this& is&also&true& in&our&hands,&we&depleted& ATAD5& in& A2780& cells& by& doxycycline;inducible& expression& of& an& shRNA&targeting& the& 3'UTR& of& ATAD5.& Western& Blots& of& whole& cell& extracts& (Fig.& 3& A)& and&immunofluorescence& staining& after& pre;extraction& (Fig.& 3& B)& confirmed& that& PCNA&accumulates& in& A2780& cells& upon& ATAD5& knock;down.& Interestingly,& the& amount& of&ubiquitylated& PCNA& (PCNAub)& was& also& increased,& as& shown& in& HEK293& chromatin&extracts&transfected&with&siRNA&targeting&ATAD5&(Fig.&3&A).&&Since&PCNA&accumulation&on&DNA&could&potentially&create&problems&during&replication,&especially& on& the& lagging& strand,& we& asked& whether& the& cell& cycle& of& ATAD5;depleted&cells& is& disturbed.& FACS& analysis& with& propidium& iodide& (PI)& staining& showed& a& slight&increase&in&the&S;phase&population&(Fig.&3&C),&but&not&a&profound&block&in&any&cell&cycle&phase,&as&also&reported&by&others&[13,&14].&However,&this&small&S;phase&retention&did&not&result&in&any&observable&increase&in&DNA&damage&under&control&conditions,&indicated&by&immunofluorescence&staining&of&γH2AX,&a&marker& for&DNA&strand&breaks& (Fig.&3&D).& In&order&to&gain&a&better&understanding&about&how&cells&progress&through&the&cell&cycle,&we&released&cells&from&a&G1&double&thymidine&block&(DTB)&and&simultaneously&treated&them&with&1&μM&MNNG& in& the&presence&of& 10&μM&O6;benzylguanine.& FACS&profiles& indicated&that&ATAD5;depleted&cells&progressed&slightly&slower&through&S;phase&(apparent&at&the&6&h,&10&h&and&12&h&time&points)&compared&to&control&cells&under&those&conditions&(Fig.&3&E).& Notably,& unmodified& as& well& as& ubiquitylated& PCNA& accumulated& on& chromatin& if&ATAD5&was&missing,&especially&at&early&time&points&after&release&from&the&DTB&(3&h&and&6&h),&when&cells&were&progressing&through&S;phase&(Fig.&3&F).&&
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Fig.3! A)!Western! Blot! of! doxycycline3inducible! ATAD5! knock3down! in! A2780! (1533)! cells! and!accumulation! of! PCNA! in! whole! cell! extracts! (WCE).! B)! Immunofluorescence! staining! of! pre3extracted!A2780!shATAD5!(1533)!cells!using!DAPI!and!the!anti3PCNA!(sc356)!antibody.!C)!FACS!cell!cycle!profiles!of!asynchronous!A2780!shATAD5!(136!and!1533)!cells.!The!percentage!of!cells!present!in!S3phase!is!indicated!in!red.!D)!Immunofluorescence!imaging!of!A2780!shATAD5!(1533)!cells! stained!with! DAPI! and! anti3γH2AX! antibody.! E)! FACS! cell! cycle! profiles! of! asynchronous!(AS)!population!A2780!shATAD5!(1533)!cells!and!cells!released!from!a!double!thymidine!block!(DTB).!F)!Western!Blot!analysis!of!chromatin!extracted!A2780!shATAD5!(1533)!cells! that!were!pre3treated!with! 10! µM!O63BG! for! 1! h! before! release! from! a!DTB! and! simultaneous! treatment!with!1!µM!MNNG!for!the!indicated!times.!!
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To# further# investigate# whether# accumulation# of# unmodified# PCNA# or# PCNAub# causes#genome# instability,#we#generated#a#doxycycline=inducible#HEK293#TRex#FlpIN#cell# line#in# which# we# can# simultaneously# downregulate# endogenous# PCNA# and# overexpress#either#eGFP=tagged#wild#type#PCNA#(eGFP=PCNA_WT)#or#a#PCNA#mutant#that#cannot#be#ubiquitylated#on# lysine#164#(eGFP=PCNA_K164R).#siRNA=mediated#depletion#of#ATAD5#increased#the#retention#of#residual#endogenous#PCNAub#on#chromatin#also#in#these#cells#(Fig.# 4#A)# and# likewise# increased# the# amount#of# exogenous#wild# type#eGFP=PCNAub#on#DNA# (Fig.# 4# B).# In# contrast,# the# eGFP=PCNA_K164R# mutant# was# as# expected# not#ubiquitylated#even#in#the#absence#of#ATAD5#(Fig.#4#D).##Despite# the# incomplete#knock=down#of#endogenous#PCNA,# these#cell# lines#can#serve#as#useful# tools# to# investigate# the# importance# of# PCNA# modification# by# ubiquitylation# or#SUMOylation#on#lysine#164#for#the#functional#characterization#of#ATAD5#in#maintaining#genome#stability.#One#may#envision#for#instance#that#ATAD5#is#merely#required#for#the#unloading#of#PCNAub#to#limit#or#prevent#translesion#synthesis#(TLS)#at#stalled#replication#forks.#On#the#other#hand,#ATAD5,#as#recently#proposed#for#yeast#Elg1,#could#be#a#general#unloader# that# removes#PCNA# from#DNA#after#Okazaki# fragment# ligation# [15],# possibly#independently# of# its# posttranslational# modifications.# Future# experiments# using# these#cells# will# show#whether# ATAD5# causes# sensitivity# to# DNA# damaging# agents# only# in# a#setting#where#PCNA# can#become#ubiquitylated,# or# if# it# is# generally# required# to# unload#PCNA#to#prevent#genome#instability.###
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Fig.4#A)#Western#Blot#analysis#of#chromatin#and#cytosolic#fractions#of#HEK293#TRex#FlpIN#cells#expressing# doxycyclin=inducible# shRNA# targeting# PCNA# and# simultaneously# expressing# eGFP=PCNA_WT.# The# two# lower# blots#were# incubated#with# an# anti=PCNA# antibody.# B)#Western# Blot#analysis# of# HEK293# TRex# FlpIN# shPCNA# +# eGFP=PCNA_WT# chromatin# extracts# (anti=PCNA#antibody).# C&D)# Western# Blot# analysis# as# described# in# A&B# with# HEK293# TRex# FlpIN# cells#expressing#shPCNA#and#the#eGFP=PCNA_K164R#mutant.###
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ATAD5%is%not%directly%involved%in%DNA%replication%We# reasoned# that# ATAD5# could# be# involved# in# DNA# replication# due# to# its# physical#association#with#the#replication#fork#via#PCNA#and#its#possible#role#as#a#PCNA#unloader#[18].#We# therefore# analyzed# replication#patterns# and#origin# firing#using# the#DNA# fibre#technique#in#two#different#A2780#clones#that#express#distinct#shRNAs#targeting#ATAD5#(clones# 1L6# and# 15L3)# upon# addition# of# doxycycline# to# the# cell# culture# medium.# The#length#of#CldU#tracks#was#unaffected#upon#ATAD5#downregulation,#demonstrating#that#replication#fork#speed#is#not#dependent#on#ATAD5#status#under#control#conditions#(Fig.#5# B&C).# Furthermore,# a# quantification# of# the# relative# abundance# of# certain# DNA# fibre#structures#(displayed#in#Fig.#5#D)#showed#that#there#was#no#significant#difference#in#the#percentage#of#stalled#replication#forks#or#late#origins#fired#(Fig.#5#E).#Collectively,#these#results# indicate# that# ATAD5# is# not# directly# involved# in# replication# under# native#conditions,#despite#its#direct#association#with#the#replication#fork#mediated#by#its#PCNA#interacting# motif# (PIP).# Additional# proof# for# this# was# provided# by# another# set# of#experiments#where#we#overexpressed#eGFPLtagged#wild# type#ATAD5# in#HEK293#TRex#FlpIN# cells.# Tow#different# clones# expressing# ectopic# eGFP_ATAD5# (clones# 1.2# and# 2.4)#upon# doxycycline# supplementation# showed# no# apparent# replication# fork# progression#defects# (Fig.# 5# F&G).# ATAD5# overexpression# alone# thus# does# not# appear# to# lead# to#uncontrolled# unloading# of# PCNA# from# chromatin,# which# would# interfere# with# active#replication.##In# order# to# test# whether# ATAD5#may# instead# be# required# for# replication# of# damaged#DNA,#we#also#measured#replication#fork#speed#in#ATAD5Ldepleted#cells#that#have#been#exposed#to#different#DNA#damaging#agents#previously#shown#to#induce#hypersensitivity#in# those# cells# (Fig.# 1).# None# of# these# agents# (MNNG,# MMC# or# Olaparib)# had# any#significant# impact# on# replication# fork# rates# at# the# indicated# exposure# times# and#concentrations# (Fig.# 6# ALC).#We# therefore# conclude# that# ATAD5# is# indeed# not# directly#involved#in#replication,#neither#on#undamaged#DNA#nor#across#different#types#of#lesions#induced# by#MNNG,#MMC# or# Olaparib.# Alternatively,# it#may# be# required,# like# the# yeast#Elg1/RFC2L5#complex,#for#PCNA#unloading#after#replication#and#ligation#of#each#Okazaki#fragment#had#been#carried#out#[15].#These#results#further#suggest#that#there#might#be#an#alternative#way#to#'recycle'#PCNA,#in#order#to#provide#a#sufficient#pool#of#free#PCNA#that#can#be#loaded#again#at#each#Okazaki#fragment#to#facilitate#normal#replication.#One#may#envision#that#alternative#unloader#complexes#take#over#when#ATAD5#is#missing,#or#that#the#PCNA#trimer#may#even#spontaneously#open#and#disassociate.####
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Fig.5! A)! Schematic! representation! of! the! labeling! protocol! with! CldU! and! IdU! in! a! DNA! fibre!assay.! Cells! cultured! in! the! absence! or! presence! of! 100! ng/ml! doxycycline! (Dox)! were!supplemented!first!with!CldU,!washed!once!and!subsequently!exposed!to!IdU!in!the!cell!culture!medium.!B)!Representative!images!of!A2780!shATAD5!(1N6!and!15N3)!cells!labeled!with!CldU!and!IdU!for!30min!each.!C)!Quantification!of!replication!fork!speed!(represented!as!CldU!track!length)!of!indicated!clones.!Only!progressing!replication!forks!(see!D)!were!analyzed.!D)!Representative!images! of! individual! DNA! fibre! structures.! E)! Quantification! of! relative! amount! of! beforeNmentioned!DNA! fibre! structures! in!A2780! shATAD5! (1N6! and!15N3)! clones.! F)!Western!Blot! of!doxycyclineNinducible!expression!of!stably!transfected!eGFP_ATAD5!in!HEK293!TRex!FlpIN!cells.!Two! clones! (1.2! and! 2.4)!were! chosen! for! analysis.! G)!Quantification! of! replication! fork! speed!(represented!as!IdU!track!length).!!
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Fig.6!A)!DNA!fibre!experiments!performed!using!A2780!shATAD5!(1>6)!cells!upon!pre>treatment!with!O6>BG!for!1h!and!exposure!to!MNNG!at!the!indicated!concentrations!for!30h.!The!cells!were!subsequently!labeled!with!CldU!and!IdU!for!30min!each!and!replication!fork!speed!measured!for!both! CldU! and! IdU! tracks.! B)! DNA! fibre! experiments! in! A2780! shATAD5! (15>3)! cells! upon!exposure!to!MMC!at!5!µM/ml!for!1h!and!subsequent!labeling!with!CldU!and!IdU!for!30min!each.!C)!DNA!fibre!experiments!using!A2780!shATAD5!(15>3)!cells!treated!with!10!µM!Olaparib!for!2h!before!exposure!to!CldU!for!45min!and!IdU!for!20min.!!
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Discussion(ATAD5(has(been( suggested( to(play(an( important( role( in(maintaining(genome(stability.(We(set(out(to(investigate(the(exact(function(and(molecular(mechanism(of(ATAD5(action(in(human(cells(with(special(focus(on(its(predicted(role(as(a(PCNA(unloader.(Our(results(confirm( a( contribution( of( ATAD5( to( preserving( genome( stability,( especially( upon(exposure(to(DNA(damaging(agents,(such(as(MNNG,(MMC(or(Olaparib.(This(is(highlighted(by( the( fact( that( ATAD5Edeficient( cells( are( hypersensitive( towards( these( agents( and(display( increased( accumulation( of( DNA( DSBs( and( a( greater( propensity( to( apoptosis.(While(the(hypersensitivity(observed(with(MMC(and(Olaparib(might(point(towards(a(role(of( ATAD5( in( homologous( recombination,( previous( experiments( using( DSBEreporter(assays(did(not(show(a(clear(effect(and(varied(depending(on(the(siRNA(sequence(used(to(knockEdown(ATAD5.(Controversial(reports(are(also(found(in(the(literature(on(the(role(of(ATAD5( in( HR,( some( stating( that( Elg1Edeficiency( causes( increased( spontaneous(recombination(events,(while(others(show(reduced(HR(frequency(in(reporter(assays([18,(19].(This(could(be(due(to(a(general(difference(in(spontaneous(recombination(versus(DSBEinduced( recombination( events;( however,( since( our( results( are( also( inconclusive,( we(cannot( state( at( this( point( that( ATAD5( indeed( plays( a( role( in( HR( of( DSBs.( One( may(speculate(though(that(ATAD5(is( involved(in(HREmediated(repair(of(stalled(or(collapsed(replication( forks,(which( are( induced( by(MMC( and(Olaparib,( respectively.(We( have( not(directly( tested( this( hypothesis,( but( several( of( our( experiments( indicate( that(ATAD5( is(not( involved( directly( in( the( process( of( replication.( First,( we( did( not( observe( any(significant( sensitivity( upon( ATAD5Edepletion( towards( replication( inhibitors,( such( as(camptothecin( and( hydroxyurea( or( the( G4Equadruplex( stabilizers( TMPyP4( and( S2T1E6OTD,(all(of(which(cause(replication(fork(stalling.(Furthermore,(DNA(fibre(experiments(provided(more(direct( evidence,( showing( that( replication( fork( speed(was(unaffected( in(ATAD5Edeficient(cells,(both(under(control(conditions(and(upon(DNA(damage(induced(by(either( MNNG,( MMC( or( Olaprib.( We( also( did( not( observe( increased( replication( fork(stalling(or(excessive(usage(of(late(origins(under(any(of(the(aboveEmentioned(conditions,(indicating( that( there(are(no(major(problems(causing( replication(blocks(or(deregulated(origin(firing.(Additionally,(overexpression(of(ATAD5(did(not(result(in(replication(defects,(suggesting( that( overrepresentation( of( ATAD5( alone( does( not( lead( to( uncontrolled(unloading(of(PCNA(from(the(DNA,(which(would(likely(cause(replication(inhibition.(This(points( towards( a( highly( regulated( role( of( ATAD5( in( removing( PCNA( from( DNA(when(replication( (of( individual( Okazaki( fragments)( has( finished,( or( alternatively,( at( specific(sites( in(the(genome.(In(agreement(with(these(results,(we(found(no(major(defect(during(cell( cycle( progression,( except( a( slightly( retarded( progression( through( SEphase( when(ATAD5( was( missing.( It( thus( seems( like( replication( fork( progression( and( cell( cycle(progression(are(largely(unaffected(by(ATAD5(status,(despite(the(fact(that(unmodified,(as(well(as(ubiquitylated,(PCNA(accumulates(on(chromatin(upon(ATAD5(depletion.(We(also(did(not(observe(an(enhanced(DNA(damage(response((DDR)(under(normal(conditions,(as(indicated( by( γH2AX( immunofluorescence( staining.( Conversely,( DNA( strand( breaks(clearly( accumulate( upon( exposure( to( DNA( damaging( agents,( as( discussed( above.( One(may( thus( speculate( that( unloading( of( PCNA( at( sites( of( DNA( damage( or( blocked(replication( forks( is( required( to( maintain( genome( stability,( rather( than( unloading( of(PCNA( from( undamaged( DNA.( Alternatively,( ATAD5( could( be( specifically( required( for(removal( of( ubiquitylated( PCNA,( for( instance( to( avoid( translesion( synthesis( at( stalled(forks( and( promote( other( DNA( repair( pathways.( In( order( to( investigate( whether(accumulation(of(PCNA(or(PCNAub(is(causing(genomic(instability(upon(ATAD5(depletion,(we(generated(cell(lines(that(enable(downregulation(of(endogenous(PCNA(by(shRNA(and(simultaneous( overexpression( of( wild( type( PCNA( or( a( mutant( that( cannot( be(ubiquitylated(on(lysine(164((PCNA_K164R)(any(more.(These(cells(will(be(useful(tools(to(investigate(whether(the(phenotypes(observed(upon(ATAD5Edepletion(are(dependent(on(
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PCNA%ubiquitylation%or%not.%However,%additional% transfection%of% siRNA% targeting%PCNA%will%be%required,%due%to%the%incomplete%knockAdown%of%the%endogenous%protein.%%In%order%to%characterize%functional%domains%of%ATAD5,%we%have%generated%cell%lines%that%enable%inducible%replacement%of%endogenous%ATAD5%with%GFPAtagged%wild%type%ATAD5%or% different%mutants% (data%not% shown).% Expressing%ATPaseAdead%mutants% (ATAD5_KR)%will% clarify%whether%ATP%hydrolysis% is% required% for%PCNA%unloading%or%other%unknown%functions% of% ATAD5.%We% have% also% generated% a%mutant% that% is% unable% to% interact%with%PCNA% via% its% PCNAAinteracting% peptide% (PIP)% motif% and% another% one,% which% cannot%interact% with% the% USP1AUAF1% complex% that% deubiquitylates% PCNAub.% Careful%characterization% of% these% mutants% will% hopefully% shed% light% on% the% role% of% ATAD5% in%preserving%genome%stability%and%domains%required%therefore.%%In% conclusion,% this% study% has% provided% further% evidence% that% mammalian% ATAD5% is%indeed%involved%in%maintaining%genome%stability.%However,% thus%far%we%were%unable%to%characterize%its%exact%function%in%DNA%metabolism.%This%is%mainly%due%to%the%difficulties%to% identify% a% pronounced% and% reproducible% phenotype.%We% believe% that% ATAD5% is% not%directly% involved% in% DNA% replication,% but% unfortunately% we% cannot% conclude% thus% far%whether% unloading% of% PCNA% or% PCNAub% is% an% essential% function% of% ATAD5.% Further%experiments,% using% the% generated% tools,%will% hopefully% clarify% how%ATAD5% operates% to%maintain%genome%stability.%%%%References%%1.% Kanellis,%P.,%R.%Agyei,%and%D.%Durocher,%Elg1(forms(an(alternative(PCNA5interacting(
RFC( complex( required( to(maintain(genome( stability.% Curr% Biol,% 2003.%13(18):% p.%1583A95.%2.% Bellaoui,% M.,% et% al.,% Elg1( forms( an( alternative( RFC( complex( important( for( DNA(
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complex(related(to(replication(factor(C.%Proc%Natl%Acad%Sci%U%S%A,%2003.%100(17):%p.%9906A11.%5.% Cejka,% P.% and% J.% Jiricny,% Interplay( of( DNA( repair( pathways( controls( methylation(
damage(toxicity(in(Saccharomyces(cerevisiae.%Genetics,%2008.%179(4):%p.%1835A44.%6.% Banerjee,% S.% and% K.%Myung,% Increased(genome( instability( and( telomere( length( in(
the( elg15deficient( Saccharomyces( cerevisiae( mutant( are( regulated( by( S5phase(
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13.$ Kubota,$ T.,$ et$ al.,$ The$ Elg1$ replication$ factor$ C3like$ complex$ functions$ in$ PCNA$
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CANCER	  &	  DNA	  REPAIR	  Genome	  instability	  is	  a	  hallmark	  of	  cancer	  and	  has	  been	  described	  as	  both	  a	  cause	  and	  a	  consequence	  of	  tumor	  initiation	  and	  progression	  [10,	  11].	  It	  is	  thus	  not	  surprising	  that	  novel	  approaches	  in	  oncology	  aim	  at	  targeting	  DNA	  damage	  signaling	  and	  repair	  pathways	  in	  an	  attempt	  to	  eradicate	  cancerous	  cells	  [7,	  349].	  In	  fact,	  ionizing	  radiation	  as	  well	  as	  commonly	  used	  chemotherapeutics,	  which	  have	  been	  applied	  for	  the	  treatment	  of	  human	  malignancies	  since	   many	   decades	   (e.g.	   nitrogen	   mustard	   analogues,	   antimetabolites,	   cisplatin	   and	  mitomycin	  C),	  induce	  DNA	  damage	  to	  inhibit	  tumor	  growth.	  This	  rationale	  has	  proven	  to	  be	  effective,	  because	  DNA	  lesions	  interfere	  with	  normal	  replication	  and	  transcription	  and	  even	  induce	  apoptosis	  when	  they	  exceed	  a	  certain	  threshold.	  DNA	  damage	  is	  thus	  a	  double-­‐edged	  sword:	  on	  the	  one	  hand,	  it	  can	  drive	  and	  enhance	  tumor	  progression	  through	  enabling	  the	  evolution	   of	   cells	   with	   a	   proliferative	   advantage	   and	   resistance	   to	   anti-­‐growth	   signals	   or	  other	  adverse	  conditions.	  On	  the	  other	  hand,	  generation	  of	  excessive	  DNA	  damage	  is	  used	  in	  the	  clinic	  to	  overload	  the	  capacity	  of	  cellular	  DNA	  repair	  mechanisms	  and	  trigger	  cell	  death	  by	   apoptosis.	   In	   general,	   chemotherapeutic	   agents	   that	   induce	   DNA	   damage	   are	   not	   very	  selective	  for	  cancer	  cells,	  but	  target	  any	  dividing	  cell	  or	  are	  more	  toxic	  to	  cells	  that	  replicate	  actively.	  Hence,	  administration	  of	  such	  drugs	  leads	  to	  side	  effects	  that	  are	  often	  quite	  severe	  and	  therefore	  dose-­‐limiting.	  They	  are	  characterized	  by	  problems	  of	  the	  hematopoietic	  and	  digestive	   systems,	   the	   skin	   and	   hair	   follicles	   due	   to	   the	   high	   turnover	   and	   associated	  replication	  and	  growth	  rates	  of	  cells	  in	  these	  tissues.	  	  A	  major	   focus	  of	  research	   in	   the	  past	  decade	  has	  therefore	  been	  put	  on	  the	  discovery	  and	   development	   of	   novel	   therapies	   that	   specifically	   target	   malignant	   cells	   and	   spare	  normal	  tissues.	  Interestingly,	  cancer	  cells	  themselves	  harbor	  high	  loads	  of	  DNA	  lesions	  due	  to	   oncogene	   activation,	   the	   microenvironment,	   or	   oxidative	   stress	   caused	   by	   aberrant	  metabolism	  [6,	  350,	  351].	  Those	  cells	  are	  thus	  likely	  more	  dependent	  on	  active	  DNA	  repair	  mechanisms	  and	   inhibition	  of	   cell	   cycle	   regulators,	   such	  as	  p53,	  CHK1/2	  and	  CDKs.	   Some	  tumors	   actually	  upregulate	   certain	  DNA	   repair	  pathways	   in	  order	   to	   increase	   their	   repair	  capacity	   and	   cope	   with	   the	   elevated	   levels	   of	   DNA	   damage;	   this	   was	   shown	   to	   induce	  resistance	   towards	   conventional	   chemotherapy	   [352-­‐355].	   Inhibition	   of	   DNA	   repair	   thus	  represents	  an	   interesting	  strategy	   to	   improve	   the	  efficacy	  of	   current	  anticancer	   treatment	  options	   and	   reduce	   the	   toxicity	   to	   normal	   cells.	   Some	   cancer	   cells	   exhibit	   defects	   in	  DNA	  repair,	   which	   results	   in	   replication	   stress	   that	   further	   drives	   genomic	   instability	   and	  thereby	   promotes	   tumorigenesis	   [356].	   In	   this	   case,	   inhibition	   of	   a	   redundant	   or	   backup	  pathway	  mediates	  synthetic	  lethality,	  as	  cancer	  cells	  more	  heavily	  rely	  on	  those	  alternative	  repair	   mechanisms	   than	   normal	   cells.	   Numerous	   inhibitors	   targeting	   various	   different	  enzymes	   involved	   in	   DNA	   damage	   signaling	   and	   repair	   have	   already	   been	   generated,	  however,	  thus	  far	  only	  few	  have	  made	  it	  to	  the	  clinic.	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One	  class	  of	  drugs	  targeting	  DNA	  repair	  proteins	  are	  PARP	  inhibitors,	  which	  specifically	  kill	  homologous	  recombination	  (HR)-­‐deficient	  cancer	  cells	  as	  a	  consequence	  of	  a	  synthetic	  lethal	  interaction	  [2,	  3].	  PARP1	  is	  an	  enzyme	  involved	  in	  the	  repair	  of	  single-­‐strand	  breaks	  (SSBs),	   lesions	  that	  must	  be	  repaired	  rapidly,	  before	  the	  replication	  machinery	  encounters	  them,	  in	  order	  to	  avoid	  their	  collapse	  into	  deleterious	  double-­‐strand	  breaks	  (DSBs).	  Efficient	  and	   faithful	   repair	   of	   DSBs	   requires	   an	   active	   HR	   pathway,	   which	   uses	   the	   intact	   sister	  chromatid	  for	  repair.	  While	  in	  normal	  cells	  both	  the	  SSB	  repair	  pathway,	  as	  well	  as	  the	  HR	  repair	  pathway	  are	   intact,	  BRCA1-­‐	  or	  BRCA2-­‐mutated	   cancer	   cells	   lack	   functional	  HR	  and	  are	  thus	  sensitive	  to	  inhibition	  of	  PARP,	  due	  to	  an	  accumulation	  of	  toxic	  DNA	  strand	  breaks.	  	  Small	  molecule	  PARP	  inhibitors	  are	  actually	  used	  as	  stand-­‐alone	  monotherapies	  for	  the	  treatment	  of	  BRCA1-­‐	  or	  BRCA2-­‐mutated	  cancers.	  In	  an	  intact	  genome	  where	  strand	  breaks	  arise	   rarely,	  HR	   can	  deal	  with	   their	   repair	  without	   having	   to	   rely	   on	  PARP,	   so	   its	   activity	  should	  be	  dispensable	  in	  cells	  that	  have	  not	  been	  challenged	  with	  exogenous	  DNA	  damaging	  agents.	  Due	  to	  loss	  of	  heterozygosity	  of	  either	  BRCA1	  or	  BRCA2,	  HR	  is	  inactivated	  in	  tumor	  cells	   of	   patients.	   Furthermore,	   as	   a	   consequence	   of	   enhanced	   metabolism	   and	   oncogene	  activation,	  cancer	  cells	  do	  exhibit	  high	  levels	  of	  endogenous	  DNA	  damage	  in	  comparison	  to	  normal	  cells.	  We	   thus	  hypothesized	   that	   the	  underlying	  sources	  of	  DNA	   lesions	   leading	   to	  PARP	  inhibitor	  sensitivity	  are	  a	  consequence	  of	  endogenous	  stress	  that	  causes	  accumulation	  of	  SSBs	   in	   the	  genomic	  DNA.	  The	  exact	   type	  of	  DNA	   lesion	  contributing	   to	  PARP	   inhibitor	  sensitivity	   in	   HR-­‐deficient	   cells	   has	   been	   a	   matter	   of	   speculation	   and	   not	   proven	  experimentally	  thus	  far.	  	  One	  very	  common	  source	  of	  DNA	  damage	  is	  oxidation.	  Reactive	  oxygen	  species	  (ROS)	  are	  generated	  for	  instance	  due	  to	  oncogene	  activation	  and	  as	  byproducts	  of	  metabolism	  that	  is	   elevated	   in	   cancer	   cells.	   Especially	   the	   bases	   in	   the	   DNA	   are	   highly	   susceptible	   to	  oxidation,	  which	  can	  change	   their	  base-­‐pairing	  properties;	  8-­‐oxoguanine	   (GO)	   for	   instance	  can	  base-­‐pair	  with	  both	  C	  and	  A.	  GO:A	  mispairs	  are	  potentially	  mutagenic	  (when	  GO	  is	  in	  the	  template	  strand)	  and	  their	  repair	  is	  initiated	  by	  the	  base-­‐excision	  repair	  (BER)	  glycosylase	  MYH	   that	   excises	   the	   misincorporated	   A	   to	   allow	   insertion	   of	   a	   correct	   C	   [255].	   MYH-­‐induced	  repair	  of	  GO:A	  base-­‐pairs	   thus	  creates	   transient	  SSBs	  as	   repair	   intermediates	   that	  could	  activate	  PARP	  to	  facilitate	  efficient	  downstream	  repair.	  	  
Oxidative	   DNA	   damage	   repair	   initiated	   by	   MYH	   contributes	   to	   PARP	   inhibitor	  
sensitivity	  in	  HR-­‐deficient	  cells	  We	  hypothesized	  that	  oxidative	  lesions	  generated	  by	  endogenous	  ROS	  are	  contributing	  to	  PARP	  inhibitor	  sensitivity	  in	  HR-­‐defective	  cancer	  cells.	  To	  test	  this	  we	  co-­‐depleted	  MYH	  together	  with	   BRCA1	   in	   several	   different	   cancer	   cell	   lines	   and	   found	   that	   knock-­‐down	   of	  MYH	   reduces	   the	   toxicity	   of	   the	   PARP	   inhibitor	  Olaparib	   in	   these	   cells.	   Furthermore,	   SSB	  and	   DSB	   accumulation	   was	   reduced	   when	   cells	   were	   depleted	   of	   MYH,	   indicating	   that	  processing	   of	   GO:A	   mispairs	   by	   MYH	   actually	   does	   lead	   to	   genomic	   instability	   and	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consequently	   sensitivity	   to	   treatment	   with	   Olaparib.	   Similar	   results	   were	   obtained	   upon	  depletion	  of	  MYH	  together	  with	  Rad51,	  suggesting	  that	  this	  is	  a	  general	  effect,	  which	  is	  true	  for	   HR-­‐deficient	   cells	   and	   not	   dependent	   on	   BRCA1	   status	   alone.	   In	   addition,	   these	  experiments	  prove	  that	  intrinsic	  oxidative	  stress	  substantially	  contributes	  to	  PARP	  inhibitor	  sensitivity	  and	  that	  PARP	  is	  indeed	  involved	  in	  the	  processing	  of	  MYH-­‐mediated	  BER	  in	  vivo.	  	  
	  
Fig.22:	  Model	  for	  MYH-­‐induced	  BER	  of	  oxidative	  DNA	  damage	  leading	  to	  PARP	  inhibitor	  toxicity	   in	  HR-­‐
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oxidative	   or	   metabolic	   stress.	   However,	   it	   shows	   that	   SSBs	   generated	   as	   transient	  intermediates	  during	  BER	  have	  the	  potential	  to	  activate	  PARP	  and	  induce	  cell	  death.	  	  Considering	  this,	  one	  may	  speculate	  that	  next	  to	  MYH	  also	  other	  repair	  pathways	  might	  generate	   transient	   SSB	   repair	   intermediates	   that	   could	   be	   'highjacked'	   by	   PARP	   and	   thus	  induce	  PARP	  inhibitor	  sensitivity	  in	  an	  HR-­‐deficient	  background.	  With	  respect	  to	  oxidative	  DNA	   damage,	   OGG1	   as	  well	   as	   the	  NEIL	   family	  members	   (NEIL1-­‐3)	   come	   to	  mind.	   These	  BER	   glycosylases	   recognize	   and	   excise	   different	   types	   of	   oxidized	   nucleotides	   in	   the	  DNA	  and	   are	   therefore	   interesting	   candidates.	   Our	   preliminary	   results	   on	   OGG1	   showed	  increased	   DSB	   accumulation	   and	   a	   high	   variability	   in	   the	   survival	   experiments	   (data	   not	  shown).	  Furthermore,	  we	  observed	  a	  surprising	  toxicity	  of	  OGG1	  knock-­‐down	  alone,	  which	  could	  mask	  any	  effect	  on	  resistance	  and	  genomic	  instability	  induced	  by	  PARP	  inhibitors	  in	  OGG1-­‐depleted	   cells.	   Interestingly,	   the	  mechanism	   of	   action	   of	  MYH-­‐	   and	  OGG1-­‐mediated	  BER	  is	  different.	  While	  MYH	  is	  a	  DNA	  glycosylase	  that	  is	  thought	  to	  induce	  long-­‐patch	  BER,	  which	  requires	   the	  activity	  of	  PCNA,	  RPA	  and	  Polδ/ε,	  as	  well	  as	  FEN1	  and	  LigI,	  OGG1	   is	  a	  glycosylase/lyase	  that	  triggers	  short-­‐patch	  BER,	  carried	  out	  by	  Polβ,	  XRCC1	  and	  LigIII.	  The	  process	   of	   long-­‐patch	   BER	   presumably	   requires	   more	   time	   than	   the	   short-­‐patch	   repair	  process,	  which	  could	  allow	  sufficient	  time	  for	  the	  recruitment	  of	  PARP	  specifically	  to	  long-­‐patch	  repair	  sites,	  where	  it	  may	  be	  required	  to	  coordinate	  the	  repair	  process.	  Additionally,	  MYH-­‐initiated	   repair	   of	   GO:A	   mispairs	   restores	   GO:C	   pairs	   that	   additionally	   need	   OGG1	  activity	  to	  restore	  the	  original	  G:C.	  This	  two-­‐step	  repair	  process	  is	  consequently	  much	  more	  time	   consuming	   and	   requires	   the	   induction	   of	   at	   least	   two	   transient	   SSBs	   before	   the	   G:C	  base	  pair	   can	  be	   re-­‐established.	  Another	   important	   difference	   is	   that,	   in	   contrast	   to	  MYH,	  OGG1	   excises	   GO	   from	   lesions	   that	   are	   not	   directly	   mutagenic,	   namely,	   GO:C	   pairs.	   These	  lesions	  can	  arise	  throughout	  the	  cell	  cycle	  by	  oxidation	  of	  G	  residues	  in	  genomic	  DNA.	  GO:A	  mispairs	  (with	  GO	  in	  the	  template	  strand)	  on	  the	  other	  hand,	  which	  are	  recognized	  by	  MYH,	  can	  only	  be	  generated	  during	  S-­‐phase	  by	  misincorporation	  of	  A	  opposite	  an	  already	  oxidized	  GO	  present	  in	  the	  template	  strand.	  This	  is	  why	  MYH	  activity	  must	  be	  high	  during	  S-­‐phase	  to	  efficiently	   take	   care	   of	   those	   lesions,	   while	   OGG1	   has	   sufficient	   time	   to	   repair	   GO:C	   pairs	  throughout	  all	  phases	  of	  the	  cell	  cycle.	  With	  regards	  to	  PARP	  inhibitor	  sensitivity,	  it	  would	  be	   very	   interesting	   to	   dissect	   the	   differential	   roles	   of	   MYH	   and	   OGG1	   in	   the	   repair	   of	  oxidative	  DNA	   lesions	   and	   their	   impact	   on	  PARP	   activation,	   as	   this	  might	   have	   important	  implications	  for	  personalized	  medicine.	  	  Due	   to	   time	   constraints,	  we	  were	  not	   able	   to	   investigate	   in	  detail	   the	   contribution	  of	  other	  BER	  glycosylases,	  such	  as	  the	  NEILs,	  UNG,	  SMUG1,	  TDG,	  MBD4,	  MPG,	  NTH1	  on	  PARP	  inhibitor	   sensitivity	   in	  HR-­‐deficient	   cells.	   However,	   it	   is	   likely	   that	   next	   to	   oxidative	  DNA	  damage,	   processing	   of	   other	   types	   of	   endogenous	   DNA	   lesions	   can	   trigger	   PARP	   activity	  through	   the	  generation	  of	   transient	   repair	   intermediates.	   Spontaneous	  depurinations	   also	  represent	   a	   threat	   to	  genome	   integrity,	   leading	   to	   loss	  of	   about	  5000	  purines	  per	   cell	  per	  day.	   The	   resulting	   apurinic	   sites	   are	   recognized	   and	   incised	   by	   APE1,	   generating	   more	  potential	   substrates	   for	   PARP.	   Furthermore,	   it	   is	   believed	   today	   that	   APE1	   is	   required	  during	  most,	   if	  not	  all,	  BER	  reactions	  for	  incision	  of	  abasic	  sites	  or	  at	   least	  for	  trimming	  of	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inappropriate	  ends	  generated	  by	  bifunctional	  glycosylases	  that	  are	  not	  ready	  for	  gap	  filling	  by	  the	  polymerases.	  Inhibition	  of	  APE1	  could	  therefore	  potentially	  have	  the	  greatest	  impact	  amongst	   BER	   enzymes	   on	   the	   contribution	   to	   PARP	   inhibitor	   sensitivity	   in	   HR-­‐deficient	  cells.	   However,	   APE1	   is	   an	   essential	   enzyme,	   which	   is	   why	   its	   depletion	   or	   inhibition	   is	  highly	  cytotoxic	  and	  might	  mask	  the	  effects	   that	  we	  aimed	  at	   investigating.	  There	  are	  also	  other	   end-­‐processing	   enzymes,	   such	   as	   PNKP,	  which	   are	   required	   to	   create	   suitable	  DNA	  ends	  following	  DNA	  glycosylase-­‐mediated	  excision	  of	  the	  base.	  These	  are	  clearly	  interesting	  candidates,	   since	   it	   is	   also	   possible	   that	   such	   enzymes	   could	   prevent	   PARP	   activation,	  instead	  of	  promoting	  it,	  by	  binding	  with	  high	  affinity	  to	  the	  SSBs	  and	  thereby	  abolish	  access	  of	  PARP	  to	  the	  nicks.	  However,	  this	  remains	  a	  matter	  of	  speculation	  and	  will	  be	  clarified	  by	  future	  investigations.	  Enzymes	   that	   remove	   damaged	   nucleotides	   from	   the	   DNA	   precursor	   pool	   could	  potentially	  also	  contribute	  to	  PARP	  inhibitor	  sensitivity.	  MTH1	  is	  a	  hydrolase	  that	  degrades	  oxidized	   nucleotides,	   such	   as	   8-­‐oxo-­‐dGTP	   and	   2-­‐OH-­‐dATP,	   to	   prevent	   their	   incorporation	  into	   the	   DNA	   during	   replication.	   Recently,	   it	   was	   shown	   that	   inhibitors	   of	   MTH1	   induce	  'cancer	  phenotypic	  lethality'	  [8,	  287].	  MTH1	  is	  thus	  considered	  to	  be	  an	  essential	  protein	  for	  cancer	   cells,	   while	   being	   dispensable	   in	   normal	   cells	  where	   levels	   of	   oxidative	   stress	   are	  low.	   MTH1	   inhibitors	   increase	   the	   levels	   of	   oxidative	   DNA	   damage	   due	   to	   enhanced	  incorporation	  of	  oxidized	  nucleotides,	  which	  should	  then	  be	  substrates	  for	  MYH-­‐	  or	  OGG1-­‐induced	  BER	  that	  create	  transient	  SSBs.	  A	  combination	  therapy	  using	  both	  PARP	  and	  MTH1	  inhibitors	  in	  a	  HR-­‐deficient	  background	  may	  represent	  a	  promising	  strategy.	  We	  have	  tested	  this	   hypothesis	   experimentally	   (data	   not	   shown)	   and	   found	   that	   it	   is	   rather	   difficult	   to	  combine	   the	   MTH1	   inhibitor	   TH588	   with	   other	   drugs,	   due	   to	   the	   limited	   concentration	  window	   in	   which	   TH588	   is	   active,	   but	   not	   yet	   toxic	   to	   the	   cells.	   However,	   preliminary	  experiments	   using	   siRNA	   to	   mediate	   knock-­‐down	   of	   MTH1	   together	   with	   BRCA1	   point	  towards	   a	   small	   increase	   in	   Olaparib	   sensitivity	   when	   compared	   to	   BRCA1	   knock-­‐down	  alone	  (data	  not	  shown).	  Novel	  MTH1	  inhibitors	  may	  be	  more	  useful	  to	  test	  the	  above-­‐stated	  hypothesis	  and	  clarify	  whether	  MYH-­‐	  or	  OGG1-­‐initiated	  BER	  are	  capable	  of	  dealing	  with	  the	  increasing	   amount	   of	   oxidized	   nucleotides	   incorporated	   into	   the	   DNA	   in	   the	   absence	   of	  MTH1.	  	  The	   experiments	   we	   have	   performed	   in	   this	   study	   were	   all	   carried	   out	   without	  addition	   of	   exogenous	   DNA	   damaging	   agents	   in	   order	   to	   mimic	   situations	   where	  endogenous	  stress	  is	  the	  predominant	  source	  responsible	  for	  the	  generation	  of	  DNA	  lesions.	  We	  expect,	  however,	  that	  addition	  of	  oxidizing	  agents,	  such	  as	  H2O2	  or	  KBrO3,	  would	  further	  increase	   the	   sensitivity	   of	   BRCA1-­‐depleted	   cells	   towards	   PARP	   inhibitors.	   Conversely,	   co-­‐depletion	   of	  MYH	   should	   reduce	   this	   toxicity,	   as	   it	  would	   prevent	   processing	   of	   oxidative	  lesions	   and	   thus	   avoid	   generation	   of	   PARP-­‐activating	   intermediates.	   Preliminary	   results	  (data	   not	   shown)	   using	   H2O2	   are	   difficult	   to	   interpret	   due	   to	   the	   labile	   nature	   of	   this	  compound	  and	  the	  resulting	  variability	  within	  different	  experiments.	  Nevertheless,	  it	  seems	  that	   H2O2	   does	   have	   a	   negative	   effect	   on	   survival	   of	   BRCA1-­‐depleted	   cells	   exposed	   to	  Olaparib.	  Notably,	  H2O2	  induces	  at	  high	  concentrations	  not	  only	  oxidized	  DNA	  bases,	  such	  as	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8-­‐oxoguanine,	  but	   also	  DNA	  strand	  breaks	  and	  of	   course	  oxidation	  damage	   to	  proteins	   as	  well	  as	   lipids.	  This	   reduced	  specificity	   is	  especially	   important	  when	  considering	  results	  of	  other	   studies	   that	   apply	  high	  doses	  of	  H2O2	  or	  other	  DNA	  damaging	  agents.	  The	   standard	  cell	   culture	   conditions	   also	   do	   not	   fully	   represent	   normal	   physiological	   conditions,	  especially	  the	  heterogenic	  tumor	  environment,	  where	  most	  cells	  are	  actually	  under	  hypoxic	  conditions,	  while	  others	  located	  in	  close	  proximity	  to	  the	  afferent	  vessels	  are	  actually	  highly	  oxygenated.	   Other	   factors	   in	   the	   microenvironment	   might	   also	   affect	   oxidative	   stress,	  especially	   tumor-­‐infiltrating	   immune	   cells,	   which	   elicit	   a	   response	   that	   includes	   ROS	  production	  and	  release.	  Cell	  culture	  experiments	  are	  thus	  not	  able	  to	  fully	  recapitulate	  the	  complex	   nature	   of	   the	   tumor	   environment,	   especially	   with	   respect	   to	   factors	   that	   induce	  oxidative	  stress	  in	  a	  real	  tumor.	  On	  the	  other	  hand,	  it	  is	  also	  difficult	  to	  predict	  the	  amount	  of	   endogenous	   oxidative	   stress	   present	   in	   tumor	   cells	   and	   it	   might	   vary	   considerably	  between	   different	   cell	   types	   and	   even	   within	   the	   heterogenic	   population	   of	   tumor	   cells	  themselves.	  	  	  Interestingly,	   we	   and	   others	   show	   that	   siRNA-­‐mediated	   depletion	   of	   PARP1	  dramatically	  reduces	  the	  toxicity	  of	  PARP	  inhibitors	  in	  BRCA1-­‐deficient	  background	  [358],	  irrespective	  of	  MYH	  status.	  These	  results	  confirm	  the	  hypothesis	  that	  PARP	  inhibitors	  trap	  PARP	  on	  the	  DNA,	  as	   the	  enzyme	  cannot	  catalyze	   the	  addition	  of	  negatively-­‐charged	  poly-­‐ADP-­‐ribose	  polymers	  on	  itself	  that	  would	  normally	  lead	  to	  repulsion	  of	  the	  protein	  from	  the	  DNA.	   The	   resulting	   PARP-­‐DNA	   complexes	   are	   highly	   cytotoxic,	   presumably	   representing	  major	   blocks	   to	   replication	   and	   transcription	   [358].	   Furthermore,	   they	   require	   repair	  mediated	   by	   HR,	   which	   is	   impeded	   in	   BRCA1-­‐depleted	   cells.	   This	   would	   also	   explain	   the	  high	  amount	  of	  DNA	  DSBs	   in	   those	  cells	  upon	   treatment	  with	  Olaparib.	   In	  order	   to	  better	  understand	   this	   mechanism,	   one	   should	   use	   inhibitors	   of	   PARP,	   which	   block	   the	   DNA	  binding	   domains	   instead	   of	   the	   catalytic	   core.	   Furthermore,	   it	   would	   be	   interesting	   to	  dissect	   the	   contribution	   of	   other	   PARP	   family	   members	   involved	   in	   DNA	   repair,	   namely	  PARP2	  and	  PARP3.	  Today	  we	   still	   rely	  on	   siRNAs	   to	  do	   so,	  because	  none	  of	   the	   currently	  available	   PARP	   inhibitors	   are	   strictly	   selective	   and	   target	   several	   different	   PARP	   family	  members.	  	  As	  mentioned	  earlier,	  the	  sources	  of	  endogenous	  DNA	  lesions	  are	  manifold	  and	  do	  not	  only	   include	   oxidative	   DNA	   damage.	   We	   decided	   to	   investigate	   one	   other	   very	   common	  lesion,	   namely	   ribonucleotides	   (rNTPs),	   that	   are	   very	   frequently	   incorporated	   by	   the	  replicative	  polymerases.	  Ribonucleotides	  present	  in	  genomic	  DNA	  constitute	  a	  major	  threat	  to	   the	   stability	   of	   the	   genome	   and	   are	   normally	   repaired	   by	   RNaseH2	   [359].	   Our	   results	  indicate	   that	   despite	   the	   abundance	   of	   these	   lesions,	   RNaseH2-­‐mediated	   repair	   of	   rNTPs	  does	   not	   contribute	   to	   PARP	   inhibitor	   sensitivity	   in	   HR-­‐defective	   cells.	   In	   other	   words,	  processing	   of	   rNTPs	  does	   not	   create	   suitable	   SSB	   repair	   intermediates	   that	   require	   PARP	  activity.	   In	   contrast	   to	   MYH,	   RNaseH2-­‐induced	   repair	   might	   either	   create	   repair	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intermediates	  that	  are	  not	  substrates	  for	  PARP	  or	  not	  accessible	  to	  it	  due	  to	  tight	  binding	  of	  RNaseH2	  or	  downstream	  repair	  factors.	  We	  actually	  observed	  increased	  levels	  of	  DSBs	  upon	  RNaseH2	  depletion	  and	  treatment	  with	  PAPR	  inhibitors,	  confirming	  that,	   in	  the	  absence	  of	  RNaseH2,	  alternative	  processing	  or	  hydrolysis	  of	  rNTPs	  leads	  to	  an	  accumulation	  of	  strand	  breaks	  [359].	  In	  order	  to	  confirm	  that	  RNaseH2-­‐induced	  repair	  of	  these	  lesions	  really	  does	  not	  give	  rise	  to	  suitable	  substrates	  for	  PARP,	  in	  vitro	  assays	  should	  be	  carried	  out.	  	  	  To	  quantify	   the	   contributions	  of	  different	   repair	   factors,	   it	  would	  be	  advantageous	   to	  base	   future	  work	  on	  a	   clean	  genetic	   system	   that	  does	  not	   rely	  on	   siRNA-­‐mediated	  knock-­‐down	  efficiencies	  or	  other	  variables	   that	  are	  difficult	   to	  control.	  BRCA1-­‐	  or	  BRCA2	  knock-­‐out	  cell	  lines	  from	  patients	  do	  exist,	  however,	  they	  often	  have	  unstable	  phenotypes	  and	  are	  thus	  difficult	  to	  compare	  over	  time	  in	  cell	  culture	  setting.	  CRISPR/Cas9-­‐mediated	  knock-­‐out	  of	  HR-­‐factors	  BRCA1	  or	  BRCA2	  in	  combination	  with	  MYH	  (or	  other	  glycosylases	  and	  repair	  enzymes)	  knock-­‐out	  or	  depletion	  could	  be	  an	  interesting	  alternative	  to	  test	  our	  hypothesis	  in	  the	  future.	  	  	  
The	  role	  of	  ATAD5	  in	  genome	  maintenance	  Thus	   far,	   PARP	   inhibitor	   toxicity	   has	   been	   reported	   in	   cells	   displaying	   a	   defect	   in	  homologous	   recombination,	   due	   to	   the	   synthetic	   lethal	   interaction	   of	   this	   DNA	   repair	  pathway	   with	   SSB	   repair.	   Surprisingly,	   we	   found	   that	   cells	   depleted	   of	   ATAD5	   are	   also	  hypersensitive	  to	  treatment	  with	  Olaparib.	  A	  role	  for	  ATAD5	  in	  genome	  stability	  has	  already	  been	  suggested	  a	   few	  years	  ago	  [61];	  however,	   the	  observation	   that	  ATAD5-­‐deficient	  cells	  are	   particularly	   sensitive	   to	   Olaparib	   is	   new	   and	   points	   towards	   a	   contribution	   of	   the	  protein	  in	  HR.	  Unfortunately,	  previous	  results	  using	  HR-­‐reporter	  assays	  (DR-­‐GFP)	  failed	  to	  give	  a	  clear	  answer	  to	  the	  question	  whether	  ATAD5	  is	  indeed	  involved	  in	  the	  process	  of	  HR.	  It	   would	   therefore	   be	   interesting	   to	   further	   study	   HR	   in	   ATAD5-­‐depleted	   cells,	   e.g.	  investigate	  the	  spontaneous	  cellular	  HR	  frequency	  by	  measuring	  sister	  chromatid	  exchange	  (SCE)	   rates,	   instead	   of	   quantifying	   the	   repair	   efficiency	   of	   an	   artificially	   induced	   double-­‐strand	  break.	  We	  reasoned	  that	  instead	  of	  being	  required	  for	  HR	  at	  two-­‐ended	  DSBs,	  ATAD5	  function	  might	   instead	  be	  necessary	   for	  HR	  at	  collapsed	  replication	   forks	   that	  manifest	  as	  one-­‐ended	  DSBs.	  We	  therefore	  carried	  out	  DNA	  fibre	  experiments	  that	  allow	  visualization	  of	  DNA	   replication	   tracks	   and	   therefore	  quantification	  of	   replication	   speed,	   origin	   firing	   and	  fork	   stalling.	   Similarly	   to	   results	   from	   the	   Myung	   lab	   [50],	   we	   did	   not	   observe	   any	  discrepancies	   in	   replication	   fork	  progression	   rates	  upon	  ATAD5	  depletion	   in	  unperturbed	  cells.	  Additionally,	  we	  did	  not	  detect	  any	   increase	   in	  the	  percentage	  of	   late	  origin	   firing	  or	  early	   terminations.	   These	   results	   imply	   that	   origin	   firing	   is	   not	   deregulated	   and	   further	  show	   that	   downregulation	  of	  ATAD5	  by	   itself	   does	  not	   lead	   to	   replication	   fork	   stalling	   or	  collapse	   on	   undamaged	   genomic	   DNA.	   In	   order	   to	   test	   whether	   ATAD5	   may	   instead	   be	  important	   for	   replication	   over	   different	   DNA	   lesions,	   we	   exposed	   cells	   to	   DNA	   damaging	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agents	  prior	   to	  DNA	   fibre	  analysis.	  Our	   results	   indicate	   that	  ATAD5	   status	  does	  not	   affect	  replication	   of	   damaged	   DNA	   either,	   as	   fork	   speed	   was	   unperturbed	   upon	   exposure	   to	  MNNG,	  MMC	   and	  Olaparib,	  which	   all	   induce	   different	   types	   of	   DNA	   lesions.	   However,	  we	  have	   to	   take	   into	   consideration	   that	   although	   DNA	   fibre	   assays	   are	   useful	   tools	   to	  investigate	   global	   replication	   patterns,	   the	   technique	   is	   not	   very	   sensitive	   and	   relies	   on	  effects	  that	  are	  strong	  enough	  to	  affect	  replication	  on	  a	  genome-­‐wide	  level.	  In	  other	  words,	  if	   the	  damage	   induced	  by	  certain	  agents	   is	   rare	  or	  only	  present	   in	  a	  minor	   fraction	  of	   the	  genomic	   DNA,	   it	   will	   not	   be	   detectable	   using	   DNA	   fibre	   analysis.	   It	   is	   thus	   easy	   to	   miss	  certain	   effects	   due	   to	   low	   drug	   concentration	   or	   specificity	   of	   lesions	   induced	   only,	   or	  preferentially,	   in	  certain	  regions	  of	   the	  genome.	  We	  cannot	  strictly	  rule	  out	   the	  possibility	  that	  this	  is	  the	  case	  here,	  however,	  we	  have	  chosen	  well	  studied	  agents	  and	  concentrations	  that	  are	  well	  above	  the	  toxic	  threshold	  and	  negatively	  affect	  survival	  of	  treated	  cells,	  while	  still	  allowing	  replication	  to	  take	  place.	  Interestingly,	  it	  was	  recently	  shown	  that	  lesions,	  such	  as	  interstrand	  crosslinks	  (ICLs),	  which	  were	  previously	  believed	  to	  cause	  strict	  replication	  fork	  blocks,	  are	  traversed	  to	  prevent	  stalling	  and	  collapse	  of	  active	  replication	  machineries	  [360].	  It	  is	  thus	  reasonable	  to	  assume	  that	  also	  other	  types	  of	  DNA	  damage	  can	  be	  traversed	  and	  do	  not	  cause	  fork	  stalling,	  at	  least	  not	  for	  long	  periods	  of	  time.	  If	  this	  is	  indeed	  the	  case,	  DNA	  fibre	  assays	  would	   fail	   to	  detect	   them	  and	  thus	  underestimate	   the	  number	  of	   lesions	  generated	   by	   the	   applied	   DNA	   damaging	   agent(s).	   Such	   lesions	   could	   subsequently	   be	  repaired	  post-­‐replicatively	  and	  we	  cannot	  exclude	  the	  possibility	  that	  ATAD5	  is	  taking	  part	  in	  the	  later	  repair	  processes.	  	  Nevertheless,	  ATAD5	  travels	  with	  the	  replication	  machinery	  and	  has	  been	  implicated	  in	  the	  unloading	  of	  PCNA,	  as	  well	  as	  ubiquitylated	  and	  SUMOylated	  PCNA,	  from	  chromatin	  [49,	  50].	  Until	  recently,	  it	  was	  unclear	  whether	  ATAD5	  is	  involved	  in	  global	  PCNA	  unloading,	  or	  whether	  removal	  of	  PCNA	  by	  ATAD5	  is	  restricted	  to	  certain	  regions	  of	  the	  genome,	  such	  as	  centromeres,	   telomeres	   or	   sites	   of	   cohesion	   or	   DNA	   damage.	   New	   data,	   using	   yeast	   as	   a	  model	   system,	   showed	   that	   Elg1	   (the	   yeast	   homolog	   of	   ATAD5)	   is	   required	   for	   PCNA	  unloading	  following	  Okazaki	  fragment	  ligation	  on	  a	  genome-­‐wide	  scale	  [59].	  However,	  it	  is	  unclear	   whether	   this	   is	   also	   true	   for	   human	   ATAD5.	   Furthermore,	   it	   also	   still	   remains	  enigmatic	  whether	  unloading	  of	  PCNA	  or	  rather	   its	  modified	   forms	  PCNAub	  or	  PCNASUMO	   is	  crucial	  to	  maintain	  genome	  stability.	  In	  an	  attempt	  to	  better	  understand	  the	  importance	  of	  the	   modification	   of	   PCNA	   regarding	   ATAD5s	   function,	   we	   have	   generated	   HEK293	   TRex	  FlpIN	   cells	   that	   enable	   simultaneous	   downregulation	   of	   endogenous	   PCNA,	   while	  overexpressing	   eGFP-­‐tagged	   wild	   type	   PCNA	   or	   a	   mutant,	   which	   cannot	   be	   modified	   on	  lysine	  164	  (K164R).	  This	  residue	  is	  normally	  ubiquitylated	  in	  response	  to	  replication	  stress	  in	   order	   to	   recruit	   translesion	   synthesis	   (TLS)	   polymerases	   to	   sites	   of	   DNA	   damage	   [31].	  K164	  is	  SUMOylated	  in	  S-­‐phase,	  presumably	  inhibiting	  inappropriate	  recombination	  events	  by	   recruitment	   of	   anti-­‐recombinases,	   such	   as	   Srs2	   in	   yeast	   or	   PARI	   in	   human	   cells	   [35].	  Unfortunately,	   due	   to	   time	   constraints,	   I	   was	   not	   able	   to	   test	   whether	   the	   phenotypes	  observed	   upon	   ATAD5	   depletion	   are	   dependent	   on	   modification	   of	   PCNA	   or	   not.	  Nevertheless,	  the	  above-­‐mentioned	  cell	  lines	  will	  hopefully	  serve	  as	  useful	  tools	  to	  test	  this	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experimentally.	   I	  would	   like	   to	  mention	   at	   this	   point	   that	   it	   has	   proven	   rather	  difficult	   to	  characterize	  ATAD5-­‐deficient	   cells	   phenotypically,	   due	   to	   effects	   on	   genome	   stability	   that	  are	  minor	  at	  best	  and	  a	  high	  variability	  within	  the	  individual	  experiments.	  This	  could	  be	  due	  to	  redundant	  functions	  of	  ATAD5	  with	  other	  proteins,	  such	  as	  alternative	  PCNA	  unloaders,	  or	   because	   ATAD5	   plays	   only	   a	   minor	   role	   in	   genome	   maintenance	   in	   human	   cells.	  Furthermore,	   discrepancies	   and	   contradictions	   within	   the	   literature	   have	   aggravated	  research	   concerning	   ATAD5.	   Despite	   these	   difficulties,	   it	   remains	   a	   highly	   interesting	  candidate	  in	  the	  DNA	  repair	  field	  and	  deserves	  to	  be	  investigated	  further.	  If	  we	  manage	  to	  find	  conditions,	  where	  ATAD5	  is	  absolutely	  required	  to	  maintain	  low	  levels	  of	  DNA	  damage	  that	   are	   compatible	   with	   cell	   survival,	   we	   might	   be	   able	   to	   dissect	   its	   basic	   biological	  function.	  	  Especially	  its	  proposed	  role	  as	  a	  PCNA	  unloader	  is	  interesting,	  since	  PCNA	  is	  a	  central	  player	   in	   DNA	   metabolism,	   orchestrating	   DNA	   replication	   and	   repair	   events	   [23].	   We	  believe	  that	  ATAD5	  is	  not	  directly	  involved	  in	  replication,	  since	  depletion	  of	  ATAD5	  did	  not	  cause	   any	   replication	   defects	   as	   mentioned	   earlier.	   Neither	   did	   ATAD5	   overexpression,	  which	  shows	  that	  removal	  of	  PCNA	  from	  chromatin	  by	  ATAD5	  is	  a	  highly	  regulated	  process	  that	  likely	  requires	  completion	  of	  Okazaki	  fragment	  ligation	  (as	  in	  yeast)	  or	  another	  type	  of	  signaling.	  Preliminary	  data	  from	  our	  laboratory	  indicate	  that	  ATAD5	  may	  have	  a	  role	  in	  the	  timely	   repair	   of	   single-­‐strand	   breaks	   induced	   by	   the	   oxidizing	   agent	   KBrO3	   (data	   not	  shown).	   These	   results	   are	   in	   line	  with	   the	   experimental	   evidence	   reported	   here,	   showing	  that	  ATAD5-­‐depleted	  cells	  have	  reduced	  capacity	  to	  repair	  DNA	  lesions	  induced	  by	  MNNG,	  MMC	  or	  Olaparib,	  as	  measured	  using	  Pulse	  Field	  Gel	  Electrophoresis	  and	  the	  Alkaline	  Comet	  assay.	   Further	   experiments	   are	   required	   to	   confirm	   these	   observations	   and	  one	   aspect	   of	  our	   future	  work	  will	   surely	   focus	   the	   recovery	   of	  DNA	   strand	   breaks.	   SSBs	   are	   especially	  interesting	   in	   this	   context,	   because	   they	   are	   recognized	   by	   PARP	   and	  we	   show	   here	   that	  ATAD5-­‐deficient	  cells	  are	  hypersensitive	  to	  treatment	  with	  the	  PARP	  inhibitor	  Olaparib.	  A	  combinatory	  treatment	  of	  Olaparib	  together	  with	  DNA	  strand-­‐break	  inducing	  agents	  could	  therefore	   potentiate	   the	   effect	   of	   ATAD5-­‐depletion	   and	   give	   rise	   to	   a	   more	   robust	  phenotype.	   Endogenous	   oxidative	   stress	   is	   one	   of	   the	   most	   common	   threats	   to	   genomic	  stability,	  causing	  oxidative	  DNA	  damage	  as	  well	  as	  DNA	  strand	  breaks	  that	  in	  turn	  activate	  PARP.	   ATAD5	   may	   be	   required	   for	   the	   repair	   of	   such	   lesions,	   which	   would	   explain	   the	  sensitivity	   of	   ATAD5-­‐deficient	   cells	   to	   PARP	   inhibitors	   and	   the	   delayed	   repair	   of	   KBrO3-­‐induced	  SSBs.	  With	  respect	  to	  this,	  it	  would	  be	  interesting	  to	  investigate	  Olaparib	  sensitivity	  upon	  ATAD5	  depletion	  in	  an	  HR-­‐deficient	  background.	  If	  ATAD5	  is	  not	  directly	  involved	  in	  HR,	   it	   should	   potentiate	   PARP	   inhibitor	   sensitivity	   in	   those	   cells	   and	   thus	   not	   show	   an	  epistatic	  effect.	  	  Thus	   far,	   we	   have	   not	   been	   able	   to	   fully	   uncover	   the	   role	   of	   ATAD5	   in	   maintaining	  genome	  stability	  and	  elucidate	  whether	   removal	  of	  PCNA	  has	  an	   important	   impact	   in	   this	  respect.	   Future	   work	   with	   the	   generated	   tools	   will	   hopefully	   resolve	   these	   unanswered	  questions	  and	  give	  important	  insights	  into	  DNA	  metabolism	  connected	  to	  ATAD5	  and	  PCNA.	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CONCLUDING	  REMARKS	  &	  FUTURE	  PERSPECTIVES	  
	   Synthetic	   lethality	   has	   been	   proven	   to	   be	   a	   valid	   approach	   to	   selectively	   kill	   cancer	  cells,	  however,	  resistance	  often	  occurs	  and	  reduces	  the	  applicability	  of	  agents	  used	  in	  such	  therapeutic	   approaches.	   It	   is	   thus	   highly	   important	   to	   understand	   the	   basic	   biological	  mechanism	  and	  find	  suitable	  biomarkers	   in	  order	  to	  predict	  possible	  clinical	  outcome	  and	  enable	  personalized	  medicine.	  A	   synthetic	   lethal	   interaction	  between	  PARP	   inhibitors	  and	  homologous	   recombination	   (HR)-­‐deficient	   cells	   was	   demonstrated	   about	   ten	   years	   ago	  experimentally	   and	   has	   recently	   been	   applied	   in	   the	   clinic	   [2,	   3].	   PARP	   inhibitors	   are	  currently	  used	   for	   treatment	   of	  BRCA1-­‐	   and	  BRCA2-­‐mutated	  breast,	   ovarian	   and	  prostate	  cancers.	  However,	  they	  represent	  only	  the	  fourth	  line	  treatment	  options	  thus	  far	  and	  several	  resistance	  mechanism	  have	  already	  been	  described	  [182,	  346,	  347],	  hampering	  the	  efficacy	  of	  these	  agents	  in	  certain	  patients.	  Surprisingly,	  the	  exact	  biological	  role	  of	  the	  main	  target,	  PARP1,	   is	   not	   fully	   unraveled	   and	  mechanistic	   insights	   into	   the	  molecular	   basics	   are	   also	  incomplete.	  With	   this	   study	  we	   took	   an	   important	   step	   in	   clarifying	   the	  mode	   of	   action	   of	   PARP	  inhibitors	   in	  HR-­‐deficient	   cells.	  By	   showing	   that	  MYH-­‐depletion	   reduces	  Olaparib	   toxicity,	  we	   were	   able	   to	   demonstrate	   that	   endogenous	   oxidative	   DNA	   damage	   represents	   one	  underlying	   source	   of	   single-­‐strand	   breaks,	   which	   eventually	   feed	   into	   the	   HR	   pathway	  inactivated	   by	   BRCA	   malfunction.	   These	   results	   further	   imply	   that	   hypoxia	   and	   low	  expression	   or	   mutation	   of	   MYH	   will	   negatively	   affect	   PARP	   inhibitor	   efficacy	   in	   those	  tumors.	   As	   far	   as	   personalized	  medicine	   is	   concerned,	   these	   novel	   insights	  might	   help	   to	  exclude	   patients,	   which	   will	   likely	   not	   benefit	   from	   treatment	   with	   these	   agents.	   Other	  sources	  of	  endogenous	  stress	  remain	  to	  be	  identified,	  however,	  we	  were	  able	  to	  show	  that	  RNaseH2-­‐mediated	   processing	   of	   ribonucleotides	   in	   genomic	   DNA	   does	   not	   contribute	   to	  PARP	   inhibitor	   sensitivity.	   Furthermore,	   it	   is	   clear	   that	   alternative	   mechanisms,	   such	   as	  PARP	  trapping	  on	  DNA,	  must	   lead	  to	  the	  toxicity	  of	  PARP	  inhibitors,	  since	  PARP-­‐depletion	  reduced	  the	  sensitivity	  of	  Olaparib.	  Taken	  together,	  these	  results	  show	  how	  important	  it	  is	  to	   gain	   a	   detailed	   understanding	   of	   the	   basic	   mechanism	   of	   clinically	   relevant	  chemotherapeutics	   and	   all	   biological	   pathways	   that	   are	   involved	   in	   order	   to	   design	   and	  develop	  more	  efficient	  treatment	  regiments.	  	  	  Interestingly,	  we	  observed	  that	  ATAD5-­‐deficient	  cells	  display	  hypersensitivity	  to	  PARP	  inhibitors.	  This	  would	  place	  ATAD5	  in	  the	  HR	  pathway,	  according	  to	  the	  proposed	  synthetic	  lethality	  model.	   However,	   it	   has	   also	   been	   shown	   that	   PARP	   trapping	   on	   DNA	   is	   actually	  more	  toxic	  to	  cells	  than	  inhibition	  of	  the	  catalytic	  activity	  of	  PARP.	  We	  may	  thus	  speculate	  that	  ATAD5,	  as	  a	  proposed	  PCNA	  unloader,	  normally	  prevents	  PCNA	  trapping	  on	  DNA.	  It	  is	  unclear	  at	  the	  moment	  if	  and	  how	  PCNA	  that	  remains	  loaded	  on	  chromatin	  is	  toxic	  to	  cells,	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but	   ATAD5-­‐depletion,	   which	   enhances	   PCNA	   levels	   on	   DNA,	   clearly	   induces	   a	   genomic	  instability	   phenotype.	  Whether	   PCNA	   accumulation	   on	   chromatin	   upon	   ATAD5-­‐depletion	  and	   genomic	   instability	   are	   connected	   is	   still	   under	   investigation	   and	   remains	   a	   highly	  interesting	  question	  to	  answer.	  Because	  PCNA	  is	  a	  platform	  for	  various	  DNA	  replication	  and	  repair	  factors,	   it	  orchestrates	  many	  of	  these	  events	  and	  is	  thus	  crucial	   for	  their	  timely	  and	  spatial	   regulation.	   It	   would	   also	   be	   interesting	   in	   this	   respect	   to	   study	   the	   exact	   roles	   of	  PCNA	  modifications,	   especially	   ubiquitylation	   and	   SUMOylation,	   as	   they	   are	   substantially	  involved	  in	  the	  regulation	  of	  replication	  and	  repair	  pathways.	  Since	  DNA	  replication	  is	  not	  affected	  by	  either	  downregulation	  or	  overexpression	  of	  ATAD5,	  we	  conclude	  that	  ATAD5	  is	  not	  directly	  involved	  in	  replication,	  but	  might	  instead	  be	  required	  for	  PCNA	  unloading	  after	  Okazaki	  fragment	  maturation	  or	  alternatively	  in	  post-­‐replicative	  repair	  processes.	  	  To	   date,	   we	   have	   not	   been	   able	   to	   fully	   unravel	   the	   precise	   biological	   function	   of	  ATAD5.	   However,	   due	   to	   its	   proposed	   role	   as	   a	   PCNA	   unloader	   and	   gatekeeper	   of	   the	  genome	   it	   might	   have	   possible	   clinical	   implications,	   due	   to	   the	   hypersensitivity	   towards	  Olaparib	  and	  other	  DNA	  damaging	  agents.	  If	  it	  proves	  to	  be	  a	  factor	  involved	  in	  homologous	  recombination,	   it	   could	   broaden	   the	   spectrum	  of	   tumors	   treated	  with	   PARP	   inhibitors,	   in	  case	   ATAD5-­‐deficiency	   is	   observed	   in	   any	   tumor	   types.	   We	   are	   far	   from	   such	   deeds,	  however,	   investigating	   the	   basic	   molecular	   mechanism	   of	   ATAD5	   and	   its	   connection	   to	  PCNA	  will	  surely	  bring	  us	  one	  step	  closer	  to	  understanding	  important	  facets	  of	  global	  DNA	  metabolism.	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  motiviert,	  anspornt	  und	  herausfordert!	  	  	  
Mama	  &	  Papa	  -­‐	  DANKE!	  Ihr	  seid	  meine	  Felsen	  in	  der	  Brandung,	  mein	  Rückhalt	  und	  meine	  Ruhe!	  Zu	   wissen,	   dass	   ihr	   hinter	   mir	   steht	   macht	   es	   so	   viel	   leichter	   den	   Abenteuern	   und	  Herausforderungen	  des	  Lebens	  mit	  offenen	  Armen	  und	  strahlenden	  Augen	  entgegen	  zu	  treten!	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